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i 
Abstract 
With the growing trend of globalization and rapid development of high technologies, 
emerging economies face more challenges in technology development because they are 
chasing a fast-moving frontier. They need to identify global technology trends and adapt 
to local needs and capabilities. Strategies for technology development differ among 
countries at different developmental stages.  
In this research, a technology policy choice framework is developed to link 
prospective high-tech areas, technology development strategies, and various innovative 
resources. The research approach is to develop a hierarchical decision model (HDM) and 
apply the analytic hierarchical process (AHP). Experts are invited from diverse sources to 
provide a balanced perspective representing different stakeholders. This research focuses 
on the fast developing Chinese biopharmaceutical industry as a case study.  
The results of this research have identified thirteen prospective biotech areas that 
China should invest more resources for development. These technology areas include:  
recombinant therapeutic proteins, recombinant vaccines, monoclonal antibody 
technology, cell and tissue engineering, gene therapy, antisense therapy, RNAi, 
nanobiotechnology, synthetic biology, bioinformatics, pharmacogenetics, gene 
sequencing, and biotechnology diagnostics. For most of these technology areas, the 
results have indicated an imitative innovation strategy should be taken as a better strategy 
under current technological conditions in China. The research has further found that high-
tech small-to-medium companies and multinational corporations are major innovation 
contributors in the Chinese biopharmaceutical sector. 
ii 
The research outcomes can serve as guidelines in resource allocation and policy 
making for technology development. Based on the overall research findings, policy-
makers can apply more specific policy instruments to support innovation activities. 
Appropriate policy measures may help the country to construct an innovative ecosystem 
that can serve as the driving force for future technology development. 
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Chapter 1 – Introduction 
1.1 Problem Statement 
“No nation can afford to be without its own independent Science and Technology 
capacity.” [1]         --- Kofi Annan  
Innovations in science and technology (S&T) constitute the core of national 
competitiveness [2]. Nations across the world invest heavily in high technology 
innovations, but they are facing different challenges due to different developmental 
contexts. Western developed countries need to maintain their technological 
competitiveness and sustain their innovative leadership [3] [4]. Emerging economies aim 
to improve technological competitiveness through catching up and leapfrogging [5] [6]. 
Strategic innovation policy for effective technology development has become a key issue 
for all countries. The fundamental and common problem is how nations achieve and 
sustain S&T competitiveness.  
With the growing trend of globalization and rapid development of high technologies, 
emerging economies face more challenges because they are chasing a fast-moving 
technological frontier. They need to identify global technology trends and adapt them 
according to local needs and capabilities. Even though technology programs such as 
foresight studies generally provide broad pictures about the future, implementation of 
various high technologies remains a common challenge. The development of high-tech 
industries suggests that it is necessary but difficult to find balance between local and 
global, internal and external innovation. How much an industry can benefit from external 
alliances largely depends on the effectiveness and efficiency of the national innovation 
2 
system [7]. Emerging economies may rely more on learning advanced technologies from 
advanced countries, but they face the “make or buy” dilemma in technology development. 
International technology transfer can be a major channel to obtain state-of-the-art 
technologies from advanced countries. However, it is also a high-risk process since there 
is no guarantee that technology transfer would result in future innovation for the host 
country. A comprehensive technology development framework at the strategic level 
becomes necessary in the present environment of global competition. 
Strategies for technology development differ among countries because of huge gaps 
in terms of social values, economic status, and political environments. Technology policy 
issues vary significantly due to the diversified conditions between developed and 
developing countries. While many Western developed countries strictly control high-tech 
export, China adopted a countermeasure policy of “Trading of Domestic Market for 
Technology.” This policy deliberately trades market access for technologies, obliging 
foreign investors to share technologies if they want to sell to the Chinese market. German 
scholars found that the strategy is unique because only large economies with high 
potential markets (China and India) can apply it [8]. However, many scholars cast doubts 
on this policy, questioning whether this unique catch-up process can foster innovation. 
Literature suggests that such a policy is not successful in many high-tech sectors [9] [10]. 
Scholars suggest that a multi-level perspective is necessary for technology policy to 
consider the complex factors of various levels including macro-, meso-, and micro-scale 
issues [11]. Further research is needed on policy making to strengthen technological 
competitiveness and innovative capability in the long run.  
3 
1.2 Research Objective and Questions 
The objective of this research is to develop a hierarchical decision model to assist 
technology policy decision makers in leveraging various technologies, strategies, and 
resources for sustainable innovation. Make or buy has long been a strategic problem for 
technology development in emerging economies. For instance, international technology 
transfer has been viewed as a direct contributor toward technology advancement, but it 
can also stifle domestic innovation when treated improperly. There are no current models 
to arrive at effective policy design that can align development strategies and resources 
allocation toward long-term technological innovation. This study develops such a 
research framework that can assist decision makers in emerging economies to develop 
guidelines for investments toward the goal of technological innovation. This research will 
explore different strategies in technological development, and find efficient pathways to 
allocate various input resources for innovation. This research will be achieved through 
exploring prospective technology areas, strategic factors, innovation resources, and 
measuring related judgments from expert panels.  
Through literature review, five research questions have been formulated to deal with 
current problems and support the research objective. These research questions (RQ) are 
summarized as: RQ1 - What technologies to develop and acquire for emerging economies? 
RQ2 - What strategies are more efficient in technological development and innovation? 
RQ3 - What innovation inputs can promote and accelerate the development process? RQ4 
- How should technologies, strategies, and resources be prioritized to strengthen 
competitiveness and support innovation? RQ5 - Where are the areas of disagreements 
among stakeholders? What are the related policy implications? The model will be applied 
4 
to the fast-growing Chinese pharmaceutical industry as a case study, so the questions will 
be answered and demonstrated through detailed research in China’s context.  
1.3 Research Methodology  
To cope with the questions and achieve objectives, a hierarchical decision model 
(HDM) is developed. The model has the purpose of leveraging controllable resources to 
foster long-term innovation. The methodology to be utilized is Analytic Delphi study. 
Delphi offers a technique to make assessments over future uncertainties and strategic 
concerns. AHP will be applied to quantify experts’ judgments on identified criteria or 
issues. Expert panels are formed of diverse sources to provide a balanced perspective 
representing industry and government.  
Figure 1 provides a schematic overview of the research process. It is divided into 
seven phases. Related and supportive research in each phase is briefly discussed. In Table 
1, these research phases are linked to the above-mentioned research questions. 
 
5 
 
 
 
Phase 1 – Literature Review: The purpose of the review is to develop a solid 
background and understanding of the research topics. Major aspects include international 
technology transfer, innovation systems, technology foresight, and technology policies. 
Research gaps will be identified and highlighted. 
Phase 2 – Identification of Technology Areas: The rationale of this phase is to 
identify global technology trends and adapt them to local needs and capabilities. This 
means identifying potential high tech areas where competitive advantages can be 
achieved through catching up and leapfrogging. The related and supportive research 
includes foresight/forecasting studies, industrial report, market analysis, academic 
research, expert recommendations, etc. The outcome will be a narrowed list of the 
technology alternatives. The list will serve as input to the following research phases 
Phase 1: 
Literature Review 
Phase 2: 
Identify Prospective 
Technology Areas 
Phase 3: 
Identify Technology 
Development Strategies 
Phase 4: 
Identify Innovation 
Resources 
Phase 5: 
HDM Development 
-Mission 
-Technologies 
-Strategies 
-Resources 
Phase 6: 
Data Collection & 
Analysis 
Phase 7: 
Result Validations & 
Recommendations 
Figure 1: Outline of Research Approach 
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where strategic judgment is required. The studies in Phase 2 address the research question 
of identifying appropriate technologies to be developed by emerging economies.  
Phase 3 – Identification of Technology Development Strategies: This part will 
investigate different strategies in the technological development process. Related studies 
will compare different conditions in developed countries and emerging economies. The 
chosen strategies will be based on the host country’s developmental context, technology 
level, and research capabilities. Studies in Phase 3 explore the research question 
regarding what strategies are more efficient in technology development.  
Phase 4 – Identification of Innovation Resources: This part serves to identify 
effective innovation input to support technological development strategies. Since 
innovation resources may vary from country to country and from industry to industry, 
this related study will focus on the innovation systems in emerging economies. 
Environmental factors such as framework conditions will be considered accordingly. Due 
to investment constraints, a combination of input resources will be identified and tailored 
toward the overall innovation objective. Studies in Phase 4 will answer the research 
question of what input resources can promote and facilitate the technology development 
process.  
Phase 5 – HDM Development: Develop a hierarchy structure to illustrate the multi-
level relationships represented in the situation and the judgment process. The research 
model utilizes information collected in the above phases as alternatives and criteria inputs 
for the decision process. The hierarchy includes the mission, technology alternatives, 
development strategies, and innovation resources. The criteria in the hierarchical decision 
model are presented to the expert panels for further validation.  
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Phase 6 – Data Collection and Analysis: Pair-wise comparison research instruments 
will be developed and sent to expert panel members to determine the weights of criteria 
in the hierarchical structure. According to their expertise fields, the expert panel will 
quantify the relative weight of importance for the elements in each level. Consistency 
level and disagreement of the experts will be calculated. Studies in Phase 5 and 6 will 
answer the research question of how to prioritize various technologies, strategies, and 
resources for competiveness and innovation. 
Phase 7 – Result Validation and Recommendations: The quantification results will 
be validated and analyzed. The relationship between the elements in different levels will 
be clarified and explained. Sensitivity analysis will be employed to help improve the 
understanding of relationships among different levels. The analysis quantifies the range 
of difference of the optimal set if there are changes in related sub-criteria, and provides 
the basis to assist policy-makers in modifying the hierarchy for selection of the optimum 
strategy. Based on result analysis, discussions and recommendations will be given. 
Studies in Phase 7 explore the research question in the area of disagreement and related 
implications. 
According to the overall research findings, policy-makers can apply more specific 
policy instruments such as direct and indirect funding, regulation support, and 
improvement in framework conditions. More detailed public policies will be potential 
areas for future research.  
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Research Phases  Research Questions Addressed  
Phase 2 – Identification of Prospective 
Technology Areas  
1. What technology to develop and acquire for 
emerging economies?  
Phase 3 – Identification of Technology 
Development Strategies 
2. What strategies are more efficient in 
technological development and leapfrogging?  
Phase 4 – Identification of Innovation 
Resources  
3. What innovation inputs can promote and 
accelerate the development process?  
Phase 5 – Hierarchical Model Development 
Phase 6 – Data Collection and Analysis 
 
4. How should technologies, strategies, and 
resources be prioritized to strengthen 
competitiveness and support innovation? 
Phase 7 – Result Validation and 
Recommendations 
5. Where are the areas of disagreements and 
agreements? What are the related policy 
implications?  
Table 1: Connecting Research Phases and Research Questions 
 
1.4 Research Applications 
To demonstrate the model in detail, the research will develop a case application from 
the perspective of China. Among other developing countries, China is in the critical 
period of trying to catch up with developed countries and implementing a new path of 
industrialization. The issue of how to accelerate development and foster technological 
innovation has aroused great concern from government, industry and academic sectors, at 
the same time, provided an opportunity for research.  
China has been developing fast in terms of economic and social achievements, with 
a lot of visible improvements but also many underlying weaknesses in technology 
management. The Chinese innovation system is still at an early stage and its development 
is always determined by the macro environment. In order to achieve national 
competitiveness in S&T, the country needs to improve its innovative capacity. One of the 
most determinative factors is its strength of sustained innovation in a globalized 
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environment. The core objective of the country is to locate its right position in the global 
innovation networks, and to construct an innovation infrastructure that can serve as the 
driving force for future development. Appropriate technology policy measures can 
integrate domestic innovation efforts along with foreign innovation resources. Such 
measures may help the country to catch up with the developed world or even leap ahead 
into the global innovation frontier. The dissertation develops a research model to help in 
achieving this objective. The research results may also be helpful to other emerging 
economies for achieving innovation objectives and promoting national competitiveness. 
1.5 Outline of Dissertation 
Chapter 1 provides an introduction and gives an overview of the dissertation. 
Research background, objectives, and approaches are briefly presented to give a complete 
picture of the study. 
Chapter 2 constitutes the theoretical foundations supporting the research. It contains 
a comprehensive search of literature in major areas including international technology 
transfer, innovation management, technology foresight, technology policy, and related 
methodologies. Outstanding gaps are identified that motivate the research. 
Chapter 3 links the literature gaps with research questions, and further clarifies the 
research goals. It presents the research methodology, research framework, and research 
approach. The research process is divided into several phases and discussed in detail. 
Chapter 4 develops a case application for the model, which is about the 
biopharmaceutical industry in China. The customized model criteria, as well as the 
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structure, are validated by experts. Research instruments are developed to quantify expert 
judgment. The data collection process is discussed.  
Chapter 5 presents the quantification results in charts and tables. The overall 
contributions of criteria are calculated in matrices. The data are analyzed for 
inconsistencies, disagreement, and sensitivity. 
Chapter 6 discusses the result implications according to various levels in the model. 
Policy recommendations are included based on research results as well as experts’ 
feedbacks during the validation process.  
Chapter 7 concludes the research from the aspects of contributions, assumptions, 
limitations, and future research areas.   
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Chapter 2 – Literature Review  
The literature reviewed in preparation for this research is focused on several major 
aspects – international technology transfer, innovation management, technology foresight, 
technology policies, and related methodologies. The purpose of this chapter is to develop 
a solid background and understanding of the research topics. In each section, technology 
policy and strategies are examined in various countries. A special section will focus on 
technology management issues in China. Literature gaps are highlighted at the end of this 
chapter.  
2.1 International Technology Transfer 
International technology transfer is a direct approach to improve the national 
technology level and strengthen national competence. As many emerging economies face 
the question of ‘‘make or buy’’ in technology development, introducing new technologies 
from advanced countries can serve as a fast track to boost the speed of catching up [12]. 
Through technology import, host countries can often shorten the learning time, enjoy the 
latecomer advantage, and achieve technology leapfrogging. However, international 
technology transfer is not an easy process. Barriers exist due to different conditions 
among countries in terms of social values, economic development, and technology level. 
There are more complicated issues if technology exporters belong to the developed world, 
while the technology importers come from the developing world. Scholars suggest that 
technology transfer needs to be perceived in terms of achieving three core objectives [13]: 
1) the introduction of new techniques by means of investment in new plants; 2) the 
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improvement of existing techniques; and 3) the generation of new knowledge. This 
section will analyze various issues related to international technology transfer and 
identify literature gaps for improvement.  
2.1.1 Levels of International Technology Transfer  
International technology transfer can be studied from different perspectives. One 
approach is to focus on the entities involved in the process, i.e. technology exporter, 
technology importer, and technology itself. Another approach is to explore the growing 
trends of international technology transfer from different perspectives of various levels. A 
careful examination of the literature reveals that international technology transfer issues 
can be categorized into several interrelated levels including: national level, enterprise 
level, and technology level [14] [15]. International technology transfer is a complicated 
system process that involves not only the activities of market and economy, but also 
politics, culture, and society. Many obstacles still exist and are unsolved at each of these 
levels. A good understanding of influential factors provides better insight for policy-
making. 
At the national level, literature findings show that there are many environmental 
factors influencing international technology transfer, which include policy, economic 
growth, and market trend. For example, technology transfer needs appropriate legislation 
on intellectual property protection. It is also directly influenced by market need and 
investment. International technology transfer and acquisition should align with national 
goal in technology development. Macro-level regulations and incentives can have major 
impacts on the efficiency of the technology transfer process. International technology 
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transfer, especially high-tech exports and imports, are being strictly controlled by 
governments at the national level. Western developed countries have issued various 
regulations regarding cross-border technological transactions. These restrictions have 
largely deterred international technology transfer activities. For example, the United 
States has limited technology transfer to China in many high-tech areas, which includes: 
electronics and communications technologies, ship-building, airplane, satellite, materials, 
nuclear energy, etc [16]. This policy even inflicts many other EU countries working in 
high-tech projects with China. As a result, China cannot solely rely on international 
technology transfer in high-tech industries. Indigenous innovation should be emphasized 
and promoted at the national level.  
At the enterprise level, many actors of international technology transfer have been 
identified in the literature. In the process of technical transactions, strategies of 
stakeholders are the determinants for the success of international technology transfer. The 
technology development process can be accelerated by cooperative interactions among 
the players. This is closely related to the robustness of technological innovation systems. 
Multinational companies are important sources for emerging economies to acquire 
foreign technologies, but there are many factors to consider such as intensified 
competition, crowding out of domestic enterprises and newcomers. Recent literature 
showed that international technology transfer can exist in some new channels such as 
R&D collaboration and cross border M&A. Technology learning has also been enhanced 
by some non-formal channels which include academic communication, flow of scientists 
and engineers, etc. These channels are new opportunities for the emerging economies to 
accelerate their catching up process.  
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At the technology level, many studies focus on the issues of technology selection 
and assessment. Characteristics of technology play a significant role in international 
technology transfer. These features may include availability, maturity, adaptability, and 
gaps, etc. From the perspective of developing countries, an emerging technology can 
provide a window of opportunity for technology leapfrogging [17]. Much has been 
written in the literature about the need to transfer appropriate technologies for developing 
countries. Therefore, technology adaptability in a foreign market is an important factor 
for the success of international technology transfer [18]. Technology gaps describe the 
distance between the domestic technological competency level and international state-of-
the-arts technologies. Literature examining institutions and technological development 
found technology gap may either enhance or deter the efficiency of international 
technology transfer. Technology management techniques can be applied to international 
technology transfer for evaluation of technology alternatives, selection and acquisition of 
appropriate technologies. Emerging high-tech areas bring new challenges for developing 
countries to catch up and realize the latecomer advantage. Not only do they need to select 
the right technological direction, but they also need to accumulate technology learning 
capabilities. 
2.1.2 Technology Transfer and Innovation  
The intimate connection between technology transfer and innovation has been 
highlighted in the literature. For example, scholars  claim that technology transfer is a key 
contributor to innovation performance, competitiveness and economic development of a 
country [19]. Some scholars developed linear growth models to illustrate technology 
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progress in industrializing economies. The development process was seen as a series of 
successive upgrading in parallel with a nation's economic environment.  
 
 
In Figure 2, Guan et al. (2006) presented a technological progress trajectory for the 
catching up countries from imitation to innovation which comprises acquisition, 
assimilation and improvement of technology [19]. Wang and Zhou (1999) considered the 
role of foreign enterprises and created a model of “transfer-digestion-absorption-
innovation-dissemination” from China’s perspective of increasing involvement in 
international production and trade activities [20]. Leonard-Barton (1995) proposed a 
model to describe import substitution, which starts from import kits, progresses to 
localization of parts and components, then to product redesign, and finally to novel 
product design [21]. Hobday (1995) suggested a linear model for newly industrialized 
countries: from the first stage of cheap labor assembling, through the second stage of 
original equipment manufacturing (OEM), then to the third stage original design 
Acquisition Assimilation Improvement 
Import Kits Localization 
of Parts 
Product 
Redesign 
Novel Product 
Design 
Cheap Labor 
Assembling 
Original Equipment 
Manufacturing 
Original Design 
Manufacturing 
Original Brand 
Manufacturing 
Transfer Digestion Absorption Innovation Dissemination 
Figure 2: Linear Models of Technology Progress in Industrializing Economies 
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manufacturing (ODM), and finally to original brand-name manufacturing (OBM). The 
author emphasized the importance of OEM as a learning platform, calling it “an enduring 
technological training school for latecomers” [22]. 
Most of the above models connect international technology transfer with the concept 
of innovation or improvement in technology. However, implementation in the real world 
is not as easy as the models have depicted. For example, the literature has conceded that 
there are many problems, or at least it is still a difficult task for China. Scholars [20] 
argued that lack of sufficient technological capability is a major inadequacy at the firm 
level for implementation. The restructuring of the Chinese R&D system from a centrally 
planned mechanism into a flexible system should be an attempt to solve the problem. The 
literature has reported that China spent more on technology acquisition—the earliest 
stage of the technological progress trajectory but much less on the last two stages than 
Japan and Korea when their economies started booming [19]. Scholars  also pointed out 
that the proportion of hardware transfer is high [23]. Except for some large-sized 
companies, most importers stay at the level of cooperation in transferring hardware. 
There is a negative influence on domestic industry in that it is a mature technology which 
is still largely transferred. Facing incessantly changing technologies and intense global 
competition, Chinese authors argued that the country should acquire more state-of-the-art 
technologies that lead to innovation and improvement [24]. 
Although international technology transfer can be an effective strategy to catch up 
with the leading countries in many high-tech sectors, it may not necessarily result in 
future innovation of the receiver. For instance, the literature explored the relationship 
between technology transfer activities and innovation performance with special reference 
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to Chinese industrial firms. Based on a nationwide survey covering more than 2000 firms, 
statistical results showed that technology transfer activities may impede the innovation 
performance of high-tech firms [19]. Recent research (2011) shows that regarding 
international R&D spillovers facilitated by FDI, the spillover effect on indigenous 
technical change is mostly insignificant or negative except in the medium low-technology 
sectors [25]. These facts mainly result from low absorption capabilities of domestic 
industries. Therefore, it is critical for policy makers to better utilize technology transfer 
as a tool to foster innovation and sustain future development. Many scholars from 
developing countries focus on how latecomers can catch up with advanced countries by 
leapfrogging or direct innovation at the technological frontier [26-28]. Lee (2005) 
identified two catch-up modes: Taiwan followed the sequential steps of OEM, ODM and 
OBM, by learning from foreign countries; Korea jumped from OEM directly to OBM 
without consolidating design technology. The author suggests that China might be a third 
model mixing elements of both Korean and Taiwanese models, but more research is 
needed [29].  
2.1.3 Different Motivations and Interests  
During the process of technological transactions, there are noticeable differences in 
strategic objectives among the host government, foreign technology providers, and 
domestic partners. Their strategies are the determinants for the success of international 
technology transfer. Scholars argued that research should not only analyze technology 
strategy in subsidiaries of MNEs, but also examine how such development differs from 
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that of domestic firms [30]. Their differences decisively affect the implementation of 
technology transfer.  
2.1.3.1 Foreign Interests 
The motivations of foreign technology providers have been studied in detail in the 
literature. Through four cases of Swedish manufacturing firms which have transferred 
technology to China, the literature generalized some of the Western companies’ 
motivations for transferring technology to China. These include [14]:  
1) Access to the Chinese market for China’s future development potentials;  
2) Achieve Short-term revenues through direct sales of machinery or plants;  
3) Utilization of China’s low labor costs and improving access to certain resources;  
4) Achieve long-term revenue from their equity investment in joint ventures. 
The above motivations cannot be easily realized, and major barriers or difficulties 
for Western companies exist in many aspects. A major threat to foreign companies arises 
from losing the technological lead to China in high-tech sectors. Most foreign companies 
are aware of this threat and are sensitive about raising potential Chinese competitors [31]. 
In the short run, there might be more common interests than conflicts between the foreign 
companies and their Chinese counterparts, such as growth in local market share and profit. 
However, in the long run, the Chinese counterparts might emerge as international 
competitors and capture more market share globally. Considering all the good prospects 
of the original motivations, this issue might therefore be a “double-edged sword” for the 
foreign companies. The literature also examined the question of technology transfer from 
the perspective of techno-economic security and how companies respond to the 
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possibility of losing competitive advantage through misappropriation or leakage. Techno-
economic security raises the issue from a company level to a political level. Since this 
risk is often exacerbated by insufficient legal protection of Intellectual Property Rights 
(IPR) in China, the Europe Union officially urged China to strengthen related protection. 
The issue of techno-economic security relating to technology transfer to China also has a 
special significance because of uncertainty about, and non-transparency of, the legislation 
compared to Western systems [31].  
2.1.3.2 Local Interests 
The motivations of Chinese technology receivers are quite different from their 
foreign counterparts. Firstly, they focus on the acquisition of advanced technology, 
reputable trademark, technical and managerial know-how; Secondly, they want to gain 
access to international markets through export of the product produced by means of the 
acquired technology and earnings of foreign exchange; Thirdly, they want to become 
competitive in the local market and secure a technological base for long-term profits; 
Fourthly, they hope to develop R&D capacity; Last but not least, they may benefit from 
government’s subsidies which encourage technical cooperation with foreign firms [14]. 
There are many difficulties for the domestic players to implement the above goals. 
For example, based on a questionnaire survey covering 200 sample companies and 
factories in mechanical industries in China, the literature provided a detailed analysis on 
various difficulties perceived by Chinese technology importers [23]. Major difficulties 
include inappropriate technology, limited access to overseas market information, 
misunderstanding and lack of mutual trust, steep price of the advanced technology, 
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unmatched engineering standard, incompatible production management system, training 
and on-spot service support, difficulties improving the transferred technology, and extra 
restrictions in the contract articles. Many uncertainty factors may influence the purchase 
behaviors of foreign technologies by the Chinese companies. Their practical 
considerations for evaluating foreign technologies can include: domestic market value of 
the technology, profit return from the technology, foreign advanced level of the 
technology, market value cited from other exporters, market value of an alternative 
technology, domestic advanced level of the technology, international market value of the 
technology, method of payment for purchasing the technology, risk level of the 
technology import for recipient firms, and supplier’s cost for the technology (R&D and 
transferring cost) [23] 
2.1.4 Implications for Emerging Economies  
Although international technology transfer is a fast track in technology development, 
it may not naturally result in long-term innovation, or sustainable innovation [32]. It is 
widely accepted that the adoption of transferred or purchased technologies has both 
positive and negative impacts on domestic companies. Technology transfer activities will 
generally improve production and market performance of many domestic firms, but it 
might also impede the innovation performance of high-tech firms. Many domestic firms 
have been relying on costly generation technologies (e.g. key equipment and apparatuses), 
resulting in negative impacts of technology transfer on cultivating their core competence 
[19]. Most domestic companies of developing countries stay at the bottom segment of the 
“smiling curve”, where production generates low marginal profit [33]. Although these 
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companies can receive a certain degree of technology transfer through outsourcing, the 
high-tech core is always retained by MNCs in the developed countries. Research [34] has 
shown that many outward-oriented and highly competitive industries, which are based on 
imported technology and foreign affiliates, seem to have had limited impact on local 
production and on the diffusion of technology in domestic industry. 
From the perspective of emerging economies, there are more issues to consider about 
the negative effects brought by foreign investment. The entrance of MNCs may 
deteriorate the industry infrastructure of developing countries. Although the 
demonstration effect may lead domestic companies to upgrade their technology level, it 
also intensifies market competition. With a weaker technology edge and limited capital 
support, domestic competitors are easily ruled out of the market by technology lock-in. 
The technology absorptive capacity of the domestic company is the primary factor as to 
whether it can take advantage of spillovers [35, 36]. This will in turn depend on the 
company’s strength of investment in R&D. However, R&D expenditures of domestic 
firms can rarely parallel those of large MNCs. Moreover, MNCs have different R&D 
strategies when going abroad, and they tend to minimize spillovers so as to keep 
competitive advantages [37]. In recent years, MNCs are getting more involved in vertical 
technology transfer. This new trend has shown that MNCs prefer to establish wholly 
owned subsidiaries in foreign countries. As a result, knowledge transfers tend to be 
internalized between the MNC and its wholly owned subsidiaries [38]. This makes 
domestic companies unlikely to benefit from technology transfer. 
To resolve the differences in motivations and interests, the policies of the host coun-
try can have a crucial influence on technology transfer and its outcome. Technology 
22 
importers should adjust their technology acquisition strategy on the basis of their actual 
level of economic development, technological accumulation and long-term industrial 
plans. Scholars have developed an extension of the technology acceptance model (TAM) 
to study international technology transfer. Several antecedents have significant influence 
on the success of technology transfer, which include: technological compatibility, ease of 
adoption, technical and economic benefits to the adopting firm [39]. Therefore, decision 
makers need to prioritize various factors in technology development. A fairer policy 
should be considered for both domestic enterprises and foreign technology providers. 
Mutual understandings are required for both sides. Finding ways of increasing the 
effectiveness of technology transfer has strategic implications for both the host country 
and foreign investors. 
From a broader perspective, the innovation process is a cooperative interrelation 
between enterprises and other actors. International technology transfer should be utilized 
as a supportive strategy to accelerate technology development and promote innovation. 
The goal of the host government is to achieve long-term social benefits for the host 
country through the acquisition of advanced technologies. This means localization of 
high-tech products and improvement of innovation capabilities of domestic industries. 
However, domestic companies are weaker in terms of technology level and knowledge 
accumulations. Due to intense market competition, these companies lack enough 
resources for long-term R&D. With the growing pace of internationalization, domestic 
enterprises are eager to transfer better technologies from foreign countries to increase 
market competency in the shortest amount of time. The issues faced by the host 
government are to adjust related policies and provide an innovative environment, thus 
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promoting industrial innovation capability. The goal is to leap into the ranks among 
technology leaders and thus engender a competitive status worldwide. 
2.2 Innovation Management 
Based on issues identified in international technology transfer, this section aims to 
further examine innovation and technology policy. Starting from the innovation theory, 
this section explores various types of innovation systems and related government 
innovation policies. With such literature reviewed, the analysis will focus on innovation 
management issues in emerging economies.  
2.2.1 Innovation as National Competence  
It has been widely accepted that innovation is the engine for development in the 
Western developed countries. Porter (2002) indicated that innovation has become the 
most important source of competitive advantage in advanced economies, and building 
innovative capacity has a strong relationship to a country's overall competitiveness and 
level of prosperity [40]. Technological competitiveness is often measured by the 
innovation capability of industries in a country. The innovation concept in Western 
market economies has gone through several stages. During the 1950s and 1960s, the 
industrial innovation process, was generally perceived as a linear progression from 
scientific discovery, through technological development in firms, to the marketplace 
(Figure 3) [41]. Starting from the 1970s, perceptions of the innovation process began to 
change with a marked shift towards emphasizing market need (Figure 4) [41]. According 
to the new model, the market was the source of ideas for directing R&D, which had a 
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merely reactive role in the process. In the mid-1980s, a new model combining the 
technology push and market pull emerged, and was widely adopted by both industry and 
academia (Figure 5) [41].  
 
Basic Science Design and 
Engineering Manufacturing Marketing Sales 
Figure 3: Technology Push Model 
Source: Rothwell (1994) 
 
Market Need Development Manufacturing Sales 
Figure 4: Market Pull Model 
Source: Rothwell (1994) 
 
Scholars also developed more complicated models to include various kinds of 
influencing factors of innovation. The following model (Figure 5) divided the innovation 
process into a series of functionally distinct but interacting and interdependent stages. In 
other words the process of innovation represents the confluence of technological 
capabilities and market-needs [41]. In recent research, Nemet (2009) proposed that the 
factor “Government Led” should be added to “Technology Push” and “Market Pull” [42]. 
In developing countries, governments can develop policies to encourage transfer of 
advanced technologies from developed countries. From different viewpoints, many 
scholars from emerging economies focus on how latecomer countries can catch up with 
advanced countries through leapfrogging or disruptive innovation [26-28].  
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Source: Rothwell (1994) 
 
2.2.2 The Evolution of Innovation Systems 
The linear models of innovation are somehow limited in scope and do not cover the 
whole picture of complexity. Both industry and academia noticed that innovations were 
influenced by many environmental factors. Freeman argued that, to realize large techno-
economic system transitions, society needs to develop a new model of innovation, 
combining some features of the much criticized linear model with features of the 
systemic innovation model [43]. This leads to the emergence of an innovation system as a 
tool to understand the interactions of innovation activities. An innovation system is a very 
important determinant of technological change. The emergence of a new system and 
changes in existing systems co-evolve with the process of technological change [44]. 
Here we explore how the concept of innovation systems evolved. 
Innovation is characterized by complicated feedback mechanisms and mutual 
interactions involving science, technology, learning, production, policy, and demand [45-
47]. Edquist claimed that “firms never innovate in isolation” [45]. In this process, 
innovators interact with other organizations to develop and exchange various kinds of 
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Figure 5: The Coupling Model of Innovation 
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knowledge, information, and other resources. These organizations can include other firms 
(upstream, downstream, or even competitors), universities, research institutes, 
government agencies etc. Various types of relationships can be established among these 
innovators during their innovation process. Therefore, innovating firms should not be 
regarded as isolated or individual decision making units [45, 48]. According to Elzen and 
Wieczorek, innovations emerge in multiple interrelated societal domains, including 
technology, economics, politics, and culture [49]. All of these studies indicate that firms 
operate within Innovation Systems. In recent years, more discussions and research about 
developing competitiveness and technological advancement have dealt with innovation 
systems. Mainly, four types of innovation systems are studied, which include National 
Innovation systems, Regional Innovation Systems, Sectoral Innovation Systems, and 
Technological Innovation Systems.  
Freeman introduced the concept of National Innovation Systems (NIS) in 1987 [2]. It 
was further developed by Lundvall and Nelson in the early 1990s [50] [51]. NIS includes 
not only industries and firms, but also various actors and organizations of related fields in 
science and technology. Freeman defines NIS as a network of public and private 
institutions that through its activity and interaction creates, brings, modifies and spreads 
new technologies. Scholars defines NIS as “a system of interacting private and public 
firms, universities, and government agencies aiming at the production of science and 
technology within national borders” [52]. Metcalfe defines that a NIS is “a set of distinct 
institutions which jointly and individually contribute to the development and diffusion of 
new technologies and which provide the framework within which governments form and 
implement policies to influence the innovation process” [53]. These definitions show that 
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NIS is a social and dynamic system, characterized by positive feedback and reproduction. 
The processes of learning and innovation can be promoted by the elements of the 
Innovation System that reinforce each other, or conversely, that block such processes 
when they combine into constellations that are unfavorable [50].  
The Regional Innovation System (RIS) concept was evolved from the NIS concept. 
Krugman carried out some related research in regional innovation environments, 
innovation networks, and innovation clusters [54]. Other scholars further developed the 
RIS concept from the perspective of system evolution and regional innovative 
infrastructure [55] [56] [57]. Doloreux focused on the key elements in a RIS, where firms, 
institutions, knowledge structures and holistic innovation policies played important roles. 
He emphasizes three aspects of RIS, including interactive learning, milieu and 
embeddedness [58]. Several conceptual models have been developed for RIS, such as the 
triple helix model, which illustrates a top-down approach to the RIS focusing on the 
R&D functions of universities, public and private research institutes and corporations 
[59]. RIS is characterized by its regional features which can include a whole set of norms, 
attitudes, and routines that slowly evolve over time. These assets can make it difficult for 
actors from other regions to imitate similar practices, thereby protect the technological 
edge of the first mover region [60] [61]. Regional assets can have significant impacts on 
the innovation behaviors of actors within the region.  
Sectoral innovation system (SIS) is another concept evolved from the NIS origin. 
Breschi and Malerba defined it as “a system (group) of firms developing and making a 
sector’s products and generating and utilizing a sector’s technologies” [62]. Actors in SIS 
may share some specific knowledge areas, technologies, needs, and demand. The focus of 
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SIS lies on agents and firms, which put much emphasis on non-market interactions and 
on the processes of transformation of the system [63]. Malerba further suggested that the 
SIS framework has three major dimensions: knowledge and technological domain; actors 
and networks domain; and institutions domain [64]. SIS reveals the fact that different 
circumstances and conditions exist among various industrial sectors. For example, each 
sector operates under different technological regimes, which are characterized by 
particular combinations of opportunity and conditions, degrees of cumulativeness of 
technological knowledge and characteristics of the relevant knowledge base [65]. The 
research of SIS focuses on the relationships among firms through considering the impact 
of their surviving environment. The boundaries of SIS emerge from the specific 
conditions of each sector, by focusing on the sources of knowledge and on the role of the 
environment in the process of knowledge transmission [62]. 
Technological Innovation System is defined as “a network or networks of agents 
interacting in a specific technology area under a particular institutional infrastructure to 
generate, diffuse, and utilize technology”[66]. TIS consists of networks of firms, R&D 
infrastructure, educational institutions, and policy-making bodies [67]. In comparison to 
other innovation systems, the TIS approach focuses on specific technology areas. There 
can be many technological systems in a NIS, but the national borders do not necessarily 
form the boundaries of the system [65]. TIS may not necessarily be restricted within any 
sectoral branch. The national boundary may constitute a natural limit of technological 
systems, or it can further form regional or local subsystems. The boundaries of TIS 
depend on various circumstances including the technological and market requirements, 
the capabilities of various agents, and the degree of interdependence among agents [66]. 
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TIS are often used to analyze an emerging system rather than a mature system. As the 
systems evolve over time, the need for longitudinal studies is justified [65]. 
The innovation system includes three levels: macro perspective (NIS), meso 
perspective (RIS and SIS), and micro perspective (TIS). In order to achieve the desired 
performance of a system, it is necessary to understand the inner mechanism in the system, 
and it is also important to explore the outer dependencies among different systems. 
Technological innovation systems play important roles in developing a regional 
innovation environment, while the sectoral innovation networks and regional innovation 
systems can be embedded in the national innovation networks. Chung (2002) suggests 
that a regional innovation system is a good tool to generate an effective national 
innovation system, as it can effectively create different sectoral innovation systems in 
different regions [68]. The sectoral system experiences changes in a dynamic 
evolutionary process, which in turn affects many elements of the system. The TIS are the 
fundamental elements of various RIS and SIS, which in turn, are embedded in the NIS. 
From the perspective of a specific technology, TIS cut through both the geographical and 
the sectoral dimensions [44]. There are several different perspectives of studying 
innovation systems. Most commonly is to study the interdependency of different 
innovation systems within a country. Another approach is to compare innovation systems 
that are different from country to country, i.e. developed countries, developing countries, 
transitional economies, etc. Still another approach is to study relationships and 
interdependency of innovation systems among themselves. Owing to the differences in 
histories and traditions of different nations, and also in their size and development stage, 
the structure of national innovation systems differs substantially across the globe.  
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2.2.3 Globalization of Innovation Resources  
In the era of globalized competition, the speed of high tech development and the 
capability of sustained innovation are vital for enterprises' survival. The concept of NIS 
provided a metric to study actors sharing a common culture, history, language, social and 
political regime within the national boundaries [45]. However, the trend of globalization 
and economic liberalization brings new challenges to this limitation. The emergence of 
global synergic innovations is getting more prevalent and dispersive across the world. 
The question is whether geographic boundaries are still relevant or not in high tech 
innovation.  
Innovation systems were originally utilized to study the Western developed world. 
Since innovation has become the most influential factor for technological development 
and national competitiveness, the Western developed countries have made it a priority in 
policy-making. These countries have done so by creating and strengthening their NIS to 
promote technological and economic development [69]. The innovation system 
framework often links various national innovation resources (education, R&D institutes, 
and enterprises) to technological outputs (publications, patents, and new products). 
Fukuda (2008) argues that technology policy should generate innovation with a view to 
constructing co-evolution among heterogeneous players with different degrees of 
competitive advantage. Each player is required to recognize and develop its core 
competence through learning inspired by other players. The agility, adaptability, and 
alliance among heterogeneous players should be maintained and enhanced [4]. 
Innovation systems define the ecosystems of related entities, and ensure that potential 
innovation resources are effectively explored and utilized.  
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In recent years, an increasing number of geographically dispersed innovation 
networks have been formed between developing and developed countries. This is 
partially due to the expansion of multinationals from the developed countries. To fit the 
challenges of globalization, multinational companies are trying to utilize more dispersive 
innovation resources through establishing strategic alliances with companies from 
developing countries. For example, there are many types of international technology 
transfer activities such as original equipment manufacturers (OEMs), original design 
manufacturers (ODMs), electronics manufacturing service (EMS), and virtual 
organization (VO) [70]. Related studies indicate that the more progressive liberalization 
and deregulation of international trade and investment are, the more rapid the 
development and diffusion of technology will be, which will fundamentally change the 
global competitive dynamics in which MNCs operate [28]. Cooperative alliances have 
become an increasingly important part of the competitive landscape of multinationals 
[71]. It is a novel domain to deepen the research of systemic innovation based on 
matching foreign MNCs to SMEs and comprehend the pros and cons of global innovation 
networks. However, there are relatively few studies linking the innovation resources at 
both the macro and micro level to how an improvement could result in raising the mutual 
national Innovation Capacity [72].  
2.2.4 National Innovation Strategy  
Countries have different innovation strategies due to their differences in social, 
economic, and technological conditions. Here we explore national innovation strategies 
in developed countries and emerging economies respectively.  
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In 2010, the U.S. Federal government asked the National Research Council (NRC) 
of the National Academy of Sciences to review and analyze the S&T advancement 
strategies of six competing countries (Brazil, Russia, India, China, Japan, and Singapore) 
and to judge their likely impact on the U.S. at present and in the future. The result was 
published in a report titled “S&T Strategies of Six Countries: Implications for the United 
States.” The report argued that multiple factors affect the likelihood of achieving national 
S&T goals, including the coupling of socioeconomic and cultural drivers, the 
globalization of R&D, the opaqueness and the resulting unpredictability of programs, and 
simply countries’ available resources, priority setting and execution, disruptions, and so 
forth [73]. The report provides policy recommendations for the U.S. government based 
on the findings from other countries’ strategies. Key policy implications include: 1) 
Monitoring the transformation from a national to a global S&T innovation environment 
portends future prosperity and security for the United States and all countries; 2) The 
transfer of intellectual property by multinational corporations into domestic companies 
through S&T activities should be monitored in key countries, particularly India and 
China. The United States could join with Japan, and possibly the European Union, to 
establish a united front against such practices; 3) The U.S. should prepare for, and 
transform to a S&T innovation environment to include global exchanges in education and 
R&D talent, international as well as national recruitment of R&D talent, multinational 
corporate collaborations, and public policies that facilitate or restrain the leadership in 
global S&T innovation; 4) The U.S. should monitor a competing country’s capacity to 
facilitate the cultural changes needed to achieve its global S&T innovation environment, 
which is especially important for predicting future changes in the S&T innovation 
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environment; 5) Attracting quality researchers and providing research facilities and 
research support as important measures for the world’s S&T talents; 6) Continue to gauge 
the efficiency of research, measured by the effective uses of research talent and research 
facilities, which portends the future of a county’s innovation environment; and 7) 
Seeking mechanisms for sustainable U.S. government collaboration with the international 
community to uncover and exploit potential S&T breakthroughs [73]. 
From the perspective of emerging BRIC countries, scholars have also suggested 
various innovation strategies. Yang and Shu (2005) defined three types of innovation 
activities in China: indigenous innovation, imitative innovation, and cooperative 
innovation [74]. The concept of indigenous innovation stresses focus on the system's 
(country, industry or company) predominant core technologies and core products to 
improve its competitive ability [75, 76]. Imitative innovation refers to the adaptation 
based on the advanced innovators’ technology, driven by the influences of the leading 
innovators’ demonstration and interest mechanisms [74]. Cheng and Shiu (2008) defined 
comparable concept of re-innovation as “It is the part of new product development which 
studies the extension of existing innovations, which can only happen after the first 
generation of a new product is launched” [77]. Re-innovation is renowned for its 
potential in creating competitive advantage with reduced cost and time implications. A 
Japanese scholar suggests that imitation by lagging countries can contribute to the world 
welfare by making it possible for them to learn the latest technology and to become next-
round innovators [78]. Cooperative innovation is a strategy to implement innovative 
activities with foreign alliances and is dependent on the mutual or multi-facet cooperation 
among enterprises, research institutes, and universities. The premise of cooperative 
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innovation is that each side shares the common achievements and develops all together. 
Accordingly, enterprises with competitive relations and conflicting interest can work 
hand in hand to gain profits and development momentum [74]. Active cooperation 
between firms can enable them to achieve outcomes that they could not achieve on their 
own, while allowing each individual partner enterprise to realize its own strategic goals 
[79].  
An important reason for indigenous innovation is forced by the fact that some 
developed countries restricted high tech exports to emerging economies including China 
[80] [81]. Moreover, in some high-tech industries such as biopharmaceuticals, China 
needs to pay high prices importing foreign products, and this has led the government to 
develop indigenous technologies. As the latecomer approaches the technological frontier, 
so its strategies will shift from imitation to innovation [82]. This has been the case for 
many of the Asian countries. A common question is: Is it likely to stay stuck in catch-up 
mode as a perpetual imitator, or can it build its absorptive capacity to the point that it can 
sustain genuine innovation [83]? Indigenous innovation is a strategy with bright prospect 
for China, but the real question is how to balance it with other innovation strategies [84], 
i.e., imitative innovation and collaborative innovation, to build up the innovation capacity 
more efficiently and effectively. Fu and Gong (2011) suggested a “two-leg forward 
strategy” to maximize the benefits from existing knowledge and accelerate the catch-up 
process, where both indigenous innovation and acquisition of foreign knowledge are 
needed, but with the optimal mixture differing among sectors and stages of development. 
An effective technology policy package may thus be country-, region- and industry-
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specific, but well-focused policies to foster the absorptive capacity and innovation 
capabilities of indigenous firms are always crucial for success [25]. 
2.2.5 Challenges of Innovation Governance in Emerging Economies 
Following the global trend of innovation, emerging economies such as the BRICs are 
investing more resources to develop their innovation capability. However, the large 
majority of available studies ignore the fact that the characteristics of technological 
change of industrializing economies are largely shaped from the outside realms of foreign 
institutions in industrialized countries [85].  
A major challenge for governments is how to construct effective and efficient 
innovation infrastructure. In many aspects, the BRIC countries, due to their stage of 
development, have essentially different innovation infrastructures when compared with 
the advanced economies. There is little evidence that current frameworks of innovation 
research in developed nations are also workable for countries like the BRICs. Viotti [85] 
found that that the NIS theoretical and conceptual framework is not appropriate for 
dealing with the processes of technological change of industrializing economies, which 
are extremely different from those of industrialized countries. Emerging economies have 
very different environmental contexts and changing agents. Transition from the 
traditional institutions towards the innovation model of growth involves formation of 
better mechanisms for social development based on the balancing of new innovation 
resources [86]. To such an extent, the construction of an effective and robust innovation 
structure is extremely necessary. This calls for the need of leveraging and prioritizing 
various input resources that buildup the innovation capability of the country. Thus 
36 
concentrating resources in the areas where the host country’s competitive advantages can 
be achieved helps to boost innovation, which is a key factor that determines the 
competitive status of the national economy [87]. 
The inclusion of domestic S&T networks into the global systems of innovation also 
brings up new challenges. National innovation strategies should be designed and selected 
according to the developmental context of the host country. Technological innovation is a 
contextual process whose relevance should be assessed depending on the socio-economic 
condition it is embedded in [88]. It is a difficult task for transitional economies due to the 
legacy of inefficient or weaker innovation systems. Sectoral differences also bring 
challenges in policy making. For example, the private sector dominates biotechnology 
research in industrialized countries, but there are major market failures in developing 
countries [89]. The innovation system approach needs to be adapted to the situation in 
developing countries if it is to be allied to capacity building. Analytical efforts to better 
understand how more complete innovation and competence building mechanisms may be 
constructed in the present environment of global competition and networking need to be 
made [46]. The Global Innovation Index called for the necessity of national innovation 
strategy, but it did not propose a central operating model for widespread implementation 
issues [90]. This dissertation will probe into the background, rationale, and impacts of 
technology policy. Based on such findings, a research framework and methodology are 
developed for policy decision making. 
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2.3 Technology Foresight 
This section attempts to review technology foresight from the perspective of 
innovation systems and globalization. It includes several important aspects of technology 
foresight studies: evolution, policy impact, and implementation issues. Special emphasis 
will look into recent foresight activities in the BRIC countries. Martin (1995) defines 
technology foresight as “the process involved in systematically attempting to look into 
the longer-term future of science, technology, the economy, and society with the aim of 
identifying the areas of strategic research and the emerging generic technologies likely to 
yield the greatest economic and social benefits” [91]. This concept and rationale are 
compliant with the policy needs to deal with the increasingly globalized science & 
technology development.  
2.3.1 Foresight Initiatives in Developed Countries 
Nowadays, technology foresight has been adopted on a large scale across the world. 
However, most available foresight studies are shaped by the practices and methodologies 
from the developed countries, especially Japan and the United States. Nevertheless, the 
two countries have totally different attitude toward government-lead foresight activities. 
Japan is the most enthusiastic country in carrying out national technology foresight 
studies, but the United States does not have such large-scale foresight activities at the 
national level.  
Major themes for technology foresight in the United States have been examined in 
the literature: strong contribution to foresight methodology development, important 
narrowly focused foresight efforts in some federal agencies, and no holistic national 
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foresight studies [92]. Firstly, most of the widely applied foresight methodologies were 
developed by US researchers. These tools include: the Delphi methods, scenario planning, 
Analytic Hierarchical Process (AHP), technology roadmapping, technology assessment, 
and impact assessment. Secondly, some decentralized foresight studies have been 
undertaken at the sectoral levels. These foresight initiatives have been lead by agencies 
such as the US Environmental Protection Agency, the Department of Defense, and the 
Department of Energy. Thirdly, although there have been some foresight-like efforts in 
identifying critical technologies during the 1990s [93], there are so far no comprehensive 
national level foresight studies in the United States, and it is unlikely there will be any in 
the near future. There is no growing interest for national foresight from the Federal 
government. The United States relies more on the market mechanism to establish 
priorities and allocate resources [92]. 
National technology foresight studies in Japan are typically based on large-scale 
Delphi surveys addressed to experts in a wide range of fields. The foresight studies have 
been repeated approximately every five years since 1971. During this long time span, the 
scope of work and the range of methods applied have also expanded [94]. The first 
Delphi study took three rounds, but the Delphi studies of following years only took two 
rounds. The fifth, sixth, and seventh surveys started to address socio-economic needs 
regarding Japan’s future. The eighth Delphi Survey was conducted in 2004. It addressed 
a 30-year period from 2006 to 2035. Although the study was still based on Delphi, some 
other methods were added for improvement. These new tools include: Bibliometrics, 
Scenario analysis, Socio-economic needs analysis, cluster analysis, and AHP. The eighth 
survey consisted of 13 fields, 130 areas, 858 topics, and about 2300 participant experts, 
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most of which are researchers, engineers, public and business executives [95]. Some key 
questions include: the importance of technology, time of realization, leading countries, 
and necessity of government measures. As a country with extremely scarce resources, 
Japan continued its foresight activity for forty years and observed that it was an effective 
tool for future development [94]. Although the Delphi methodology was imported from 
the United States, it has been adapted and improved to suit Japan’s circumstances. 
Technology foresight is useful in setting stable framework conditions for technology 
development and improving engagement with policy-making in Japan [94].  
2.3.2 Generations of Technology Foresight  
The evolution of foresight activities has been significant since the 1990s. It was 
applied to various environmental settings which included the organizational, industrial, 
regional, national, or supranational level. Foresight scopes covered everything from 
limited technical experiments to major government initiatives. The timescale of foresight 
ranges from the immediate future to the far horizon. The range of actors involved, the 
process and methods used, and even the status of the activity varies considerably [96].  
Scholars developed diverse foresight models to reflect the increasing changes. 
Johnston proposed five stages in the chronology of foresight, with technology forecasting 
and futurism leading to technology foresight, from which emerged foresight, with its 
wider understanding of the economic and social processes that shape technology [97, 98]. 
The author explored the strong progression within foresight studies towards being 
embedded within and directed towards planning and decision-making processes at 
various levels. Georghiou progressively posited a generational model of foresight in the 
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last few years (Figure 6) [99-101]. The development of the generation models has 
witnessed the fast evolution of foresight studies to match with the research of innovation. 
For the first generation foresight the key issues are accuracy of prediction and diffusion 
of technologies. In the second generation the take-up of priorities and connections of both 
industrial and academic participants become key issues, while the third generation 
implies the involvement of more stakeholders and looks for broader social concerns [96]. 
The fourth generation foresight moves into the distributed roles in innovation systems. To 
certain extent, the fifth generation will further touch on the complex policy issues of 
globalized innovation systems.  
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Figure 6: Generations of Technology Foresight 
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2.3.3 Technology Foresight and Innovation 
Martin and Johnston first argued that technology foresight wires up and strengthens 
the connections within the national innovation system so that knowledge can flow more 
freely among the constituent actors, and the system as a whole can become more 
effective at learning and innovating [102]. Technology foresight exercise can be applied 
at organizational, industrial, regional, and national levels. From a similar perspective, 
comparable research on innovation systems also has a multilevel structure. Four major 
types of innovation systems are studied in the literature, including National Innovation 
Systems (NIS), Regional Innovation Systems (RIS), Sectoral Innovation Systems (SIS), 
and Technological Innovation Systems (TIS). These innovation systems can be classified 
into three levels: macro perspective (NIS), meso perspective (RIS and SIS), and micro 
perspective (TIS). These innovation systems often link various national innovation 
resources (universities, R&D institutes, and enterprises) toward technological outputs 
(publications, patents, and new products). Figure 7 shows the connections between 
technology foresight and innovation systems. 
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Figure 7: Connections between Technology Foresight and Innovation Systems 
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Technology foresight and innovation system research should be closely integrated so 
as to get a comprehensive understanding of emerging technologies and their social 
impacts. Foresight should be used to build up the new social structures, especially in the 
context of the more distributed and open innovation systems [96]. When governments 
carry out technology foresight, they should consider the broader influences from social, 
economic, and technological development. Related framework conditions have to be 
evaluated: the engagement of industry, the regulations, public support, the R&D 
infrastructure, the availability of personnel, etc. [103]. Both foreign and domestic 
technology development trends should be considered. Various types of technologies 
should also be distinguished, which include: core technology, key technology, and 
generic technology. Equilibrium should be achieved for long-term technology 
development and planning.  
Technology foresight activities should adapt to the changes brought by globalization 
of innovation resources. Environmental differences stem from country specific 
characteristics such as policy risk, financial instability, and market fluctuations. Countries 
of different sizes and capacities have different positions in the global innovation networks. 
The necessity for international cooperation is very different in some countries. For 
example, Germany has an open S&T system with exchanges of knowledge to and from 
the neighbor countries, as it is a member country of the European Union benefitting from 
joint R&D ventures within Europe. On the other hand, Japan’s S&T system is 
traditionally isolated, and not engaged in close joint R&D with other countries [103]. In 
the era of globalization and internationalization, the speed of technology development 
and innovation is vital for survival. By using national boundaries, actors sharing a 
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common culture, history, language, social and political institutions are identified [45]. 
However, science and technology systems, such as innovation systems, are becoming 
more integrated across national boundaries, raising questions about how an individual 
country can best benefit from the changing situations [102]. The speed of globally 
synergic innovation has been accelerated by economic liberalization. The geographic 
locations of global innovation cradles are getting more dispersive than ever before. These 
issues have raised new topics in the research of technology foresight.  
2.3.4 Technology Foresight in Emerging Economies 
National foresight studies are expanding from the industrialized economies to the 
developing countries in recent years. However, foresight activities and related social 
impacts in emerging economies have not been studied much in the literature, especially 
as a group of countries with similar characteristics. A common feature in these countries 
is the proliferation of new institutions and innovation systems resulting from transitional 
economies. This section will focus on the characteristics of national technology foresight 
activities in the BRICs, exploring the roles of foresight in technology development. 
Common problems and challenges will be discussed.  
2.3.4.1 Foresight in Brazil 
Although many Western techniques have been adopted in Brazil’s foresight studies, 
heavy economic and political instability of the 1980s (energy shock and recession) led to 
seriously faulty (extrapolative) forecasts [104]. Some Brazilian scholars argued that the 
synergy between Competitive Intelligence, Knowledge Management and Technological 
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Foresight should be regarded as a new mechanism to support decision-making for 
sustainable development and innovation [105, 106]. Many recent Brazilian foresight 
programs have been criticized as follows:  
1) The approaches by no means guarantee that the outcomes are easy to be 
implemented [107].  
2) There was no real evidences of the proper use of foresight results, and some 
programs were discontinued without apparent reasons [108].  
3) It is difficult to translate foresight findings into policy recommendations with a 
long-term vision. There are suggestions that a more systemic view should have been 
preferred in Brazil’s foresight research [109]. 
Globalization-related impacts impose the need for implementing new strategies in 
the industrial and technological sectors of Brazil [110]. Foresight practices in Brazil not 
only need to emphasize issues about catching up with advanced countries, but they also 
need to consider issues about competing against emerging economies with similar 
conditions. This pattern has been demonstrated in some recent Brazilian foresight studies 
[106]. In an increasingly globalized context, the Brazilian market was opened to foreign 
competition, placing more emphasis on technological innovation, quality, and 
competition. However, among the many actions and issues with which Brazil needs to 
deal is how to take advantage of its unique local assets that can provide competitive 
advantages in the global environment [111]. Despite being the world’s eighth largest 
economy, Brazil’s innovative capability is still unsatisfactory. This gap between the 
generation of science and innovation is also typical of other emergent countries [112]. 
The country needs to construct a more efficient national innovation system with an 
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operating structure integrated with the global innovation networks. Technology foresight 
should play a more important role in such a process. However, as shown in the literature, 
Brazilian foresight studies experienced difficulties in implementing the foresight results 
or providing policy recommendations. This should be an area for future improvement.  
2.3.4.2 Foresight in Russia 
Foresight studies of the Russia Federation have features of a catching up economy. 
Russian scholars raised the question regarding whether Russia will develop catching-up 
with modernization or whether it will invent its own approach for exploring the future 
[113]. The selection of critical technologies in Russia should meet several criteria: 
Competitiveness, Contribution to economic growth, and overcoming dependence on 
imports [87]. Russia’s development relies heavily on the exploitation of natural resources 
and raw materials, including energy, agriculture, and natural mineral processing. 
Although a leader in some high-tech areas, Russia still lags behind the major developed 
countries. Globalization provides Russia new opportunities in technological 
collaborations with advanced countries. How to strengthen the global competitive 
advantages of Russia is an important aspect in Russia’s policy making. Foresight reports 
state that the transition of Russia’s economics to innovation development is impossible 
without the formation of a globally competitive national innovation system and the 
creation of legal, financial and social institutions that would ensure interactions among 
the education, science, and business enterprise [86]. Although Russia has most of the 
elements in its National Innovation System, they are neither efficient nor are they 
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optimized to foster innovation [114]. The Russian foresight agenda for the future should 
include the construction of an integrated national innovation system [115]. 
The “Concept for Long-Term Russian S&T Forecast till 2025” program was 
developed in association with key ministries, science and business representatives in 
2007. The main recommendations made to policy-makers were to develop measures to 
support spin-offs and start-ups, research teams and institutes, as well as training and 
education [116]. Among all the leading countries, Russia only leads in about 10% of the 
technology topics. The United States leads in more than 50% of all technology topics, 
followed by European Union and Japan, each with more than 30%. The results are 
comparable with Russia’s innovation statistics in the last few years. As shown in Table 2 
[117], only about 10% of Russian innovations are really new worldwide (in principle). It 
also means that about 90% of Russia’s developed technologies already exist in other 
countries.  
 
Year Total 
Including 
Ratio 
New for country New in principle 
2000 688 569 72 12.7% 
2001 637 543 44 8.1% 
2002 727 606 70 11.6% 
2003 821 582 56 9.6% 
2004 676 569 52 9.1% 
2005 637 538 60 11.2% 
2006 735 642 52 8.1% 
Average 703 578 58 10.0% 
Table 2: New Technologies Developed in Russia 
Source: Eliseeva (2010) 
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2.3.4.3 Foresight in India 
The only national foresight program implemented in India is the Technology Vision 
2020 foresight program between 1993 and 1996. Although the program was completed 
more than 15 years ago, no such national level foresight study with comparable scale has 
been conducted since then. There are some follow-up projects taking place independently, 
including some regional or sectoral practices, but only in limited scale. The program 
results highlighted the fact that appropriateness of technology should be the guiding 
principle in India. It should be noted that what could be a critical technology for India 
may not be so for other developed countries such as the U.S. [118]. The technology needs 
of India ranged from strategic emerging technologies to rural development related 
technologies, all of which should be cost effective to match the domestic socio-economic 
needs [119]. The Home Grown Technology (HGT) program is an approach of the 
government to support the development of technologies by indigenous actors. The 
program supported 77 HGT projects, but was formally closed in the year 2005. Analysis 
of the programs reveals some shortcomings [120]: lack of funding for large projects, 
inadequate scale of operation, poor assessment of technology operations, lack of 
technically skilled manpower, and technology shifts which led to low market potential.  
The theme of technology programs in India has strong characteristics of catching-up 
toward the developed countries. This conforms with government’s goal which aims at 
increasing technological competitiveness and self-reliance, especially in high-tech areas 
[121]. India has suffered from the technology-control regimes of advanced nations. 
Developing indigenous capabilities for self-reliance in critical technology areas where 
denials of technology transfers by advanced countries are India’s strategic priorities [122]. 
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However, developing indigenous technologies may encounter enormous difficulties if the 
domestic innovative capacities are not ready or cannot provide enough support for 
innovation. Therefore, the country’s innovation infrastructure will need to be crafted with 
due foresight and careful planning. With a new context of globalization and inter-
dependence, an integrated approach to strategic technology planning will be essential to 
developing the requisite capabilities for the future [122]. This calls for a new generation 
of technology foresight in India. 
2.3.4.4 Foresight in China 
The technology foresight concept was introduced into China in the 1990s, but there 
was no formal foresight initiative in China until 2001, when two regional foresight 
studies were initiated in Beijing and Shanghai respectively. The Technology Foresight 
Towards 2020 program was a national-level practice led by the Chinese Academy of 
Sciences (CAS) from 2003 to 2006. The research consisted of two stages, and each stage 
covered 4 different high-tech fields [123]. A total of 8 fields, 62 sub-fields, and 737 
technology topics were studied. The foresight methodology was based on expert panels, 
scenario analysis, and the Delphi method. Scenarios were designed for achieving a broad-
based medium-level wealth society. Expert panel meetings played an important role in 
the selection of technology topics. During the Delphi survey, more than 1500 experts 
from selected areas responded to the questionnaires [124]. The methodologies of 
technology foresight in China are based on adapting practices from developed countries, 
including Japan, Germany, UK, and Korea. The foresight results showed that resource 
allocation is the most important issue to be faced by the government. The findings 
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highlight some potential improvement areas for policy-makers. For instance, under the 
criteria “Difficulty of Realization”, the results reveal some constraints on the technology 
development: 1) regulation, policy, and standards, 2) human resources, 3) research 
funding, and 4) basic research infrastructure, etc.  
There are some interesting investigations in the survey about China’s current 
technological level compared with leading countries. When comparing the 483 
technology topics with advanced countries, China is leading in only one topic, which is 
the “Chinese character & information processing technology.” Since Western developed 
countries do not use Chinese characters, it is obvious that China can become the absolute 
leader in this field. For other high-tech areas, China has 20 technologies (less than 5%) 
on a par with international leading standards. Most technology fields (more than 90%) are 
lagging behind for 5 years or more (Table 3) [125]. 
 
Technology Fields 
China 
Leading 
China on a par 
with Leader 
China Lagging 
5 Years 
China Lagging 
6-10 Years 
Information and 
communications 
1 5 66 3 
Biotech and life science 0 7 76 0 
New materials 0 6 49 9 
Energy 0 2 81 0 
Resources and environment 0 0 99 1 
Advanced manufacturing 0 0 52 26 
Total 1 20 423 39 
Table 3: China’s Technological Level Compared with Other Countries 
Source: MOST (2004) 
 
 
Foresight revealed that China’s technology level is lagging behind advanced 
Western countries. Table 4 shows the results of technology leading countries [123]. The 
USA leads in all technology fields, followed by Japan and the European Union. Russia 
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ranked fourth, and other countries are barely perceived as technology leaders. One 
exception is South Africa, which leads in the energy sector for a certain type of coal and 
petroleum processing technology.  
  
Field 
No. of 
Topics 
USA Japan EU Russia Others 
1st 2nd 1st 2nd 1st 2nd 1st 2nd 1st 2nd 
Information, 
Communications and 
Electronics 
150 150 0 1 97 0 56 0 0 0 0 
Energy Technology 72 50 17 5 17 15 38 2 1 1 0 
Materials S&T 86 73 11 12 68 2 6 0 1 0 0 
Bio-tech & Medicine 101 94 7 6 23 1 74 0 0 0 0 
Advanced 
Manufacturing 
90 79 10 8 48 4 34 0 0 0 0 
Resources & 
Environment 
82 64 13 7 17 14 52 1 2 0 0 
Chemistry & 
Chemical Tech 
78 72 4 4 24 3 51 0 0 0 0 
Space Technology 78 76 2 0 0 0 50 2 26 0 0 
Total 737 658 64 43 294 39 361 5 30 1 0 
Table 4: Technology Leading Countries 
Source: CAS (2006)  
2.3.5 Common Challenges of Foresight in Emerging Economies 
Catching-up is the main theme of technology development in emerging economies. 
As we can see from the above comparative analysis, technology levels in BRIC are 
generally lagging behind world leading standards. Therefore, identifying critical 
technology areas that are suitable for leapfrogging is a primary concern. Since these 
countries differ in terms of historic evolution, economic development, technology 
capacity, and other social factors, technology foresight activities have to consider local 
needs, capabilities, and social differences. For example, an Indian scholar argued that 
critical technologies in India may not be that critical for the United States [118]. 
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Appropriate technologies suitable for breakthrough development should be selected and 
prioritized accordingly. Since no country, however rich, can afford to pursue all the 
possible opportunities in science and technology, there needs to be better mechanisms for 
choosing between competing alternatives and resources [102]. They should focus on 
areas where comparative advantage can be achieved through technology leapfrogging. 
New models and approaches should be developed to identify and take advantage of 
opportunity windows, and to underpin areas of strategic research likely to yield the 
greatest economic and social benefits.  
Another common challenge is how to transfer foresight results into effective policy 
measures and implementation strategies. The BRIC countries faced the problem of how 
to implement the technology topics identified in their foresight studies. There is evidence 
that in many emerging economies, after carrying out their foresight studies, the 
implementation of technologies was disappointing because little effort was dedicated 
toward strategic innovation management. One important reason for BRIC to rely more on 
independent innovation is forced by political reasons that major developed countries have 
strict export control of high technologies. The implication is that successful foresight 
must include understanding of the interaction of foresight outputs with the strategic 
behavior of policy and economic actors [126]. Globalization of innovation resources has 
increasingly changed the culture of technology development as well as the strategic 
behavior of the implementing bodies. The foresight programs have to cover both the 
technology status in the world and in host country. Brazilian scholars have used the term 
“gloCalization” to describe the strategy of “think globally, act locally” [105]. This idea 
perfectly matches the goal of technology development today. Latecomer countries should 
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try to avoid “reinventing the wheel” or remaking the mistakes of advanced countries. 
This may be achieved by learning through foreign experience, and adapting to its own 
situation but not by just following. Therefore, the decision on innovation strategy is an 
extremely important topic in an increasingly globalized innovation environment.  
2.4 Technology Policy 
It is technology that builds the core competence of nations. High technology has 
become the key factor in promoting regional economies and realizing sustainable 
development. Strengthening technology competitiveness and enhancing innovative 
capability have been the principal objectives for all countries. Government interventions 
in technology development are very common worldwide nowadays. Technology policy 
has the goal of making the best use of technology to achieve the national goals of 
improved quality of life for all citizens, continued competitive economic growth, and 
national security [127]. Through their responsibilities for social welfare and economic 
development, governments have profoundly shaped the nature of innovation within and 
across countries. They especially look to innovation in response to the great challenges of 
the age — in energy, health, and the environment [128]. Based on findings from the 
literature, this section discusses the political issues and feasible pathways for a 
government to enact technological policies and for industries to foster innovation. 
Different framework conditions between developed and developing countries have made 
the topic more complicated to study. Here we examine government policy related to high-
tech industries from the perspectives of both. 
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2.4.1 Technology Policy in Industrialized Countries  
Governments of developed countries are increasingly concerned with the impact of 
technology on their international competitiveness. The United States and other Western 
countries are attempting to develop effective technology policies that are in tune with 
global market realities [129]. Even though developed countries are in the frontier of 
technology development, they worry greatly about technological competitiveness, and 
how to maintain their competitive lead over other countries [3]. The United States now 
faces more challenges from technology competitors around the world. The agencies of 
the Federal government have conducted series of studies on how to strengthen national 
S&T competitiveness [3]. Most developed countries invest huge amount of capital in 
R&D to maintain their technological competitive edge. The U.S. introduced the 
American Competitiveness Initiative (ACI) in 2006, a major policy initiative to ensure 
that the United States continues to be the world's leader in S&T [130]. The ACI plans to 
commit $50 billion to increase funding for R&D and $86 billion for R&D tax incentives 
in ten years [131]. The target areas for these investments are high-tech industries that are 
important to the U.S. economy. In the past two decades, America's research-intensive 
industries: aerospace, chemicals, pharmaceuticals, communications equipment, 
computers and office equipment, scientific instruments, semiconductors, and software 
have been growing at about twice the rate of the economy as a whole [132]. The 
government’s support aims to sustain these achievements through continuous innovation 
at the technology frontiers. 
Technology policy in developed countries focuses on providing various supports for 
innovations. Through technology and innovation policy, the government can guide the 
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industry moving it in a preferred direction that caters to social and economic interests. 
However, market failures have been noticed by economists and politicians in some high 
tech industries [133]. For instance, President Obama’s innovation strategy report (2009) 
has highlighted the priorities in technology policy as follows: “There are certain sectors 
of exceptional national importance where the market is unlikely to produce the desirable 
outcomes on its own. These include developing alternative energy sources, reducing costs 
and improving lives with health IT, and manufacturing advanced vehicles. In these 
industries where markets may fail on their own, government can be part of the solution” 
[134]. In fact, many high-tech sectors need heavy investment and have long development 
cycles that cannot be supported merely by the market mechanism. Examples of such 
sectors can include: aerospace, defense, healthcare, energy, and environmental protection. 
Private companies may not be able to afford long-term R&D investment for 10 to 20 
years, or even longer periods. Only the government can guide and subsidize such projects 
for decent paybacks in the long run. Long-term R&D is an engine for sustainable growth, 
thus it is important for governmental policy to provide more support for private 
companies that conduct “challenging” or “future-business oriented” R&D activities [135].  
2.4.2 Technology Export Control  
Uneven development is a common phenomenon of the world economy, and the 
technology gap is vast among different countries. Not only do countries invest heavily to 
develop new technologies, but they also apply various measures to protect their high-tech 
competitive edge. The transfers of technology, including technology exports and imports, 
have to strictly conform to a government’s regulations. Different countries have issued 
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numerous legal terms and regulations regarding cross-border technical transactions. 
These regulations are updated frequently to strengthen a government’s control of 
international technology transactions. Many technology exporting countries, especially 
Western developed countries, have strict limits on high-tech exports to foreign countries 
to prevent technology leakage which may potentially damage national competitiveness 
and other interests.  
The United States has very strict and systematic control of technology exports. The 
Export Administration Act (EAA) and Export Administration Regulations (EAR) build 
the foundation of America’s legislation on commodity and technology exports [136]. 
Although it expired in 1989, the EAA is still in effect through the President’s powers 
under the International Emergency Economic Powers Act (IEEPA). According to these 
regulations, technology exports must be approved by the federal government through 
licensing. The licenses are divided into General License and Validated License. The later 
has more restrictions that will take longer to process. The Department of Commerce 
maintains a Commodity Control List [137], which includes all sensitive commodity or 
technologies that need special censorship. This list of sensitive exports includes 
telecommunications and advanced electronic equipment, precision machine tools, 
guidance technology, aerospace and jet engine technology, synthetic materials, 
specialized manufacturing and testing equipment, and so forth [138]. The list contents are 
frequently updated by the federal government to include newly developed technologies. 
Another important aspect is the destination or end user of the export. Foreign countries 
except Canada are divided into seven categories: Z, S, Y, W, Q, T, and V. Each category 
represents different controls on exports. For example, countries belonging to Z category 
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are under a complete embargo. According to various regulations, the United States has 
restricted technology transfer to China in many high-tech areas, including information 
and communications technologies (ICT), shipbuilding, aviation, space & satellite, and 
nuclear power [16]. Moreover, the American Congress passed the Exon-Florio 
Amendment (EFA) to the 1988 Omnibus Trade and Competitiveness Act [139]. EFA 
aimed to prohibit any foreign acquisition, merger, or takeover that might impair U.S. 
national security. It is certain that the concept of national security includes both 
traditional foreign policy criteria and defense issues. However, it is controversial whether 
economic considerations should be included. Indeed, there are inherent links among 
national security, industrial security, free trade, and the free flow of capital across borders. 
From the applications of EFA in recent years, it can be inferred that the term “national 
security” be interpreted broadly to include economic considerations. Many cross-border 
economic and technological activities are restricted by these regulations [140]. 
2.4.3 Technology Policy in Emerging Economies  
While the developed nations try to maintain their technology advantage by 
tightening export control measures, many industrializing countries are trying to improve 
technological competitiveness and innovative capability [6]. Examples of these countries 
include China, India, and Brazil. The trend of globalization has significantly improved 
the condition for these latecomers’ catching-up process. Innovation resources are 
allocated more diversely around the world. New learning channels are now available for 
the emerging economies. Technological innovation can be a high risk and expensive 
economic investment, but the risk and cost of learning from available technologies are far 
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below that of innovation. Many industrializing countries develop policies to attract FDI 
and encourage transfer of advanced technologies from abroad. These measures include: 
investment grants, taxes incentives, reduced tariffs, export subsidy, education and 
training. These are attractive terms for MNCs to introduce new technologies into 
latecomer countries. 
Rapid development and intense competition of high technology have pushed 
emerging economies to develop more effective policies. Major policy considerations 
include national security, economic growth, social improvement, and foreign affairs. The 
success of the East Asian Tigers brought attention to the fact that most newly 
industrialized countries had been very interventionist during their early development 
stages. Examples of such countries include Japan, South Korea, and Taiwan. Their 
governments had enacted many regulations in trade, FDI, technology transfer and 
domestic resource allocation [133]. These policies often aimed at improving local 
competency and weakening the reliance on foreign technologies or products. Many 
countries require FDI in the form of joint ventures rather than wholly owned subsidiaries 
of MNCs. In countries like Japan and South Korea, during their developing stages, when 
policy gave priority to technology acquisition, MNCs were prohibited from establishing 
wholly owned subsidiaries [141, 142]. Since FDI can either foster or restrain the 
development of domestic industries, it is the government’s role to balance the interests of 
both local and foreign stakeholders and thus guide and regulate investment. In order to 
make diffusion and spillover happen, technology policy in host countries should try to 
improve absorptive capability and innovative capacity.  
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The concept of technology leapfrogging was brought forward from the research of 
East Asia’s miracle, especially from the experience of Japan and South Korea [143, 144]. 
Hobday (1994) argued that a developing country may leapfrog some steps and catch up to 
a developed country directly, bypassing huge investments in technological accumulation 
[145]. Path dependency in technology development can assist latecomers to achieve 
technology leapfrogging. The rapid development of new technologies also provided 
emerging economies with “windows of opportunities” to realize the latecomer advantage. 
The premise is that not only do they need to accumulate enough technology capabilities, 
but they also need to select the right technological direction that fits into the global 
innovation networks. Most of the windows of opportunity will emerge in high technology 
fields such as nanotechnology, biotechnology, and information technology. However, 
each of these fields consists of different areas, and adopting a single technology policy is 
not optimal for all. Accordingly, countries should carefully adopt a set of technology 
policies so that each policy is aimed at addressing the specific requirements of a specific 
high-tech category [146]. Technology development can be viewed as a vibrant process 
where innovations are driven by investment, market, and policies. Since the government 
has the control of resources, it can provide support to guide development in key 
technology areas. Macro policies can also impact on the efficiency of innovation systems. 
The best use of policy instruments can protect the interests of stakeholders, and promote 
their innovation activities.  
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2.4.4 Policy Instruments for Innovation 
The search for effective policy instruments to foster innovation has long been a task 
for decision makers and researchers in technology management. Here we review the 
major types of policy tools. These research findings will provide the foundations for 
future result analysis and recommendations in policy making.  
Innovation policies have been studied from different perspectives, and scholars have 
established categories that include: direct funding, indirect support, and information and 
learning [147]. As presented in Table 5 [147], the 3 major areas include 15 policy tools. 
Firstly, the direct funding part is primarily to identify appropriate actors in the innovation 
system, and provide them with R&D contracts or funding. Secondly, the indirect support 
part provides the innovators with more benefits in terms of credits and services. Thirdly, 
the information and learning part emphasizes the general industrial support measures. In 
addition to these three major aspects, the author also mentioned that macro conditions 
may influence innovation. These factors are commonly categorized into framework 
conditions.  
Through studying policy practices applied in 25 member countries of the EU, Reid 
and Peter (2008) explored the sectoral differences of innovation policies [148]. The 
authors gathered hundreds of innovation-related policy measures from 11 different 
sectors. There are clearly sectors with an above average number of innovation policy 
measures such as biotechnology (129), ICT (128), and energy (117). Some other sectors 
have fewer measures, such as machinery (94) and textiles (96). An implication from this 
study is that each sector has a different innovation structure and patterns. Most of these 
policy instruments are geared to support various actors in each specific sector.  
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Categories Policy tools  
Direct Funding 
 R&D contracts with private firms  
 R&D contracts and grants with universities.  
 Intramural R&D conducted in government laboratories.  
 R&D contracts with consortia that include two or more actors. 
Indirect Support 
 Patent protection.  
 R&D tax credits.  
 Tax credits or production subsidies for firms bringing new 
technologies to market.  
 Tax credits or rebates for purchasers of new technologies.  
 Government procurement.  
 Demonstration projects.  
Information and 
Learning  
 Education and training  
 Codification and diffusion of technical knowledge  
 Technical standards-setting. 
 Technology and/or industrial extension services.  
 Publicity, persuasion, consumer information 
Table 5: Policies for Innovation 
Source: Reid and Peter (2008)  
 
 
As governments’ goals and expectations toward technological innovation may vary 
from country to country and from sector to sector, different sets of policy tools or 
instruments will be developed to support various actors. It is understandable that each 
country has a unique framework context due to social, economic, and technological 
differences. These variations should be considered when developing innovation policies. 
Since this model will take China as a case study, framework conditions or limitations in 
China will be discussed in later chapter sections. 
2.4.5 Implications for Priority Setting on Technology Policy 
The necessity of priority setting in technology policy design cannot be 
overemphasized. The rapid development of high technology has made stable technology 
policy a difficult task in every country. The ever changing environment of world politics 
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and economies has further complicated the uncertainties in policy-making. Like many 
other public policy measures in society, technology policy is selective in nature. It is not 
uncommon that various funding and benefits are given to inappropriate innovators that 
cannot meet the government’s original plan as they were expected. Therefore, it is 
necessary to study the causal factors and intrinsic relationship of policy issues involved. 
Scholars define national technology strategy as a portfolio of desired related technology 
areas that receive governmental supports in the form of specialized goals for each branch 
of technology. This strategy assigns well-defined tasks and responsibilities to the 
pertinent innovators that are responsible for implementing the goals for each technology 
areas [146]. The authors argue that prioritization should be emphasized in the policy-
making process. Technology policy has the goal of directing technology development and 
innovation through leveraging limited resources. In both the short-term and long-term, 
policy should be prioritized so as to guide various innovators in their innovation process 
and maximize their innovative outputs. 
2.5 Technology Development in China 
Technology development and policy in China has been a topic of wide concern 
worldwide. As the largest technology importer in the world, China generates many 
business opportunities and attracts a lot of investments from developed countries. The 
lucrative Chinese market is a focal interest globally not only because of its growing rate 
and size, but also due to its increasing involvement and influence in the world economy. 
Policy measures in China can typically represent the interests of many other emerging 
economies such as Brazil and India. It is meaningful for other countries to better 
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understand similar issues and enact effective technology policies. As a developing 
country, the establishment of technology policy in China has been lagging behind the 
developed world. This section identifies some of the challenges and problems in China’s 
innovation systems and related policy issues. 
2.5.1 National Technology Programs in China  
Since China’s political regime still carries many characteristics of a planned 
economy, technology policies are often implemented along with national level 
technology programs. This section will summarize some important national technology 
programs introduced by the central government since the 1980s. Most of these programs 
served to give direction for S&T research, which focuses on the development of high-
tech industries, technology transfer, and acquisition. Through studying the objectives of 
these technology programs, we can further identify the trends of technology policies in 
China.  
The National Key R&D Program (1982) aimed to modernize traditional industries, 
upgrade industrial structures, and enhance high-tech industries. The contents of this 
program were to analyze international trends of S&T development, and carry out research 
on key S&T issues in China. The Program was fully funded by the central government, 
and was meant to concentrate the nation's resources to tackle major S&T issues [149].  
The 863 High-tech Program (1986) was the most prominent national technology 
program in the last century. The title of the program means that it was initiated in March 
1986. This program was formulated to focus on most high-tech areas for the 21st century. 
It covered biotechnology, information, automation, energy, advanced materials, space, 
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laser, and marine technology. The program’s objective was to develop high-tech 
industries for China’s mid- and long-term economic and social development.[149] [150] 
[151] 
The Torch Program (1988) was initiated by the Ministry of S&T as a guidance 
program for technological development. It provided support for establishing research 
facilities, encouraging foreign high-tech investment, and fostering the development of 
domestic high-tech companies in special zones throughout China. With this program, the 
central government selected and funded research programs with high market potential 
and commercialization prospects [152]. This program highlighted the national policy of 
reforms and opening to the world. 
The S&T Achievements Spreading Program (1990) was an important technology 
program aimed at bridging the gaps among different regions across China. The purpose 
was to apply and realize technological achievements to the development of rural areas in 
China. Technology transfer and diffusion activities from advanced coastal areas to 
backward inland provinces were written as national strategy [149]. 
The S&T Innovation Strategic Action Plan (2001) was launched in the new century, 
and it signifies that the objectives of technology programs are changing to focus on 
innovation. The program consisted of several subordinate plans, mostly in basic research, 
including life sciences, biotechnology, alternative energy, and environmental protection. 
It included many projects that were dedicated to the establishment of infrastructure and 
supporting facilities in these areas [153]. 
National Medium- to Long-Term Plan for S&T Development (2006-2020). In 
January 2006, the Chinese National Council convened the first S&T conference of the 
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new century in Beijing. During this conference, Chairman Hu, Jintao proposed the 
strategic objective of constructing China into an innovative country within 15 years (by 
the year 2020) [154]. The goal was written into the plan as a long-term policy, which 
implies that China is resolute to boost its technology level to match that of developed 
countries. The core of this program is to promote China's innovation capability and to 
rely more on domestic research and development. The plan emphasizes raising 
innovation capabilities to generate original invention through basic research [153]. 
2.5.2 Landscape of Innovation in China 
By reviewing China’s national technology programs, we can identify that the main 
theme of its policy on technology development has been switching toward innovation, 
but how can the Chinese NIS operate effectively? It depends on the strengths of various 
innovators or technology implementers. Technology policies need to consider and 
address the many issues faced by stakeholders and actors. Through reviewing recent 
literature, this section examines the unique characteristics of each participant or innovator 
in the innovation system. The situation in China is more complicated than many other 
developing countries due to its legacy of a central planned economy. The analysis will 
focus on issues faced by some key actors in China’s evolving innovation systems. The 
following table presents recent literature (2006-2011) on technology development and 
innovation in China (Table 6). The stakeholders and innovators being examined in these 
studies have been identified and listed. Analysis will be followed to discuss major 
barriers and obstacles faced by each of these identified stakeholders.  
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Author Year Innovators 
Studied 
Brief Summary 
J. Wu and N. 
Pangarkar [155] 
2006 MNCs, 
SMEs, 
SOEs 
Explores how domestic firms in emerging markets can 
counter the threat posed by the entry of MNCs. Performance 
levels depend on the strategy adopted by the firm 
P. Fan [156] 2006 SOEs Domestic firms should focus on in-house R&D development 
to build their innovation capability, supplemented with 
external alliances. 
W. S. Siu et al. 
[157] 
2006 SMEs Examines the interplay of government intervention, 
manufacturing systems and business approaches and impacts 
upon the new product development of SMEs in China. 
X. D. Chen and G. 
Reger [158] 
2006 MNCs The motives for German FDI are long-term based and market-
oriented, which can be characterized through seeking new 
markets and enlarging market shares. Technology transfer is 
mainly dedicated to production and managerial facilities. 
J. Duanmu, F. M. 
Fai [159] 
2007 MNCs, 
SMEs 
Investigates vertical knowledge transfers from inward-
invested multinational enterprises to indigenous Chinese 
suppliers 
Xiaohui Liu, 
Trevor Buck [160] 
2007 FR&D, 
MNCs 
Foreign R&D activities by multinational enterprises in a host 
country significantly affect the innovation performance of 
domestic firms 
Xudong Gao, et 
al. [32] 
2007 MNCs, 
SMEs, 
SOEs 
Development of strong manufacturing capabilities may not be 
an effective strategy for domestic firms competing against 
MNEs. The way to go is developing innovation capabilities 
and core technologies. 
K. Motohashi and 
X. Yun [161] 
2007 SOEs, 
SMEs, 
PRIs, 
University 
Chinese manufacturing firms still possess only a low level of 
technological capability. Collaboration with PRIs and 
universities needs to be promoted. 
G. Hutschenreiter 
and G. Zhang 
[154] 
2007 SOEs, 
PRIs 
Technology imports, and international technology transfer 
will continue to play important roles in China’s development, 
but the country needs to continue investing in R&D and 
education and to overcome the institutional and structural 
weaknesses 
K. Chen and M. 
Kenney [162] 
2007 PRIs, 
University 
Explores the role of URIs in the development of the Chinese 
economy through the comparison of developments of regional 
technology clusters 
Xiaohui Liu, 
Huan Zou [163] 
2008 FR&D Foreign R&D activities by MNCs in China significantly affect 
the innovation in domestic firms and there exist both intra-
industry and inter-industry spillovers 
K. Fisher-Vanden, 
G.H. Jefferson 
[164] 
2008 SOEs Explores different purposes of internal R&D and Technology 
imports. Chinese firms simultaneously expend resources on 
disparate forms of technical change that embody different 
factor biases. 
J. Zheng et al. 
[165] 
2008 SOEs China's reform measures often resulted in one-time level 
effects on productivity, but further institutional reforms are 
required to consolidate China’s move to a full-fledged market 
economy 
W. Hong [166] 2008 University Examines university–industry collaborations in China, and 
shows a decentralizing / localizing trend in knowledge flow. 
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S. Girma and Y. 
D. Gong [167] 
2008 SOEs, 
MNCs 
Reforming the largely inefficient SOEs presents a major 
challenge. Limited regional linkages and low level of 
absorptive capacity are found to be the main reasons for the 
disappointing performance. 
J. Y. Kim and L. 
Y. Zhang [168] 
2008 SOEs, 
MNCs 
This paper investigates the clustering of Chinese electronics 
manufacturers with foreign producers. It analyzes how 
MNCs’ collaboration with local firms fosters local economic 
development. 
K. Asakawa and 
A. Som [169] 
2008 FR&D, 
MNCs 
Compares the MNCs in managing their R&D in China and 
India. The paper supports the trend that more innovation is 
required by firms and managers to strategize their R&D 
investments in China. 
S. Girma and Y. 
D. Gong [170] 
2008 SOEs Competition from sectoral FDI has a deleterious impact on 
the growth and survival probability of SOEs. 
K. Kiyota et al. 
[171] 
2008 MNCs, 
CMOs 
Examines the determinants of the backward vertical linkages 
of Japanese foreign affiliates in manufacturing, focusing on 
the local backward linkages, or local procurement in China. 
L. G. Ying [172] 2008 FR&D, 
CROs 
The Chinese R&D productivity growth depends on the 
simultaneous expansion of the domestic and foreign 
knowledge stock in China. It largely depends on spillovers of 
the pioneer R&D. 
H. Kroll and I. 
Liefner [173] 
2008 University, 
SMEs 
Spin-offs have been proven to be appropriate solutions for 
technology transfer at Chinese universities, but many of the 
companies still suffer from defective incentive structures and 
lack of performance. 
Y. Zhou [174] 2008 MNCs, 
CMOs 
Examines how the synergy between China’s domestic market 
and the international market has affected its most competitive 
indigenous companies. 
G. Bin [175] 2008 FR&D, 
MNCs 
Investigates the contributions of four technology acquisition 
channels including: in-house R&D, foreign technology 
transfer, domestic technology transfer, and inter-industry 
R&D spillover. 
S. Girma, et al. 
[176] 
2009 MNCs, 
SOEs 
Inward FDI at the sector level has a negative effect on 
innovative activity in SOEs on average, but there is a positive 
effect of FDI on SOEs that export, invest in human capital, or 
undertake R&D. 
Dong Chen, et al. 
[177] 
2009 MNCs As emerging markets develop, foreign firms are being viewed 
less and less as providers of capital and/or technology, and 
more as integral parts of society 
K. S. Swan, B. B. 
Allred [178] 
2009 MNCs The relationship between a perceived influence of China on 
technology strategy and MNC subsidiary process technology 
sourcing strategy is moderated by the innovation context 
F. Hatani [179] 2009 MNCs Drawing on the global value chain analysis and institutional 
views, MNCs inhibit technology spillovers even at the lower 
tiers of the supply hierarchy within the emerging economy 
context. 
J. C. Guan, et al. 
[180] 
2009 SOEs, 
SMEs. 
Innovation activities of Chinese firms were mainly directed at 
quality improvement. SMEs that obtain support from the 
government generally perform better. 
J. Fan, et al. [181] 2009 MNCs China’s FDI inflow is inefficiently large because weak 
institutions deter domestic investment while special initiatives 
that attract FDI are thus either unsupported or not unique to 
China. 
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C. Huang and N. 
Sharif [182] 
2009 SMEs Foreign-funded companies were less active than Guangdong 
domestic companies in pursuing research and development 
(R&D) and innovation activities. 
Brandt and Thun 
[183] 
2010 MNCs, 
SOEs, 
SMEs. 
Industrial upgrading efforts are often domestically driven, 
intense competition exists between both domestic and foreign 
firms, which stimulates the upgrading efforts of domestic 
firms 
Kroll and Schiller 
[184] 
2010 PRIs Domestic firms continue to depend more on foreign 
technology transfer than domestic technologies. PRIs will 
depend on improved management and a new funding system. 
Lu, Tao, and 
Yang [185] 
2010 SOEs Local governments can help SOEs gain access to cheaper 
production inputs, but these enterprises may be used to pursue 
private benefits for officials 
Motohashi and 
Yuan [186] 
2010 MNCs MNCs have vertical spillovers to Chinese firms. In some 
industries, only a small amount of vertical spillover effects are 
found. Horizontal spillovers do not exist in both. 
Tian [187] 2010 MNCs MNCs can manage technology spillovers through selection of 
entry modes, selection of technologies, and selection of 
investment priorities in the affiliates they establish in China. 
Tang and Hussler 
[84] 
2011 SOEs, 
SMEs, 
PRIs, 
University 
The Chinese NIS should be reconsidered and designed to 
improve the absorption and innovation capability of domestic 
firms and to strengthen their interactions. 
Fu and Gong [25] 2011 FR&D Although foreign investment appears to contribute to static 
industry capabilities, foreign R&D activities have exerted a 
significant negative effect on the technical change of Chinese 
firms. 
Koichiro Kimura 
[188] 
2011 SOEs, 
SMEs 
The Chinese firms need to strategically choose between 
“make or buy” decisions when they face technology gaps 
against foreign firms. 
Table 6: Journal Articles on Technology Innovation in China 
 
2.5.2.1 Higher Education Institutions 
Higher Education Institutions (HEIs) have long been key players in technology 
development and innovation activities. HEIs were seen as having two tasks — to train 
high-level qualified personnel with professional skills and to develop science, technology 
and culture [189]. There are more than 1000 state owned universities in China, of which 
200 have been regarded as strong in research (National 211 Program). Some selected 
premium universities are equipped with good research facilities and laboratories, where 
students and faculties can carry out scientific research in high-tech areas. Universities 
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participate in technology development through various channels, including cooperation 
with industry, collaboration with governmental departments, establishment of high 
technology spin-offs, and academic communication with other universities. 
Although expanding at high speeds, Chinese universities still encounter many 
obstacles hindering their development in recent years. First of all, the central government 
is not able to provide enough funding for all. Most Chinese universities suffer from 
budget constraints, and many of the universities have to seek funding or even try to make 
a profit by themselves. Secondly, the academic programs are not designed toward long-
term national goals. Programs in basic research give way to commercially related streams 
such as business and computer applications. Thirdly, only a very few Chinese universities 
have state-of-the-art equipment; therefore, R&D activities in many universities are below 
standard. Fourthly, Chinese universities experience difficulties in recruiting competent 
faculties. More graduates choose to work in industry, especially for foreign companies, 
where the salaries are higher. Most elite graduates seek opportunities to go abroad, either 
furthering their studies or careers. Last but not least, the performance evaluation system, 
distribution of benefits, and protection of IPR are also notable issues in Chinese 
universities [166] [173].  
2.5.2.2 Public Research Institutes 
Public research institutes (PRIs) are major sources of technological innovation in 
China. Their mission is mainly to serve the ministerial departments and enterprises within 
their industry. Due to the legacy of the centrally planned structure, technological R&D 
activities in these institutes were managed by vertical administration from the 
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government departments. However, in recent years, research institutes are encouraged to 
work with the industry, undertake research projects from other sources, and make profits 
from the outcomes of their research. Research institutes have gained more autonomy or 
have become completely independent of the government. These institutes decide which 
research projects to pursue and how to raise funds for projects and salaries [189]. 
The original purpose of these reforms was to alleviate the funding burden of the 
central government. However, such technology policies have brought negative impacts to 
the balanced growth of PRIs. To a certain extent, the S&T system reform is intrinsically 
prioritized for commercialization, which has weakened the development of basic research 
and public-benefit-oriented research [162]. Those applied-oriented research institutes 
have gained the most benefit from the reform, whereas those involved in basic research 
cannot easily obtain enough funding, neither can they attract or recruit enough top-level 
researchers. The situation is similar to the problems encountered by the Chinese 
universities. More importantly, the supply of public-benefit-oriented research has been 
insufficient to meet the basic demand of the nation. For example, the SARS scare in 2003 
exposed the weakness of the public health system to defend the nation against serious 
diseases [149]. Many challenges remain with regard to how to improve the efficiency of 
PRIs and, more strategically, as to what role the they should play in China’s emerging 
enterprise-centered innovation system [154].  
2.5.2.3 State-owned Enterprises 
State-owned enterprises (SOEs) are medium- to large-sized companies left by the 
centrally planned system, and they are referred as "the eldest sons of China.” These 
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enterprises used to enjoy preferential treatment in terms of policy and resource allocation 
through government planning [180]. In recent economic reforms, some SOEs have been 
transformed into other categories of ownership such as shareholding enterprises, limited 
liability firms, and privatized SOEs. Except for the last category, the privatized SOEs, the 
government still maintains the majority share control of companies in the other two 
categories. The corporate governance mechanism in these companies is quite different 
from other types of companies. Top executives have to be appointed by the government 
and their experiences in these companies are continual building blocks of their political 
careers. As a result, these managers tend to focus on short-term economic performance 
rather than risky long-term strategic investment in R&D [167].  
Funding and allocation of resources for thousands of SOEs across the country have 
long been an important concern for the Chinese government. The above mentioned 
economic reforms in recent years were to reduce such expenses and to increase revenues. 
However, SOEs’ performances did not improve as much as expected, and they began to 
face more challenges under new conditions. There is a large spread in returns between the 
performance of the small number of state firms that do well and the bulk of them that do 
very poorly [165]. According to OECD (2008) reports, Chinese SOEs still record much 
lower levels of productivity than other firms, often appear to be less efficient knowledge 
producers and often lack the basis for R&D [190]. Scholars found that while R&D 
activities are more concentrated among SOEs, these enterprises are not efficient in 
knowledge production [191]. More recently, many SOEs have lost their previous 
monopolistic advantages due to economic reforms. Although SOEs continue to enjoy 
some priority of access to resources, their statuses are much weakened to a lower level. 
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Another concern is about the property ownership of SOEs, especially on the issue of 
infringing state assets caused by privatization. To sustain the transition process, the 
central government has been forced to pay more attention to developing S&T policy that 
fits the strategic orientations of different forms of enterprises, particularly those of SOEs 
[180].  
2.5.2.4 Small- to Medium-sized Enterprises 
China’s economic reform in the last thirty years has resulted in the rapid expansion 
of the private sector. Small- to Medium-sized Enterprises (SMEs), which mostly consist 
of new ventures, have played a significant role and have largely contributed to industrial 
development. The growth of privately-owned SMEs also signaled that the Chinese NIS 
are transforming to a market-oriented economy. Many high-tech SMEs are emerging 
firms specializing in niche areas of some sub-sectors. They aim to profit by achieving 
competitive advantage in these market segments. SMEs usually favor more on market 
value than advanced level of technology. Therefore, their R&D activities are more likely 
to be targeted toward problem-solving rather than long-term basic research.  
Although growing at high speed, the Chinese SMEs have faced many obstacles in 
recent years. Waves of SME bankruptcies have trickled out of China during the recent 
global economic recession. Growing financial troubles among high-tech SMEs pose an 
immediate challenge to China’s technology policy. SMEs have not only encountered 
difficulties of limited financing channels, but have also experience excessive increases in 
raw material prices and labor costs. According to OECD (2008) reports, China’s financial 
system does not meet the funding needs of private firms, notably SMEs. The capital 
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market is underdeveloped and SMEs find it difficult to secure loans since banks favor 
large companies, particularly SOEs. Smaller, privately owned firms thus largely depend 
on self-funding [190]. Moreover, some policies focused on SOEs have at the same time 
crowded out support to non-state owned companies even though they hold a large 
potential [154]. Export oriented SMEs face a series of problems, including: appreciation 
of the Yuan, shrinking foreign demands, surging costs of raw materials, and competition 
looming from other developing countries. Many other factors such as increased interest 
rates and heavy taxes are adding up to deteriorate the survival environment for SMEs. In 
order to support the development of SMEs, the government needs to increase financing 
and resolve the unfavorable conditions. 
2.5.2.5 Joint Ventures and MNCs  
Equity joint ventures (EJVs) are cooperation between the foreign MNCs and 
domestic companies. EJVs have been a preferred mode for the Chinese central 
government to acquire and introduce high technology from abroad. The policy of 
“trading domestic market for foreign technologies” has been adopted since the 1980s and 
the government expects foreign investors to transfer technologies when they work 
together with domestic partners. Many MNCs who invested in China chose to form joint 
ventures with Chinese partners. Two external factors appeared to be the major 
determinants of this choice which are environment factors and the market factors. JVs 
would be preferred for the MNCs when they are not familiar with the environmental of 
the host country. The domestic partner can provide them the knowledge in dealing with 
customers and local officials. For many Western firms, China offers the attraction of a 
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large domestic market for capital goods, intermediate products, and final goods and 
services. To others China may hold the promise of becoming a low-cost production base 
from which it could eventually serve not only the domestic market, but also the global 
market [14].  
In recent years, EJVs in China have met bottlenecks for further development. 
Although China’s entry into the WTO has reinforced foreign direct investment (FDI), 
these FDIs tend to favor low-tech industries that extract more resources from China [155]. 
The quality of enterprise level cooperation and related international technology transfer is 
at a relatively low level, and high-tech components are barely transferred. As a result, 
technological innovation only improved in several limited industries, and S&T 
achievements in many high-tech areas still grow at very slow rate. Another concern is 
that the MNCs are switching away from choosing EJVs as an entry mode. The Wholly 
Foreign Owned Enterprise (WFOE) is a more prevalent set-up among many foreign 
companies [168]. It is generally accepted that such a governance mode can ensure MNCs 
to withhold knowledge leakage and protect the technology edge. An additional reason for 
the phenomenon is that the Chinese government did not provide better policy support for 
EJVs over WFOEs. In order to sustain MNCs’ contribution to domestic innovation, 
policy design should induce foreign investors toward target high-tech areas, and 
introduce technologies with internationally accepted quality standards. The government 
should offer favorable policy measures such as land, subsidy, taxation, and industry-level 
education and training. 
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2.5.2.6 Foreign R&D Centers 
A growing number of Western and Japanese firms have been launching their R&D 
operations in China [169]. This has no doubt brought China a new channel of 
international technology transfer [160]. On the one hand, some companies have 
established foreign owned in-house R&D facilities in China. On the other hand, many 
companies have setup virtual R&D networks, building partnerships with domestic 
companies and research institutes, as well as universities to conduct research. A wholly 
owned in-house R&D center in China can recruit and train high quality employees. It also 
helps the foreign side to have better control over the research process, as well as their 
investment [163]. A virtual network is a good choice for firms to reduce risks and costs. 
Risk sharing occurs when separate entities invest in a common risky endeavor. Through 
cooperation with other firms, each entity pays only a fraction of the investment. This 
allows research to be done more efficiently. It expands a company’s capacity, increases 
flexibility, and reduces fixed infrastructure. R&D contributions are not limited only to 
China, but are also expandable to other countries, or even globally. 
A notable problem is that there are more “D” activities than “R” activities in the 
foreign R&D centers. In many cases explored by available research, “development” is a 
dominant part of R&D in China. Part of the reason is that foreign investors tend to focus 
on the development of technologies that are immediately applicable to the Chinese 
market, while neglecting long-term basic research. Although many of the investigated 
foreign investors expressed a wish to expand the “research” part, including knowledge 
transfer, they have so far been reluctant to do so, because they see serious problems in 
China [31]. Some of the common issues include lack of quality local researchers, weak 
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IPR protection, and a lack of policy support. Firstly, many companies try to expand their 
R&D activities through cooperation with local universities, which can have a strong 
bearing on recruiting prospective graduates and qualified talents [175]. Secondly, some 
investors considered the R&D facilities as being very sensitive in terms of maintaining 
and increasing competitive advantage [169]. As long as the IPR issues still exist in China, 
foreign companies tend to keep their core R&D in headquarters or split up their R&D 
activities among various units to reduce risks of losing core knowledge and technology 
[31]. Thirdly, since different actors are competing for resources, policies are not geared to 
support foreign R&D centers. For example, many restrictions and regulations apply to 
foreign research in China, ranging from resource exploration to exploitation. Summarily, 
if the Chinese government were to better utilize foreign R&D centers as innovation 
instrument, policy measures need to be enhanced to guide and support their growth.  
2.5.3 Framework Conditions for Innovation  
Due to the differences in social, economic, and technological development, each 
country has different framework conditions for innovation. These include various 
institutional limitations to be considered in policy making. Since this research will take 
China as a case study, it is necessary to discuss related constraints in China’s innovation 
environment. China is shifting from a central-planned system to a “socialist market 
economy”, and its NIS is undergoing a transitional process. Innovation policy should 
consider lifting or mitigating various limitations to improve the conditions for innovation. 
The legacy of the central-planned economy has left China with a relatively stronger 
state-owned enterprise system but a weaker private sector. According to a statistical 
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report in 2010, the revenue of the top 500 private Chinese companies combined cannot 
win over that of the top two state-owned companies [192]. SOEs are still holding a 
favored position of technology development in China. Private-owned SMEs are in an 
inferior position in market competition as well as R&D activities. Due to intense market 
competition, domestic companies tend to focus on short-term revenue and financial 
performance. In general, the ratio of R&D investments to sales revenue of domestic 
enterprises is much lower than that of multinational companies. Domestic companies 
favor acquiring and transferring technologies that lead to easily replicated fields. This 
situation may lead to market failure in domestic industries, such as China’s automotive 
sector. After opening up for more than 30 years, China is still heavily relying on imported 
automobiles and parts. Considering the fact that neighboring countries such as Japan and 
South Korea had successfully established their automotive industries in only 20 years, the 
Chinese policy makers should reconsider their strategies in technology development. 
Government intervention and regulatory changes should be adjusted to promote business 
R&D and innovation.  
The distinctive Chinese R&D system is another critical issue in promoting 
innovative capability. Universities and research institutes are still under direct control of 
the government. Ideology issues and bureaucracy are still prevalent and have deterred the 
improvement of innovation conditions. For example, students are forced to take multiple 
courses in Socialism and Marxism. All universities and research institutes are required to 
have a Party Committee, and its members have to be included in the administrative and 
management levels. Such a management structure deeply interferes with teaching and 
academic research. Due to a better research environment and less control, as well as 
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higher pay, many high quality scientists and engineers choose to work for foreign-owned 
companies. Although increased investment in universities and public research institutes 
can be a major solution to ease the problem, structural reforms are needed to improve 
innovative conditions and lift unnecessary political barriers.  
At the national level, high-tech export controls over China have to be considered in 
policy decision. Technology exporting countries have various regulations to maintain 
their national interests and competitive advantage. These policies prohibit advanced 
technologies from being transferred across borders. The implications for U.S. foreign 
policy revealed the fact: “When it comes to advanced technology, national security can 
no longer be viewed in pure military terms; economic security is also a vital 
consideration” [129]. Moreover, the U.S. has allied with major developed countries to 
enact strict limits on technology transactions related to China. So far there are very 
limited actions that the Chinese government can take, except through formal foreign 
policy negotiations or lobbying activities. Although China has been isolated from the 
Western world for many decades, it becomes very necessary for the country to improve 
international relationships in the background of globalization. 
At the enterprise level, multinational companies have common concerns about 
intellectual capital protection issues, which constrain their willingness to bring new 
technologies into China. Without appropriate IPR protection, MNCs may take the risk of 
losing competitive advantages to Chinese counterparts. It is not uncommon to see in a 
joint venture when the local side learned all core technologies and then the foreign side 
was kicked away. This is the reason why some MNCs are reluctant to fully transfer their 
core technologies to developing countries. It is a challenge for them to balance the 
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collaboration and competition with domestic companies. Much research evidence shows 
that multinationals will hesitate to make investment in developing countries if their 
interests are not protected. This will influence their strategies of technology transfer, and 
lead to the transfer of low-tech products [193]. Research reveals that strong protection of 
IPRs can promote international technology transfer and bring more FDI for late-comer 
countries [194, 195]. Therefore, policy makers should consider improving the regulative 
framework to protect foreign investments. 
The above discussions briefly covered major institutional limitations of innovation 
policy in China. Overall, policy initiatives should be designed to improve institutional 
environments through better regulation, standardization, intellectual property 
management, training of workforce, etc. [148]. The innovation efficiency of actors is 
highly impacted from above by macro-level institutional factors, and from below by 
micro-level technological issues. It is natural to link these influence factors with the 
innovation infrastructure in the host country. As a result, it is necessary for policy makers 
to identify major actors and mitigate related institutional limitations. This may provide 
the actors a better environment in which to develop new technologies and thus contribute 
to technological innovation in the long run. 
2.5.4 Challenges of Innovation Management in China 
Technological innovation in China’s high-tech sectors has been deeply influenced by 
industrial policies implemented by the central government. The country has gone through 
a long way to catch up with the developed world. China’s NIS is still fast evolving and 
has caused much difficulty in policy-making. Although the central government has taken 
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initiatives to facilitate interactions among various innovation players through many 
national technology programs, policy actions concerning innovation system reforms 
aimed at improving innovation performance and efficiency are still very limited. This is 
mainly due the complexity of China’s innovation infrastructure as a fast transforming 
economy: Tylecote (2006) argued that dual innovation systems co-exist in transitional 
China [196]. One is an upper level innovation system which mimics its counterpart in 
developed economies and focuses on the development of advanced technology. The other 
is a lower level innovation system which has its roots in locally embedded industries. Li 
(2009) suggests that during the catch-up or transition process, overall economic and 
innovation performance depends largely on how China coordinates the two system levels 
[197].  
Despite rapid growth in the last three decades, China is still weak in many high-tech 
sectors but stronger in some low-tech areas. Most domestic companies rely on over-
consumption of natural resources, and specialize in labor intensive sectors. FDI tend to 
favor low-tech industries that extract more resources from China. Although China’s 
joining the WTO has further reinforced FDI, the market environment did not improve 
much for the domestic players, as they began to face more intense competitions from all 
over the world. As a result of globalization, many foreign investors have established 
localized R&D facilities in China trying to benefit from cheaper resources [198] [199] 
[169]. These investments have no doubt increased China’s research capacity in some 
low-tech areas, but the question is how China can effectively integrate these resources to 
achieve sustainable innovation. Scholars suggest that China needs to find ways to better 
integrate inward FDIs into the emerging Chinese innovation system [154].Generally 
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speaking, China needs to improve its technology policy through balancing foreign 
technology learning and indigenous innovation [84]. 
As an emerging economy with transitional innovation systems, China does not have 
effective innovation measurement mechanisms that can fully consider its unique macro 
environmental context. A benchmarking method from the Organization for Economic 
Co-operation and Development (OECD) has been adopted in the last few years. The 
Chinese Ministry of Science and Technology (MOST) formally requested OECD to carry 
out a review of innovation capacity in China. The review process was implemented as a 
joint OECD-MOST project, which took place from 2005 to 2007 [190]. OECD sent 
multiple experts and consultants to a station in China, where they guided the local 
researchers to carry out related studies. From a Western perspective, the report gives 
comparative analysis of the Chinese national innovation systems. The reports highlighted 
some key challenges to be faced to achieve China’s ambition to base its future economic 
and social progress on a stronger national innovation system. First, there are downsides to 
the current growth pattern to rely on basic and large-scale production capabilities. The 
country should strive to make the transition to a more innovation-driven and sustainable 
growth model. Second, technology policy should serve to improve the framework 
conditions for innovation. Third, the government should foster an enterprise-centered NIS. 
Fourth, policy measures are needed in the repositioning and upgrading of the public R&D 
system. Fifth, the government should prepare to meet the challenges and opportunities of 
globalization. Lastly, the report suggested strengthening innovation governance [190]. As 
we compare these OECD suggestions to literature findings, they align to each other. 
Although the OECD’s report identified many problems in the Chinese NIS, there are still 
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some noticeable deficiencies. Firstly, it did not give detailed solutions especially when 
dealing with sector-specific issues. Secondly, the report came up with some suggestions, 
but how to prioritize limited resources was left open. Thirdly, as a government (MOST) 
initiative, it did not criticize or evaluate some disputed technology policies, i.e. trading of 
the domestic market for foreign technology. Furthermore, the analysis on globalization of 
innovation resources is not enough, and it does not come up with a new implementation 
methodology.  
2.5.5 Implications for Technology Policy in China  
As it would be difficult to separate the national strategies of the Chinese government 
from those of the Chinese enterprise, one must add as motives the economic and 
industrial aims of the state that consist of foreign exchange earnings, import substitution, 
creation of new jobs, and improvement of industrial productivity, quality and capacity 
[14]. Given that the central government continues to exert a leaden impact on industrial 
innovation, technological policies should be adjusted in a timely manner to match the 
rapidly changing economic and social context.  
Policy measures implemented by the central government were in a predicament in 
recent years. For example, “Trading of domestic market for foreign technology” has been 
a major strategy of China's technology policy to attract FDI and promote technology 
development since the 1980s. In a broader sense, this policy covers all measures that 
acquire foreign technology through granting foreign companies free access to the 
domestic market. There have been many disputes on the outcome of this policy in China, 
and the topic has aroused wide attention in academia. The main argument is, “Can 
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technology be exchanged for by market share?” The rationale of this strategy assumes 
that China could use the latecomer advantages to upgrade its industrial structure and 
technology level. In the mean time, China can save lots of foreign exchange on 
technology by just giving away some market share. However, in some high-tech 
industries, the advantage of latecomers has scarcely been realized, domestic innovation 
capacity makes little improvement, and the technological gap is further widened. In some 
extreme cases, such as the automobile industry, domestic enterprises have even fallen 
into the trap of reliance on import of core technologies. In recent years, a similar 
technology policy has been applied again on technology transfer deals in the high-speed 
rail industry. China introduced Electric Multiple Units technology from four different 
countries (Japan, Germany, France, and Canada), but the core technologies are still 
controlled by the foreign side [10]. A major difficulty is that China lacks the innovation 
capacity to fully absorb foreign technologies. The government has many things to do in 
order to improve the country’s innovation systems. 
The government should strategically allocate both foreign and domestic innovative 
resources under the new condition of globalization. Technology policies should consider 
the interests of foreign investors. There are some areas in which policies and initiatives at 
the national level could protect the interests of foreign firms. These include the protection 
of intellectual property and trade liberalization. Swedish scholars found many 
challenging aspects for the foreign companies while negotiating technology transactions 
with the Chinese side [14]: The legacy of a centralized system, a poor infrastructure, a 
distinct culture and foreigners’ lack of access to adequate information on the Chinese 
technology. China’s entry into the WTO in 2001 marked a new era in technology 
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development. However, the WTO agreements cannot remove all the preconditions 
imposed on foreign investors. For example, China did not sign under the article which 
removes the requirements for transferring technology when establishing joint ventures 
with domestic partners. It is likely that China will continue to impose many restrictive 
conditions on foreign companies. Therefore, there is a necessity at the national level to 
give better transparency in policy-making, especially regulative measures for foreign 
companies. The construction of a sound regulatory framework for investment and a better 
enforcement of Chinese regulations on intellectual property rights are prime examples to 
solve the problems [31]. 
Since policy is selective in nature, prioritization and optimization of innovation 
resources are very necessary. The literature has identified that a government’s 
management of resources and related constraints and impetus are most important in 
policy making. Since the central government has the privilege of resource allocation, it 
can therefore establish regulations or offer incentives and favorable measures to promote 
technology development. Scholars have introduced a conceptual framework that 
addresses major determinants of technology development and transfer in China [189]. 
The determinants include the ideology, economic system, and constraints and impetus. 
Although the authors have identified the importance of government’s management of 
resources and related constraints and impetus, no prioritization strategy was made or 
proposed (Figure 8) [189]. Moreover, little consideration has been given to include the 
increasing influence of foreign companies, which have been argued by many studies to 
have extensive impact on technology development and innovation. In order to increase 
industrial innovative capacity and strengthen China’s national innovation system, policy 
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should be designed to guide and support innovators that can contribute more toward 
technology development.  
 
 
 
 
Source: Liu and Jiang (2001) 
 
 
Overall, there are still many difficulties in China’s macro policy regarding 
technology development. These include ideology issues (Market System and Planned 
System) as indicated in Figure 8 [189]. However, such issues will not be included in this 
research because they are beyond the control of researchers or individuals. Instead, this 
research will focus on how to transform resource advantage into technology edge; how to 
better integrate international technology transfer toward long-term innovation. As China 
gained access into the WTO in the last decade, the country faces both opportunities and 
challenges resulting from globalization. To overcome various difficulties, the tasks of the 
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government are to optimize its technology policy, select appropriate strategies, and 
improve its domestic innovation structure. 
2.6 Methodology Review 
As discussed in previous sections, the impacts on technology development are 
complex and multi-leveled. Therefore, methodologies from different perspectives should 
be employed to carry out related research. Salo and Salmenkaita (2002) suggested that 
there are synergies between three intelligence tools that serve to inform policy decisions, 
i.e., technology foresight, technology assessment, and research technological 
development program evaluation [200]. Methodologies related to these criteria will be 
reviewed to study technology policy, enterprise strategy, and technology selection.  
2.6.1 Foresight Methodology 
Foresight and forecasting methodologies have been widely studied during the last 
few decades. Literature has explored related topics from various perspectives, and 
provided different threads for further research. Scholars studied technology foresight 
activities in some Central European countries, and found foresight an effective tool for 
the development of science and technology policy [103]. Oner and Saritas, (2005) 
combined the research on national development planning with technology foresight 
studies, and proposed a new model for systems analysis of technology policy in Turkey’s 
five-year development plans [201]. Some other scholars studied technology foresight 
activities in Brazil. They focused on methodology analysis, and the results were used to 
guide government agencies to fund nanotechnology R&D to help raise competitiveness 
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of the country [106]. Georghiou and Keenan (2006) argued that assessing the effects of 
foresight requires an understanding of many aspects of public policy. To be effective it 
needs to be tuned into the strategic behavior and cycles of policy and economic actors 
[96].  
The selection of technology foresight methods involves a broader knowledge of 
foresight scope, objective, and criteria, all of which may vary with the actors participating 
in foresight activities. Foresight is a process that involves consultative procedures to 
ensure feedback to and from relevant actors. The main aspects of this process can be 
summarized as 'the five Cs' : 1) concentration on the longer term; 2) coordination 
between the stakeholders’ visions, intentions and actions; 3) consensus on research areas 
that seem particularly promising; 4) communication; and 5) commitment to the 
implementation of R&D policies [91, 200]. Since many types of methods are available 
for this complex process, classification of these methods becomes an important issue. 
Generally, there are three ways to categorize foresight methodologies: 1. Exploratory or 
Normative methods; 2. Expert-based, Evidence-based, or Assumption-based methods; 
and 3. Quantitative or Qualitative methods. The third approach is supported by Porter 
(2004) and many other scholars [202]. Popper (2008) further divided the category into 
Quantitative, Semi-Quantitative, and Qualitative methods (Figure 9) [203].  
87 
 
Figure 9: Diamond of Foresight Methodologies 
Source: Popper (2008) 
 
 
Quantitative techniques are used to monitor measurable variables and apply 
statistical techniques to process and analyze numerical data or indicators. Some 
frequently used quantitative methods include bibliometrics, modeling and simulation, and 
trend extrapolation. Qualitative methods are also frequently applied techniques in 
technology foresight activities. These techniques provide interpretations to development 
and observations. However, such analyses tend to be subjective and based on particular 
standpoints, perspectives, and perceptions. Some widely used foresight methods include 
literature review, expert panels and scenarios, all of which are qualitative. Semi-
quantitative methods apply mathematical principles to quantify the opinions of experts. 
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Such methods include cross-impact analysis; Delphi; critical technologies; multi-criteria 
analysis; quantitative scenarios; stake-holder mapping; and technology roadmapping [204] 
[205].  
Due to the multifaceted environmental settings and requirements, combination of 
above methodologies is the trend in foresight and forecasting studies. Methods can be 
combined in many different ways to create a comprehensive methodology for the 
complex and lengthy foresight process. It is obvious that any methodological approach 
should be sensitive to the impacts sought from foresight. Ideally, methods should be 
selected and combined to achieve certain impacts [206]. In academic literature, scholars 
develop methodologies through some smaller scale forecasting studies. Banuls and 
Salmeron (2006) proposed a Scenario-Based Assessment Model (SBAM), which is a 
combination of the Delphi Method, Analytic Hierarchy Process (AHP), and Cross-Impact 
Analysis [207]. P. Gerdsri (2009) used AHP and expert judgment quantifications to 
develop national R&D strategies for agricultural nanotechnology in Thailand [208, 209]. 
N. Gerdsri and D. Kocaoglu (2004) proposed a systematic approach to strategically 
identify emerging technologies in order to achieve technological competitiveness. The 
authors combined the Delphi method and Hierarchical Decision Model to build a 
technology development envelope (TDE), which serves as inputs for the technology 
roadmapping process [210, 211]. Some other scholars carried out research on emerging 
technologies through the integration of bibliometrics with scenario planning, trend curves, 
and historical analogies. System dynamics is also used to simulate the dynamic 
ecosystem of the technology development [212]. Bengisu and Nekhili (2006) presented a 
method of forecasting emerging technologies with the aid of S&T databases, which was 
89 
applied to emerging technologies in the Vision 2023 foresight program previously 
conducted for Turkey [213].  
The review of the existing integrated methodologies has shown some room for 
improvement: (1) the methodologies need to be optimized and adapted to the changes in 
the fourth and fifth generation of foresights; (2) the restrictions of environmental and 
social conditions have to be considered across countries or regions; (3) some integrated 
methodologies have unbalanced integration of quantitative and qualitative tools; (4) some 
studies relied only on limited members of expert panels, and not all stakeholders were 
included, the later being crucial for real world technology implementation; and (5) 
Technology foresight evolved from technology forecasting, covering a broader scope, 
and it is still evolving fast. Foresight should be used in exploring future opportunities for 
setting investment priorities in science and innovation activities and building new 
networks and linkages across fields, sectors and markets, or around problems [96]. These 
attributes well fit the research requirement of innovation systems.  
2.6.2 Technology Assessment 
Technology assessment has been widely applied in public policy-making and in 
business decision-making [214]. It encompasses activities which analyze and evaluate the 
anticipated impacts of a given technology, examines areas of potential social conflict 
caused by its deployment, promotes a constructive dialogue between the stakeholders, 
and produces recommendations for improving the technology and the terms of its 
application [215]. Technology assessment techniques can be applied at various levels for 
the evaluation of technology alternatives, selection and acquisition of appropriate 
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technologies, and strategic technological planning. Many technology assessment 
approaches and tools have been identified to conduct related research, which include: 
structural modeling, scenario analysis, impact analysis, risk assessment, decision analysis, 
cost benefit analysis, Delphi, and evaluation of emerging technologies [214].  
The characteristics of technology are the key factors in the process of technology 
assessment. These features may include technology status, maturity, adaptability, and 
availability. For example, in the process of international technology transfer, 
technological characteristics determine the value of specific transfer objects between the 
provider and receiver. Technological unevenness endures primarily due to the spread of 
ideas and is contingent on active attempts by firms to learn, imitate, and adapt existing 
technologies [85, 216]. At the national level, technology gaps exist because countries 
invest differently in education, R&D, and other inputs [217, 218]. Here we focus the 
discussion on several important assessment features including: technology trajectory, 
technology adaptability, technology distance, and other characteristics. 
Technology assessment is closely related to both existing technological trajectories 
and institutionalized regime practices that have inherent advantages in determining the 
direction of socio-technical change [11]. Technology trajectory can be illustrated by S-
curves. Both the process of an emerging technology’s evolution and the pattern of its 
adoption in the market can be illustrated to conform to S-shaped curves. When compared 
with traditional technologies, emerging technologies may have market uncertainty and 
unknown impact on industrial development. These new technologies generate potential 
market opportunities for new investments, thus bringing great challenges to decision 
makers. From the perspective of developing countries, an emerging technology can 
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further provide a window of opportunity for technology leapfrogging, which can trigger 
significant improvements to domestic industrial structure. Technology transfer can take 
place at any stage of the technology life cycle, but not all technologies have the chance to 
reach their natural limits on the S-curve. A replacing technology may form another S-
curve through establishing a brand new technology trajectory if it satisfies the same 
market need, and there will be a trend for companies to replace the incumbent technology 
with new technology. For many MNCs in the developed world, a better choice is to sell 
or transfer the current technology rather than completely abandon it. This process has 
been illustrated by the “Flying Geese” model proposed by Japanese scholars [219]. 
Scholars proposed a reverse product life-cycle model which explores this trend in 
technology development [220]. For new firms in the industrializing economies, they are 
more likely to choose the technology at an early stage on the S-curves. However, that 
may bring challenges for the MNCs since it raises new potential competitors [34].  
Technology feasibility and adaptability in an unknown market is a notable criterion 
for technology assessment. Scholars [221, 222] have argued that, in order to understand 
the complexity of adaptability, research should deal with all three intertwined dimensions 
of the construct, which include: technology, market, and organization-related factors. 
Much has been written in the literature about developing and transferring appropriate 
technology for developing countries. For example, technology transfer in an international 
context is subjected to more diversified environmental conditions, such as cultural 
differences, thus creating greater challenges [223]. There are numerous examples of 
unsuccessful launches of new products in developing countries. Some are caused simply 
by marketing failures, while other examples which go beyond such simple failures are 
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product designs which depart from local custom as regards tastes, habits, and preferences 
and thus may never be accepted [224]. The adaptation and modification of technology 
should be viewed from a strategic and organizational perspective, as technical integration 
of the technology provider’s process with the acquirer’s system must make allowance for 
different operating contexts [225]. Literature has pointed out that technological novelty is 
sometimes far less important than relevance [226]. For instance, in the pharmaceutical 
industry, appropriate technologies are more important for serving the purpose of direct 
applications for reducing risk of infection and disease; affordability and cost-
effectiveness; saving foreign exchange; satisfying public demand with political benefit to 
the government; and promotion of social equity. A study has shown that technology 
policies of developing country comprises more than choosing technology as a means to 
production. They include the control of a broader selection of technical and non-technical 
items that link technology to strategy through capabilities of the host country [227]. 
Many other technology characteristics are identified in the process of technology 
assessment. Blalock and Gertler (2009) define “technology gap” as the distance from a 
domestic firm's technical competency level to that of international best practice [228]. 
Similarly, other scholars developed concepts such as technology distance, technological 
proximity, technological position, and technological diversification [229-231]. 
Technology distance between partners can have an impact on their choice of cooperation 
mode. However, there are some unsolved disputes about the effect of technology distance. 
From one perspective, firms with a longer distance may be too far away from the best 
practice, resulting in limited capability to learn, assimilate, and share knowledge, thus 
causing negative effects on innovation. Firms with a smaller gap should have better 
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technical competency and could easily catch up with the technology frontier. From 
another perspective, firms that are further away from the technology frontier will gain 
higher returns from learning. Firms with a smaller technology gap may have already 
mastered similar technologies that have lower returns, but making further efforts to alter 
existing practices are more difficult. Scholars from different countries carried out many 
empirical studies showing that technology gap can result in either positive [232, 233] or 
negative [234-236] impacts to the learning process. Some other scholars found that the 
relationship can be nonlinear and U-shaped [237, 238]. It is clear that technology gaps 
and distance have significant impacts on technology transfer and diffusion. However, the 
characteristics such as size and direction of the impact are still unclear. Scholars [238, 
239] claimed that absorptive capacity should be crucial for economies that have a 
sizeable distance from the technological frontier. Therefore, it is necessary to base 
technology assessment on the technological capabilities of local enterprises. 
As a short summary of related literature, research revealed that technology 
assessment is an important method in technological development and policy planning. 
Technology policy must consider the nature of technology, market trend, and enterprise 
level capabilities. Emerging technologies have distinguishing characteristics such as 
market uncertainty and unknown impact on industrial development. These new 
technologies offer a rich source for market opportunities that provide incentives for new 
investments, thus bringing great challenges to decision makers. For late-comers, 
emerging technology can further provide a window of opportunity for leapfrogging. 
Developing economies catch up only when they actively learn and adapt from leaders 
[240]. Their choices about how to invest, as well as the productivity of these investments 
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should be based on the assessment of economic, social, and technological dimensions [50, 
241]. 
2.6.3 The Delphi Method 
The Delphi method was originally developed for the U.S. Air Force as a group 
decision method [242]. It is a method for structuring group communication so that 
individual experts can act as a whole in dealing with complex decision problems [243]. 
The Delphi method has been adopted in many countries and in a wide range of fields. 
National Delphi has been conducted in Japan every five years to generate informative 
projections on potential technological advances. Many other countries such as Germany, 
Korea, and Britain have emulated similar efforts. The technique is applied to fields 
including project selection, operations management, drug policy, and administration 
management issues [244, 245]. 
There are several characteristics that make Delphi an effective method to create 
consensus among groups of experts: 1) Anonymity; 2) Iteration; 3) Controlled feedback; 
and 4) Statistical aggregation of group response [246]. The technique uses a panel of 
experts who are not allowed to interact in order that their judgments will not be 
influenced by each other. Anonymity provides at least two advantages: firstly, it avoids 
the possibility for the panel members to be influenced by other experts’ social position or 
reputation; secondly, it allows panel members to change their opinions without feeling 
intimidated by others. Iterations with controlled feedback may provide the opportunity 
for panel members to change their previous judgments. Everyone is given the group 
results after each iteration, showing statistical values such as mean, median, and variation. 
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Outliers are asked to explain their rationale to the group, which makes it possible for 
others to modify their earlier judgments. 
The Delphi process usually takes several rounds before obtaining consensus from the 
participants. It requires that experts repeatedly express their opinions through a series of 
linked questionnaires. The first round focuses on the exploration of the subject, and the 
participants will contribute additional information through answering open questions. The 
middle rounds involve the process of reaching a common understanding of how the group 
views the issues. The final results occur in the last round after all previous information is 
analyzed [247]. During the consultation process, two types of information will flow 
among experts through the effort of coordinators: 1) available data previously requested 
by respondents; and 2) considerations suggested as potentially relevant by other 
respondents [242]. To save researcher and participants’ time and effort, the first round is 
sometimes substituted by deliberate literature review. The middle rounds could be 
combined due to time constraints or low response. 
The literature summarizes some advantages of Delphi that make it more appropriate 
than traditional methods like surveys or questionnaires [243]. 1) The problem is not 
suitable for analytical techniques but could benefit from collective judgments. 2) A 
relatively large number of experts are needed in order to create more interaction than 
would occur typically in face-to-face meetings; 3) Experts have no history of previous 
communication and may represent diverse backgrounds with respect to experience or 
expertise. 4) Time and cost make frequent group meetings infeasible. 5) The efficiency of 
face-to-face meetings can be increased by a supplemental group communication process. 
6) High disagreement levels among experts so that the communication process must be 
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refereed and/or anonymity assured. 7) Bandwagon effects or domination by quantity or 
by strength of personality must be avoided to preserve the validity of results. Although it 
has many benefits, some research also points out several potential limitations of Delphi, 
which include [243] [248]: 1) Deception resulting from the data retrieval; 2) Discounting 
the future and considering the present more important; 3) Illusory expertise resulting 
from bias; 4) Optimism or pessimism bias; 5) Prediction urge by moderators; and 6) 
Simplification urge from experts. 
2.6.4 Multi-criteria Decision Analysis 
Multi-Criteria Decision Analysis (MCDA) is a type of research method aimed at 
helping decision makers to determine overall preferences among alternative options. It is 
particularly suitable for complex problems where multiple criteria are involved. MCDA 
is especially useful for policy makers to evaluate a wide range of criteria including social, 
economic, environmental, and technological factors. The method provides a logical, well-
structured decision-making process based on the quantitative analysis through scoring, 
ranking and weighting of judgmental data.  
Among many of the MCDA models, Analytic Hierarchy Process (AHP) is the most 
widely applied quantitative decision-support method. It is designed for structuring, 
measuring and synthesizing multiple factors or elements. The working process involves 
decomposition of a complex and unstructured research problem into an organized set of 
components [249]. There are several basic steps included in the process, regardless of the 
nature and scope of the research problem, which include: 1) Construction of a 
hierarchical model; 2) Prioritization of elements; and 3) Calculation of results. The most 
97 
important step in MCDA is that a HDM should be developed to illustrate the problem. 
Decision elements or criteria are identified and arranged into various levels according to 
their relationships. In the following step, decision elements at the same level are 
compared with each other regarding their contributions toward the upper level criteria. 
Different types of comparison methods have been used in this step. The constant sum 
method was developed by Comrey [250] and Guilford [251] and refined by Kocaoglu 
[252], where a total of 100 points are allocated to the comparison values. The eigenvector 
approach was adopted by Saaty [249], where 1-9 scale measurements are used. The 
constant sum method gives a more precise measurement of data. In the third step, relative 
priorities are calculated and synthesized by multiplying the local weights with those of 
the corresponding upper level elements.  
The method has several built-in advantages including simplicity of structure, ease of 
use, and flexibility. It can be applied to assist complex decision-making when a relatively 
large number of quantifiable or intangible criteria are involved. The method allows 
calculating priorities and weights in a hierarchical structure in order to identify the most 
important elements [249]. A major difficulty in decision making is to reach consensus in 
a multidisciplinary expert panel. MCDA provides a tool so that the experts do not 
necessarily need to agree on the relative importance or the rankings of the Criteria. Each 
expert individually makes his or her judgments, and jointly contributes to a group 
decision. AHP gives a clearer understanding of the situation and leads to a higher degree 
of commitment to a chosen alternative [253]. AHP was successfully applied in many 
research areas including technology selection, evaluation, resource allocation, health care, 
policy-making and strategic planning [254-257].  
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2.7 Gap Analysis 
The literature review has explored the available knowledge base in the areas of 
international technology transfer, innovation systems, technology foresight, technology 
policy, technology development in China, and related research methodologies. 
 
Areas Research Gaps Research Opportunities 
Technology 
Policy 
 
1. Latecomers face the dilemma of ‘‘make 
or buy’’ decisions in high tech development 
[12] [84] [258] [259].Technology export 
control at various levels complicates their 
problems [16] [80] [138]. 
There is a need to find a proper balance 
between various technology 
development strategies. Institutional 
limitations of the host country should be 
considered accordingly.  
2. Latecomer countries and emerging 
economies need to identify the “windows of 
opportunity” for catching-up and 
leapfrogging [27] [29]. 
Technology areas and implementation 
strategies should be prioritized 
according to local capabilities and needs. 
Technology 
Innovation  
3. International technology transfer 
activities may not necessarily result in 
sustained innovation, technology diffusion 
not efficient and spillover not obvious  [23] 
[25] [34]. 
Host countries should build up domestic 
absorption capability and innovation 
capacity to benefit from technology 
diffusion and spillovers. 
4. Different attitudes toward appropriate 
technology. Common concerns exist but 
different interests and motivations are 
obvious among the stakeholders [30] [32] 
[37]. 
Various stakeholders should be involved 
in the technology planning process. The 
disagreements should be considered in 
the development of technology policies. 
5. Globalization brings new challenges to 
the research of innovation systems; 
innovation resources are across boundaries 
[7] [72] [260].  
GloCalization: scholars suggest that it is 
necessary to find a balance between 
local and global, internal and external 
innovation.  
6. Transitional innovation systems: 
allocation of innovation resources is not 
effectively linked to national or regional 
tech development strategies [196] [197]. 
Restructuring of inefficient R&D system 
and allocation of limited resource at 
various levels according to innovation 
strategies. 
Methodology 
7. No viable framework has been developed 
to deal with technology policy problems in 
latecomer countries. A decision model for 
the implementation mechanism of selected 
technologies is needed in such countries 
[180] [208] [261]. 
A research framework that incorporates 
the importance of innovators and their 
strategic considerations should greatly 
assist decision makers.  
Table 7: Research Gaps and Opportunities 
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Through summarizing the literature search results, this part of the chapter analyzes 
various research gaps in the above mentioned areas. Connections of literature findings to 
the research opportunities are listed in Table 7. Although the research gaps were 
identified from different areas, they are interrelated and all point to improvements in 
technology policy design. Successful filling in of these gaps requires a comprehensive 
look into the issues. To link these gaps with research goals, the following section will 
critically examine and categorize them in detail.  
 
Gap 1: Technology policy problems in latecomer countries are discussed in literature, 
but no viable framework has been developed to solve these problems.  
Latecomer countries face the dilemma of “make or buy” decisions in high 
technology development. The literature has examined the problems, but no available 
models have been developed to tackle them [12] [84] [258] [259]. There are barriers for 
both “make” and “buy’’ approaches. When making the technology by themselves, 
latecomer countries may not have the technology capability, so it may take huge efforts 
and many years to catch up. If buying the technology from advanced countries, latecomer 
countries may need to pay a high price for importing it, and they risk having to 
continuously buying follow-up technologies. Since no country, however rich, can afford 
to pursue all the possible opportunities in science and technology, there needs to be better 
mechanisms for choosing between competing alternatives and resources [102]. Due to 
limited technology capability, it is unrealistic for any latecomer country to aim at 
exploring all high-tech areas on their own effort. It is especially meaningful that they 
should avoid “reinventing the wheel” or remaking the mistakes of advanced countries. 
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This may be achieved by learning through foreign experience, and adapting to their 
situations but not by just following. Globalization offers new opportunities in technology 
learning. Selecting the right strategy in technology development may help in taking the 
advantage of such opportunities, and accelerate the catching up process.   
Technology export control at various levels complicates the problem of high-tech 
development in latecomer countries. Technology blockades at national and enterprise 
levels make it difficult for latecomers to learn from advanced countries. Major developed 
countries have strict export control of high technologies. For example, the US Commerce 
Department’s Bureau of Industry and Security restricted American companies from 
selling many sensitive high-tech products to China [16] [80]. This policy negatively 
inflicts other countries working on projects with China. Recently, Brazilian companies 
working in the Sino-Brazilian satellite project were denied access to American products 
considered sensitive [80]. Moreover, at the enterprise level, many MNCs hesitate to 
transfer high technologies to foreign countries for the protection of their competitive 
advantages. These institutional limitations have pushed many emerging economies to rely 
on indigenous innovation. 
 
Gap 2: Emerging economies and latecomers need to identify the “windows of 
opportunity” for technology leapfrogging.  
Scholars have argued that in the early phases of a given technology trajectory, late-
comer countries may enjoy windows of opportunity which allow them to catch up [17]. 
However, early-stage technologies are highly risky for investment. Many efforts by the 
local governments have failed because such technologies are not sustainable in the host 
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country [18]. Late-comer countries often lack the necessary technological accumulations 
and innovative capacities. Therefore, it is unrealistic for them to devote everything to 
uncertain high technology areas. It is better for them to focus on areas where comparative 
advantage can be achieved through technology leapfrogging. The host country should 
assess whether the new technologies are suitable for local capability and needs. Therefore, 
better approaches in technology selection should be developed to underpin strategic 
research areas where the greatest economic and social benefits can be yielded. 
 
Gap 3: International technology transfer may not necessarily result in sustainable 
innovation, technology diffusion not efficient and spillover not obvious. 
It is generally accepted that technology transfer activities alone may not necessarily 
result in sustainable innovation. Relying too much on FDI has brought many 
disadvantages in the domestic industries. Technology acquisition from firms in more 
advanced countries is obviously important to firms in industrializing countries that are 
trying to catch up technologically, but technology diffusion and spillover effects may not 
necessarily happen [19]. Moreover, since technology suppliers are not usually willing to 
disseminate core technology to other enterprises, developing countries can acquire only 
some medium- or low-level technology using this source, so a technology gap exists 
when compared with the latest international technology [20]. Scholars argued that the 
innovation activities in Chinese manufacturing firms could not be boosted substantially 
merely through the acquisition of key equipment and apparatus from abroad [19]. The 
government should formulate viable technology policies for strengthening local 
absorptive capability and innovative capacity. 
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Gap 4: The stakeholders have different attitudes toward appropriate technology. 
Common concerns exist but different interests and motivations are obvious. 
It is important for technology policy makers to fully understand the diversified 
motivations and interests among the players of international technology transfer. Western 
technology suppliers and local technology receivers have different perceptions and 
criteria for success. While the foreign side aims to penetrate the domestic market, utilize 
low labor costs and maximize financial returns, domestic partners aim to acquire 
advanced technology, a reputable trademark, technical or managerial know-how, R&D 
capacity, and access to international markets [14]. Different interests also exist between 
industry and government. Industrial players are commercially motivated for profit and 
market share, while governments aim for long-term national development, social welfare, 
and technological competitiveness [31]. Technology policy should consider these 
different standpoints, and address such needs accordingly. 
 
Gap 5: Globalization brought new challenges in the research of innovation systems, 
national boundaries are dimmed in the development of high technologies 
Globalization has brought both opportunities and challenges to countries. The 
question has become who can benefit more from resource-sharing resulting from 
globalization. Globalization of innovation systems has deeply influenced the culture of 
technology development as well as the strategic behavior of the innovators. Tidd (2007) 
identified several major issues regarding globalization. Firstly, since technology and 
innovation are not evenly distributed globally, they are not easily packaged and 
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transferred across regions or firms. Secondly, different national contexts significantly 
influence the ability of firms to absorb and exploit such technology and innovation. 
Thirdly, the position of firms in international value chains can constrain their ability to 
capture the benefits of their innovation and entrepreneurship [7] [260].  
Globalization results in deeper specialization, which may deter latecomer countries 
from catching up in technological innovation. Due to the fact that latecomers lack 
innovative capabilities in advanced technologies, they are easily trapped in inferior 
positions as low-cost resource providers. Domestic companies of these countries can only 
be specialized in the manufacturing of low-tech, low-value products or services, thus they 
are unable to achieve sustainable innovation in the long run [262] [34]. This also causes 
mature or standardized technologies and related production to be transferred to latecomer 
countries [263, 264]. As a result, the latecomers cannot easily catch up with the leaders in 
the areas of advanced technologies. This may further establish an endless loop in which 
technological leaders can always outrun their imitators [265] [266]. Therefore the 
decision of innovation strategy is an extremely important aspect to support technology 
development in latecomer countries. Technology planning has to cover the technology 
trends in the world, but the actual process of development must be supported by local 
strengths in knowledge and innovation [88]. Brazilian scholars (Humbert 2005, Canongia 
2007) have used the term “gloCalization” to describe such a strategy as “think globally, 
act locally” [105]. So far, few research models have integrated this idea in technology 
implementation. 
 
104 
Gap 6: Transitional innovation systems - allocation of innovation resources is not 
effectively linked to national or regional technology development strategies. 
Emerging economies such as the BRICs are investing more resources to develop 
their innovation capability. However, there is little evidence that current frameworks or 
approaches in developed nations are also workable for these countries. This is because 
emerging economies have different environmental contexts and changing agents. Viotti 
(2002) found that the Western NIS theoretical and conceptual framework is not 
appropriate for dealing with the processes of technological change of industrializing 
economies, which are extremely different from those of industrialized countries [85]. 
New studies are necessary since the emerging economy’s unique environmental factors 
should be considered. For example, China is changing from a centrally-planned economy 
into a market-oriented economy, and its NIS is fast evolving. The legacy of traditional 
R&D infrastructure is notably inefficient for innovation activities. Longer-term 
perspectives and strategies call for better use of limited resources. The support and goal-
oriented prioritization of resources for certain technologies are very necessary [103]. 
Allocation of resources for technological innovation is an important but complicated 
issue for both government and enterprises. Technology policy should play a more 
important role in the restructuring of inefficient R&D system and allocation of limited 
resource at various levels to support innovation strategies. 
 
Gap 7: A decision model for the implementation mechanism of selected technologies 
is needed in latecomer countries 
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Available studies have developed technology assessment and selection models to 
address various social, economic, and environmental needs in latecomer countries. For 
example, Baez (2005) developed a technology assessment model for the ICT industries in 
Costa Rica [261] [267], and Gerdsri (2009) developed technology selection model for the 
nanotechnologies in Thailand [208] [209]. However, these models did not consider the 
realities of limited innovation capabilities in latecomer countries. It is impossible for 
these host countries to develop and realize some of the identified high technologies 
merely through their own efforts. These countries should consider learning from or 
collaborating with leading countries. Many latecomer countries often aim for the best and 
latest technologies, but they neglect local capabilities and innovation orientations. Bin 
(2008) has urged that government policies should be combined with commonly followed 
technological strategies in determining the relationship between domestic in-house R&D 
and foreign technology transfer [175]. Instead of innovating in the global technology 
frontiers, latecomer countries should focus on catching up. They should strive to build up 
innovative capabilities in order to develop those identified high technologies.  
Implementation of innovation strategies requires long-term investments in the 
industrial foundations and renewing innovation activity by both public and private sectors, 
and resources targeted at broad-based innovation activity should be increased at a pace 
exceeding that of general economic growth [268]. A framework that incorporates the 
capabilities of innovators and their strategic considerations should greatly assist decision 
makers. Therefore, current technology assessment and selection models should be 
extended to include strategic concerns about how to develop and realize the selected 
technologies, especially in the developmental context of latecomer countries. Appropriate 
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models and approaches should be designed to support policy making from a systematic 
perspective. In traditional models, technology alternatives are usually located at the 
bottom level of the hierarchical structure. In this research, a new model is implemented 
by bumping up technology alternatives into higher levels, indicating the prospective areas 
for technology development or potential areas for breakthrough innovation. This new 
model links technologies and innovators with corresponding innovation strategies. 
2.7.1 Short Summary of Gap Analysis  
The above section has explored the available knowledge base in various areas of 
technology management and identified major research gaps. These gaps are interrelated 
and will lead to the improvements in new research. Scholars suggest three factors of 
technological change: demand-pull, technology-push, and government-led [42]. 
Technology policy should assist to adjust the strategic differences among innovators. 
Rapid development of high-tech industries makes stable technology policy a difficult task. 
Strategies of technology development need to be adjusted in a dynamic mode to deal with 
future uncertainties. By summarizing the above literature gaps, a systematic approach 
should be developed in organizing and funding research in high technology sectors, 
guiding the public and private sectors in their investment decisions and directions, 
coordinating industries and sectors, building an efficient scientific infrastructure, and 
providing insight for improvements in national technology competency. Such a model is 
needed in both developed countries [4] [90] and industrializing countries [88] [146]. 
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2.8 Research Scope and Boundaries 
By analyzing and summarizing available literature findings, the research scope can 
be further clarified and defined. In order to make the research process manageable, it is 
necessary to delineate the scope and boundaries of the research work. This research will 
focus on crafting a research framework to formulate innovation strategies in dealing with 
the uncertainties of technology development in emerging economies. It serves as a bridge 
connecting high technologies and policy decision making (illustrated in Figure 10).  
 
 
Figure 10: Research Scope and Bounds 
 
On the input side, the supportive studies may include technology-oriented research 
such as foresight/forecasting studies, industrial reports, product analysis, and technical 
expert recommendations. On the output side, the research findings will assist decision-
makers to develop more specific policy instruments such as direct or indirect funding, 
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regulation support, and other favorable measures. The design of such detailed policies 
may be potential areas for future research. 
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Chapter 3 – Research Methodology and Approach  
Through the analysis of research gaps, this chapter clarifies the research objectives, 
research goals, and research questions. The literature review revealed that many problems 
coexist in the process of technology policy-making, especially for emerging economies. 
This chapter will highlight major research questions and use them as a starting point to 
develop the research methodology and research process. 
3.1 Research Objectives, Goals, and Questions 
The objective of this research is to provide a systematic framework for promoting 
national S&T competitiveness and innovation capacities in high-tech sectors. The 
framework serves to provide insights for both public and private stakeholders as they 
strategically plan for further technological advancement. The approach of this research is 
to formulate effective technology development strategies, linking prospective high-tech 
areas and various innovative resources to assist the decision-making process of 
technology policy.  
From the gap analysis, research goals have been developed and categorized into 
several major aspects including:  
1) Identification of appropriate technology areas for innovation and leapfrogging.  
2) Balancing different strategies in technology development.  
3) Identification and allocation of limited innovation resources.  
4) Prioritize technologies, strategies, and resources to support innovation. 
5) Identification of disagreement among stakeholders and related implications. 
110 
Referring to Table 7 in Chapter 2, the linkage between research gaps and research 
goals (RG) is established. Five research questions are proposed as guidelines for this 
research according to the research goals. The linkage between research goals and 
research questions (RQ) is illustrated in Figure 11. 
 
 
Figure 11: Connecting Research Gaps, Research Goals, and Research Questions 
 
To answer the research questions and achieve research goals, it is necessary to 
incorporate various influencing factors identified in the literature review section. There is 
a need to construct a new research framework to obtain a proper balance of appropriate 
technologies, development strategies, and innovation resources. Based on the research 
methodologies used in international technology transfer, innovation systems, technology 
foresight, and technology policy, a research framework will be developed to address the 
above mentioned issues in technology development.  
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3.2 Research Methodology 
With the research questions on mind, this research utilizes an analytical approach to 
create a model for exploring effective technology implementation mechanisms to align 
with national innovation objectives. Experts are invited to provide judgmental data in 
determining the relative relationships among the decision elements at various levels of 
the model. The methodology to be utilized is an Analytic Delphi study where experts 
assess the criteria related to technology, strategy, and innovation resources. The initial 
research includes face-to-face consultation of experts to identify critical issues and define 
the criteria. Subsequent pair-wise comparison instruments are developed based on the 
results provided by the experts in the interviews. The AHP method is followed to 
quantify experts’ judgmental data on the issues.  
Delphi offers an approach to make assessments via a panel of experts and is the 
chosen methodology because new technologies will be evaluated for an uncertain 
emerging market environment, where sufficient historical data were not available to 
effectively utilize other traditional quantification methodologies. Scholars have 
successfully applied the traditional Delphi method in technology forecasting research at 
various levels. For example, Gerdsri (2004) integrated the Delphi technique into his 
dissertation to identify technology strategies [210]. Martino describes three situations 
when the Delphi method is more suitable than other quantitative methods: “1) when no 
historical data exists and a forecast may be needed. This situation appears usually with 
the new technology; 2) when the impacts of external factors are more important than the 
internal ones of the phenomena; and 3) when ethical and moral considerations dominate 
the economical and technological goals of the development” [248]. 
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The AHP provides a systematic approach to develop priorities for alternatives based 
on the experts’ judgments. A hierarchy or network structure will be constructed to 
represent a decision problem. AHP utilizes pair-wise comparisons to give priorities for 
the alternatives or criteria based on the experts’ opinions. The appropriate alternatives are 
selected based on the quantitative solution to these rankings. AHP is selected because of 
its many benefits: 1) AHP allows for the measurement of both objective and subjective 
factors; 2) Consistency measures are easily derived to evaluate the quality of the 
judgment; and 3) AHP enables group judgment to arrive at a unique decision that can 
represent the opinions of all participants.  
AHP has been proven to be an effective quantitative decision-support method to deal 
with complex multi-attribute decisions. For instance, Gerdsri (2009) used AHP and 
expert judgment quantifications to develop national R&D strategies for agricultural 
nanotechnology in Thailand [208, 209]. The method has been widely applied in areas of 
management, policy-making, and conflict resolution. It can be utilized for structuring, 
measuring and synthesizing factors or elements that affect decision-making [249].  
This research focuses on the implementation mechanisms and realization pathways 
for prospective technology areas in emerging economies. The research direction is to 
formulate policy actions rather than predict technology areas. It is based on available 
world-class technology foresight or forecasting reports, and to customize those identified 
technologies for implementation or realization in emerging economies. This research has 
shifted away from merely forecasting the technologies, and has moved forward into the 
area of decision making in strategy selection and resource allocation. Therefore, the 
research results are not comparable to current technology forecasting reports and 
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foresight studies because similar research has not been available yet. The outcome of this 
research will serve to support government and industry decision makers to buildup 
innovation capabilities for technological competitiveness. The decision making process 
makes the MCDA an appropriate methodology for this research. 
3.3 Research Model  
To tackle the research gaps through the above methodologies, a hierarchical research 
framework is developed based on pair-wise comparisons to quantify expert decisions. It 
takes into consideration several factors in the research process, including appropriate 
technologies, implementation strategies, and allocation of innovation resources according 
to desirability for long-term benefit. Through a series of judgmental quantifications from 
the experts, the prioritized value for each innovation resource can be calculated, which 
represents its desirability corresponding to the improvement of innovation capacity. The 
results can thus indicate better investment targets to be made in the industry for selected 
high technology fields.  
The structure of the model can be used to develop implementation strategies for 
appropriate technologies for a host country. The HDM has four levels: mission, 
technology, strategy, and resource (Figure 12). 
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In Figure 12:  
M: Mission – Technological Competitiveness and Innovation 
Tk: Prospective Technology Areas (k)   k = 1, 2, 3 … K 
Sj: Technology Development Strategies (j)  j = 1, 2, 3 … J 
Ai: Innovation Resource Alternatives (i)  i = 1, 2, 3 … I 
The top level declares the technological innovation mission of the host country. 
Strengthening technological competitiveness and building innovative capabilities are 
common objectives of technology development in both developed and developing 
countries. Since this research will focus on emerging economies, the objective has been 
adjusted according to the findings from related literature review sections. Here it is 
defined as “Advancement of Technological Competitiveness and Innovation.” Scholars 
have argued that technological competitiveness at the national level is conditional on 
S1 S3 S2 Sj 
A1 A2 A3 A4 Ai 
Resource Level: 
Innovation Resource 
Alternatives 
Strategy Level: 
Technology 
Development Strategies 
T2 T4 T3 
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Technology Level: 
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Technology Areas 
Mission Level:        
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Competitiveness and 
Innovation 
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Figure 12: The Generalized Model 
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three key factors: access to competitive technologies, continuous innovation, and 
provision of the innovative environment [5] [6]. This matches the objective of technology 
development for nations, as well as the mission level of this research. 
The second level consists of a list of prospective technology areas suitable for the 
target country’s development in the future. The RAND Report 2008 argued that populous, 
low-income countries may achieve comparative advantage in R&D in certain areas if 
such countries develop the capacity and institutions necessary to apply new technologies 
[3]. The second level will identify such technology areas that support the innovation 
mission. These are high-tech fields that are suitable for leapfrogging or accelerated 
development in the host country. The focus of interest here is state-of-the-art 
technologies, including both incremental and disruptive technologies that can serve as 
possible “windows of opportunity” for innovation and leapfrogging. The selection of 
technology portfolios should be integrated into the overall national planning process at 
the higher level. Appropriate technologies should be developed to make effective use of 
the host country’s available resources and help the country to further develop innovation 
capabilities.  
The third level defines how the country should strategically develop the identified 
technologies. Several paths of technology development have been identified from the 
literature review: indigenous innovation, imitative innovation, cooperative innovation, 
and international technology transfer. In a globalized innovation network, it is necessary 
to balance the strategies for technology development to increase national competency. 
Scholars argue that the innovation strategies may vary from sector to sector and across 
time. To reveal sector/time-specific characteristics, comparative evaluations of 
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innovation strategies and their impact on organizational performance across various 
sectors and in multiple time frames may produce findings of greater relevance to policy 
makers [180]. 
The fourth level provides a list of input resources that buildup the innovation 
capability of the country. They are also regarded as innovators that generate various 
innovative outputs such as publications, patents, and new products. The innovation 
resources include all the entities that develop, implement, or provide support for the 
candidate technologies. These resources can come from different sources such as the 
public sector, private sector, and even foreign countries. Technology policies should be 
prioritized to strengthen the capability of these innovators, and to maximize their 
innovation outputs as a whole for national technology objectives. 
The generalized model is applicable to technology development scenarios in both 
developed and developing countries. When applied to a developed country, the mission 
level may be adjusted and redefined as “strengthening technological competitiveness 
through sustained innovation” or similar. It is unrealistic for any country to invest in and 
pursue all technology opportunities totally on its own effort [102]. Decisions on the 
priority of investments in high technology industries for a rapidly evolving global market 
are complicated issues and highly risky for governments in all countries. The inputs for 
the technology level can be selected from various study reports in the related industry for 
evaluation. For the strategy level, the emphasis may be different from country to country. 
For example, a developed country may focus more on indigenous innovation or 
collaboration, while a developing country may rely more on imitation or international 
technology transfer. At the resources level, each country may have different conditions or 
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environmental contexts that influence the availability of resources. Given these many 
differences, the model is still applicable for any target country if the correct criteria are 
identified as inputs in each level. 
3.4 Research Framework 
This model uses a hierarchical structure to leverage various technologies, strategies, 
and resources. It combines a top-down and bottom-up approach to consider the needs and 
strategies of both government and enterprises. This requires the judgmental inputs of 
experts from diverse sources including government, industries, and academia. However, 
this diversity may cause inconsistencies and disagreements in the research process. It is 
necessary to have correct quantification measures to deal with such issues. The research 
framework is illustrated in the following steps. 
Step 1: Criteria Definition: 
Mission (M): Technological Competitiveness and Innovation. 
Prospective Technology Areas with reference to M: Tk , with k = 1, 2, 3 ….., K 
Technology Development Strategies with reference to Tk : Sj , with j = 1, 2, 3 … J 
Innovation Resource Alternatives with reference to Sj : Ai , with i = 1, 2, 3 … I 
 
Step 2: Identification of Prospective Technology Areas: Tk , with k = 1, 2, 3 ….., K 
Sources to finalize the technology fields: 
1. Industry research reports  
2. Foresight / forecasting studies 
3. Academic research 
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4. Expert recommendations 
 
Step 3: Technological Development Strategies: Sj , with j = 1, 2, 3 … J 
S1: Indigenous Innovation  
S2: Imitative Innovation  
S3: Collaborative Innovation  
S4: International Technology Transfer  
…… 
Sj : ……  
 
Step 4: Innovation Resource Alternatives: Ai , with i = 1, 2, 3 … I 
A1: Public Research Institutes 
A2: University Research Programs 
A3: Multinational companies  
A4: State-owned Enterprises (SOEs)  
A5: High-tech Small-to-Medium Enterprises (SMEs)  
 …… 
Ai : ……  
 
Step 5: Quantification and Analysis 
The quantification process utilizes the Pair-wise Comparison Method (PCM), where 
experts are asked to allocate weights for the elements. By using the constant-sum method, 
a total of 100 points will be assigned between any two elements at the same level.  
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Under Mission (M), quantifying expert judgment of relevant technology fields to 
obtain V (Tk). For each Tk (k = 1, 2 …, K), using pair-wise comparison to determine the 
relative value of Tk in terms of their desirability for M. 
 
 
Judgmental value of the best Tk for M is based on a scale of 0 – 100, and then 
normalized to be within the range of 0 – 1. 
Determine relative importance of each strategy Sj (j = 1, 2 …, J) for Tk by pair-wise 
comparisons V(Sjk). Scaling and normalization methods are of the same ratio as the 
above level. 
 
 
Determine relative importance of Ai (i = 1, 2 …, I) for Sj by pair-wise comparisons, 
V(Aij). 
For j = 1, 2 …, J: 
Prospective Tech  
Areas: Tk 
 
 
Tech Development 
Strategies: Sj       …… 
 
Relative value V(Sjk):      0.25          0.10           0.15 ……  0.50 
S2 S1 S3 Sj 
Tk 
For k = 1, 2 …, K: 
Mission: 
 
 
 
Prospective Tech        
Areas: Tk       …… 
 
Relative value V(Tk):    0.03        0.01         0.04   ……  0.20 
T2 T1 T3 Tk 
M 
Figure 13: Determining the Priority Value of Prospective Technology Areas 
Figure 14: Determining the Priority Value of Technology Development Strategies 
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For any innovation resource alternative Ai, calculate the value of contribution toward 
M, sort V(AiM) according to its numerical value, and discuss implications. 
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Step 6: Validation and Recommendation 
In this Phase, the researcher will validate the results and conduct related analysis. 
The intermediate results will be given back and forth among the experts. The experts will 
comment on the results after reviewing the summary reports. The process will stop after 
finding a greater consensus of the experts. Otherwise, the results need to be improved by 
revising the judgment questions, and retaking the evaluation process. Sensitivity analysis 
will assist the understanding of relationships among different levels. The analysis 
quantifies the range of difference of the optimal set if there are changes in related criteria, 
and it provides the basis to assist policy-makers in modifying the hierarchy for selection 
of the optimum strategy. Policy recommendations will be given by interpretating the 
results for identification of effective and ineffective innovation resources. The results 
For i = 1, 2 …, I: 
Tech Development  
Strategies: Sj 
 
 
Innovation Resource        
Alternatives: Ai       …… 
 
Relative value V(Aij):      0.10          0.30           0.25 ……  0.35 
A2 A1 A3 Ai 
Sj 
Figure 15: Determining the Priority Value of Innovation Resources 
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support decision makers to determine where the investments and policy measures should 
be given.  
3.5 Inconsistencies 
During the above processes, inconsistency values for the constant sum method are 
calculated as follows [269]: For n elements, the constant sum calculations will result in a 
total of n! orientations with vector values represented by r1, r2 ... rn for each. If the expert 
is totally consistent, the relative values will be the same for each orientation. Otherwise, 
if inconsistency exists it will result in differences in the relative values in different 
orientations. According to Kocaoglu’s research, if the inconsistency level is less than 10% 
or 0.1, the related judgmental data should be acceptable [252].  
Let ijr  = relative value of the i
th element in the jth orientation for an expert  
ir  = mean relative value of the ith element for that expert:  
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Variance in the relative value of the ith element: 
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Inconsistency of the expert in providing relative values for the n elements is defined 
as: 
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3.6 Disagreements  
The methodology for measuring disagreement is based on the Ph.D. dissertation 
done by N. Gerdsri (2004), and then expanded by P. Gerdsri’ Ph.D dissertation in 2009 
[210, 211] [208, 209]. The intraclass correlation coefficient ( ICR ) is calculated to 
measure the degree to which k judges/experts are in agreement with one another on the 
ratings of n subjects/criteria. The coefficient ICR  may achieve the maximum of 1 when 
all experts assign the same mean values to the subjects (absolute agreement); or the value 
of ICR  is close to zero when there is a substantial difference between the mean judgment 
values among all experts. If ICR  has a negative value, the negative correlation is 
generally considered as zero. It has been accepted that a ICR  > 0.7 indicates a strong 
agreement among the experts [270]. The intraclass correlation coefficient can be 
calculated through the following equation. The related parameters are further 
decomposed and described below: 
)()1( resBJresBS
resBS
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Where: 
The mean square between-conditions MSBJ = SSBJ/dfBJ 
The mean square between-subjects MSBS = SSBS/dfBS 
The mean square between-residues MSres = SSres/dfres  
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The residual sum of squares (SSres) SSres = SST - SSBJ - SSBS 
dfBJ = between-judges degrees of freedom = k - 1 
dfBS = between-subjects degrees of freedom = n - 1 
dfres = residual degrees of freedom = (n-1)(k-1) 
dfT = total degrees of freedom 
n: denotes the number of subjects 
k: denotes the number of judges  
T: subscript denotes total 
Based on the intraclass correlation coefficient, Shrout and Fleiss (1979) developed a 
statistical procedure to test the hypothesis to discover whether or not there is an absolute 
disagreement among the judges [271].  
The null hypothesis is defined as:  
H0: ICR  = 0 
H1: not H0 
The null hypothesis means there is no correlation among the judges, which indicates 
absolute disagreement among the experts. The authors suggested applying F-test as the 
statistical measure. The F-ratio for testing the agreement among experts is defined as: FBS 
= MSBS / MSRES The computed F-ratio will be compared with the critical F-values with 
degrees of freedom df1 (= dfBS) and df2 (= dfRES) at a desirable level of significance. H0 
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will be rejected if the F-ratio is greater than the F-critical, which means that there is no 
statistically significant disagreement among the experts.  
3.7 Sensitivity Analysis  
In real world scenarios, there are various uncertainties that may lead to changes in 
policy decision-making. For example, disruptive technologies can have significant impact 
on the development of high tech industries, as well as on the decision-making in 
technology policies. It is especially meaningful for this model to characterize scenarios 
that could affect changes in the rankings of decision elements. This can be interpreted in 
reality that when technology policies give different priorities to the prospective 
technology areas, the priority rankings of supportive innovation resources may also 
change accordingly. It is beneficial to measure the range of tolerance of such changes 
through sensitivity analysis techniques. Having a good understanding of these changes 
will give policy makers better insights on investment, incentives, regulations, and other 
technology policy measures. 
This study utilizes the sensitivity analysis algorithm for hierarchical decision models 
presented in Chen’s dissertation and Kocaoglu's research [272] [273]. With this method, 
algorithms were developed based on a series of mathematical deductions. It is an accurate 
and comprehensive method to examine the impact of changes in different levels of a 
hierarchical decision model on the ranking of the alternatives. In this method, tolerance is 
defined as the allowable range in which a contribution value can vary without changing 
the ranking order of bottom level alternatives. In order to determine the tolerance, the 
allowable ranges of perturbations are always calculated first. The result will reveal the 
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tolerances of contributions of technology goals to the mission while the innovation 
resource rankings remaining the same. Before the application of the sensitivity analysis 
algorithm, it is necessary to redefine some symbols to be used in this research. 
lO : The l th objective, Ll ...2,1  
In this research, the technologies have been adapted as objectives which include: 
Chemical Pharmaceutical Technology, Biopharmaceutical Technology, and Herbal 
Pharmaceutical Technology.  
iA : The i th action, Ii ...2,1  
Here the actions represent input resources including: public research institutes, 
university programs, foreign R&D centers, state-owned enterprises, and high-tech 
small-to-medium enterprises. 
ila : Contribution of the i th action to the l th objective 
ia : Contribution of the i th action to the mission 
ri : The rank of i . rA ranks higher than nrA  , indicating nrr aa   
lo : Contribution of the l th objective to the mission 
Let’s denote the perturbation induced on one of the lo s as *l ,  
Where 
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The original ranking of all iA  will remain unchanged if the above condition is 
satisfied for n = 1, and r = 1, 2 … I-1 in this research. The top choice will remain the 
same if the above condition is satisfied for r = 1 and n = 1, 2 … I-1. 
3.8 Expert Panels 
The selection of expert panels is vital for the success of Analytic Delphi research. 
The judgmental data provided by experts strongly influence the final research outcome. 
According to the nature of this study, the experts will come from diverse sources to 
provide a balanced perspective representing both government and industry. Stakeholders 
from both domestic and foreign sources will be invited to represent different perspectives. 
The experts will have several roles during the research process: to help validate the 
construct and content of the hierarchical model, to provide the judgmental data of relative 
impacts, and to validate the results of research [274]. Several criteria are used to select 
expert panel members. Firstly, it is necessary to work with experts who have essential 
knowledge sets in the research areas. They should have an in-depth understanding of the 
subject. Secondly, the experts should have the availability and willingness to participate 
in the research. Thirdly, they should have the ability to see technological competiveness 
in a holistic way from macro and micro perspectives. Ideally, they should be able to cross 
over both traditional viewpoints and unconventional angles. Last but not least, the expert 
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panel should consist of balanced perspectives and biases. There should be no dominance 
by loudness or silent bystanders. 
The expert panel is recruited based on their expertise as well as their backgrounds. In 
the hierarchical structure, the top and second levels require more technically oriented 
people who are familiar with global technological trends. They also need to possess 
knowledge about the characteristics of local needs, capabilities, and trends. The third and 
bottom level requires more strategically oriented people who possess managerial 
experience or planning perspectives. Therefore, this research will include both 
“technological” and “strategic” types of experts in the priority setting process. Although 
different types of experts may be independent from each other, the members possessing 
multiple knowledge sets are extremely beneficial to the research. For example, senior 
managers with technical backgrounds are well-suited to represent the interests of 
enterprises and industry; Government officials who have a technical background, often 
called technocrats, are important candidates to represent the concerns of government. 
These experts can provide holistic perspectives in their judgments.  
A balanced participation from various types of experts will be considered in the 
research. This ensures the generation of specific knowledge and consensus by eliciting 
judgments according to the unique backgrounds of the experts. The expert panel is 
divided into several subgroups according to the research purpose for each level. 
Subgroup-G may consist of policy makers and scientists from the government agencies; 
Subgroup-F experts have backgrounds or interests in various foreign organizations; 
Subgroup-L experts may come from local industrial organizations or research institutes. 
This is to consider the balanced interests and perspectives among different stakeholders. 
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It should be mentioned that different viewpoints are considered for each level of the 
model hierarchy. Experts from different subgroups are distributed in the judgmental 
quantification process for each level of the hierarchical structure. These experts serve to 
provide different perspectives representing the interests of government, domestic, or 
foreign stakeholders.  
The diversity of viewpoints to be represented in the judgmental data will be 
measured by the disagreement value during the quantification process. A major concern 
of diversified participation is that the different backgrounds of the experts may lead to 
potential conflict or disagreement. However, the variety of judgments can also initiate a 
constructive conflict which is beneficial toward the research. By incorporating the Delphi 
method, the research aims for a greater consensus in the end. 
3.9 Research Validation 
The validation process consists of three major aspects: construct, content, and 
criterion-related validity. The purpose of validation is to enhance the credibility of the 
research. Experts are invited to verify the model for construct and content validity. The 
research results are tested for criterion-related validity.  
Construct validity is to ensure the appropriateness and correctness of the model 
structure. Experts are asked to comment on the validity of the structure, and the 
feedbacks are used to improve the model. Content validity is to verify that the elements 
are appropriate and cover the range of necessary decision measurements for the research. 
The criteria to be validated are extracted from related academic literature and then further 
refined by the researcher. Drafts of the research instruments are developed to 
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communicate the rationale of the model and related measurements to the participating 
experts. Comments and feedback are consolidated by the researcher and then reviewed 
again by members of the expert panel to achieve consensus. The validation results are 
reflected in the preparation of the quantification research instruments. Criteria-related 
validity refers to the review and verification of the final research outcomes. When the 
research is done and results are analyzed, the researcher will contact the experts again to 
review and confirm the validity of the results. The research outcome will be thoroughly 
assessed, and practical implications and recommendations will be discussed accordingly. 
These three major aspects of validation (construct, content, and criterion-related) will be 
applied and discussed throughout the case application in the following Chapters. 
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Chapter 4 – Case Application and Research Development 
Based on the generalized research model developed in Chapter 3, a case study 
focused on the Chinese biopharmaceutical sector will be presented in this Chapter. The 
criteria of the hierarchical model are customized according to case conditions. The 
research activities include formation of expert panels, research validations, preparation of 
research instruments, and data collection. 
4.1 Case Background 
The pharmaceutical industry is often characterized as a research-driven sector 
because of its exceptionally high ratio of R&D inputs to sales. Development of novel 
drugs is very difficult because of several issues: 1) heavy investment; 2) high risks; and 3) 
long development cycle. A novel drug may need to go through many lengthy processes 
and stages which can easily add up to 10 - 15 years. With one wrong step over the years, 
the whole project may fail. Investment can easily be hundreds of millions of dollars or 
more.  
4.1.1 The Pharmaceutical Market in China 
China’s pharmaceutical market is one of the most dynamic in the world. It grew 22% 
in 2010 to US$116 billion and ranked the fifth largest in the world [275]. With an 
average annual growth rate above 20% from 2005 to 2010, it is set to overtake Japan as 
the world’s second largest market by 2015 [276]. Due to the economic recession in the 
Western countries, the Chinese pharmaceutical market is steadily moving up toward the 
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leading position globally. However, the Chinese pharmaceutical industry faces huge 
challenges in the area of technological innovation. Breakthrough technological 
innovation from the domestic Chinese pharmaceutical sector is rarely seen for decades. 
Although China is a major exporter of pharmaceuticals, it is specialized in the production 
of crude drug substances and low-tech generics, rather than novel drugs. 
The Chinese pharmaceutical market is highly fragmented and very different from the 
market in developed countries. In 2010, generic drugs had about 76% of the entire 
pharmaceutical market in China, while only 4% of the market was comprised of 
innovative drugs still under patent protection. The remaining 20% of the market consisted 
of off-patent drugs (Figure 16) [275]. The generic drugs market has the largest segment 
and has mostly been controlled by domestic products. However, the profit margin is low 
due to intense competition. The innovative drug market has the smallest segment and is 
dominated by imported products, particularly those produced by MNCs. For the off-
patent drug segment, both imported and domestically-produced branded drugs compete to 
survive.  
 
Figure 16: Innovative and Generic Drug Market Share in China 2010 
4%
20%
76%
Off-patent 
drugs
Innovative drugs within 
patent protection
Generic 
drugs
Source: IMAP (2012)
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4.1.2 The Biopharmaceutical Sector 
China’s pharmaceutical industry consists of three major sectors: 1) chemical 
pharmaceuticals; 2) biopharmaceuticals; and 3) traditional herbal medicines. Although 
the chemical pharmaceutical technologies have been regarded as the industrial 
foundations in the last century, biopharmaceutical technologies have been emerging as a 
prospective area with huge growth potential. Many leading chemical pharmaceutical 
companies have already tapped into the biotechnology area. There has been a paradigm 
shift in industrial R&D from high-risk synthetic pharmaceuticals towards R&D in 
biopharmaceuticals. The top chemical pharmaceutical companies spent tens of billions of 
dollars to acquire biotechnology companies and in-licensing deals. Pfizer, Roche, Lilly, 
Astra Zeneca, Glaxo Smith Kline (GSK) and Bristol Myers Squibb have all underlined 
their strong commitment and highlighted their biological projects in R&D pipeline [277]. 
The Chinese biopharmaceutical industry has been developing rapidly in recent years. 
Since this is still a new area with good prospects, both established pharmaceutical 
companies and startup firms are trying to profit from the expanding market. Although the 
overall innovation capability of domestic players is not very strong, research in some 
specialty areas has already caught up with the level of leading countries. However, it is 
generally accepted that the Chinese biopharmaceutical industry still needs to increase its 
competitiveness globally, especially in high technology areas. 
4.1.3 Policy Factors 
The pharmaceutical sector is among the mostly regulated areas in healthcare. The 
innovation capability of the industry is largely influenced by macro factors including 
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regulations, economy, demographics, and technology level. For example, the 
reimbursement issue needs to be considered in the Chinese market. The government 
introduced the National Essential Drug List (NEDL) in 2009 to set the range of 
reimbursement and lower drug prices for the general public. NEDL sets upper limits of 
the retail prices for the drugs on the list. Innovative drugs are usually not included on the 
reimbursement list. These drugs are graded at the highest price in the market. Since no 
imbursement are available, the innovative drugs have a very limited market size. As 
illustrated in Figure 16, the market share was only 4% in 2010 [275]. Therefore policy 
factors can have significant impact on the direction of the pharmaceutical industry and its 
development. Successful technology policy relies on a better understanding of both 
global and domestic market environments. Decision makers need to evaluate related 
issues and adjust their strategy accordingly. In order to build a competitive and 
innovative pharmaceutical sector, both foreign factors and domestic settings call for 
effective strategic orientation to adapt to global market competition.  
4.2 Model Development  
This section will focus on crafting the model and applying it to the emerging 
Chinese biopharmaceutical sector. Decision criteria in each level of the hierarchical 
model are analyzed and customized according to the conditions in China’s 
biopharmaceutical sector. This provides a foundation for further validation by experts. 
The model will be finalized based on the feedback from expert panels. 
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4.2.1 Mission Level   
The top-level mission has been defined as “Technological Competitiveness and 
Innovation”[6]. This mission is applicable to the fast-developing biopharmaceutical 
industry in China [278] [279]. Due to historical reasons, the technology level of the 
Chinese biopharmaceutical sector remains less competitive globally, and it still faces 
challenges including weak innovative capacity and lack of R&D investment. Due to the 
high investment risk and long development cycle, the biopharmaceutical sector relies 
heavily on regulations and support from governments. Strengthening technological 
competitiveness and building up innovative capabilities are primary concerns of industry 
as well as policy makers. 
4.2.2 Technology Level – Prospective Technology Areas  
The rationale of the model’s technology level is to identify global technology trends 
and adapt to local capabilities and needs. Choosing the right technology areas and 
guiding investment are major topics in technology policy. While it is unrealistic for the 
Chinese biopharmaceutical industry to excel in all high technology areas, it is more 
realistic to focus on key areas where the country has potential capabilities to achieve 
competitive advantages. From the perspective of industrializing countries, the appropriate 
technology can offer windows of opportunity to catch-up with leading countries. In other 
words, China should look into the global technology frontiers and seize the opportunities 
for catching up. 
To represent the global technology trends and emerging areas in the model, this 
research will incorporate the findings from technology forecasting reports published by 
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international organizations such as the United Nations (UN) and Organization for 
Economic Co-operation and Development (OECD). The UN has published the research 
results in a report titled Top Ten Biotechnologies for Improving Health in Developing 
Countries (Table 8) [280]. More recently in 2009, OECD published the forecasting report 
Human Health Biotechnologies to 2015, which is based on the conditions of its member 
countries [281] [282].  
 
Rank Biotechnology 
1 Modified molecular technologies for affordable, simple diagnosis of infectious diseases 
2 Recombinant technologies to develop vaccines against infectious diseases 
3 Technologies for more efficient drug and vaccine delivery systems 
4 Technologies for environmental improvement (sanitation, clean water, bioremediation) 
5 
Sequencing pathogen genomes to understand their biology and to identify new 
antimicrobials 
6 
Female-controlled protection against sexually transmitted diseases, both with and 
without contraceptive effect 
7 Bioinformatics to identify drug targets and to examine pathogen-host interactions 
8 Genetically modified crops with increased nutrients to counter specific deficiencies 
9 Recombinant technology to make therapeutic products more affordable 
10 Combinatorial chemistry for drug discovery 
Table 8: Top Ten Biotechnologies for Improving Health in Developing Countries 
Source: UNESCO (2006) 
 
 
The available research indicates that different countries have different needs for 
technologies due to various developmental conditions [283]. As an emerging nation, 
which walks in between the developed and developing cohort, China needs to identify 
prospective technology areas based on its needs and capabilities. The following model’s 
criteria and definitions were developed based on the reports from the OECD and UN [280] 
[281] [282], and were verified by consultations with experts. 
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Recombinant therapeutic proteins – therapeutic proteins are used to treat many non-
communicable diseases. These technologies provide affordable and sustainable sources 
for treatment of chronic disease [280-282]. 
Recombinant vaccines against infectious diseases – vaccines produced using 
recombinant DNA technology. The products can be used to effectively treat infectious 
diseases [280-282]. 
Monoclonal antibody technology – Monoclonal antibodies (mAb) can be used for 
therapeutic treatment and diagnostic tests. Many therapies are undergoing clinical trials. 
Most are concerned with immunological and oncology targets [281, 282]. 
Tissue engineering technologies – These technologies involve techniques that 
replace or act directly on cells and tissues in the body. The treatment repairs tissues 
damaged from injuries and diseases [281, 282]. 
Stem cell therapy – This type of treatment leads to the production of entire organs. 
These technologies include the use of stem cells as a therapeutic method, or to repair 
specific tissues or grow organs [281, 282]. 
Gene therapy – This technology involves the treatment of a disease by introducing a 
new gene into a cell. It either uses or acts directly on nucleic acids, which are the 
molecules that serve as the building blocks for DNA and RNA [281, 282]. 
Antisense therapy – Antisense drugs are being researched to treat a wide range of 
diseases such as cardiovascular diseases, asthma, and arthritis. There are currently more 
than 30 anti-sense therapies in clinical trials [281, 282].  
RNAi (ribonucleic acid interference) – This includes all entries for products which 
act therapeutically via an RNA interference mechanism. There have been a great number 
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of research activities in this new area. Most proposed clinical uses are aimed at treating 
infections [281, 282].  
 Nanobiotechnology for efficient drug and vaccine delivery – This type of 
technology aims for improved drug delivery systems from the convergence between 
biotechnology and nanotechnology [281, 282].  
Synthetic biology – The design and construction of new biological parts, devices and 
systems that do not exist naturally; The redesign of existing biological systems to 
perform specific tasks [281, 282]. 
Bioinformatics to identify drug targets and examine pathogen-host interactions – 
These technologies cover the manipulation and analysis of large datasets of genetic and 
health information [280-282].  
Pharmacogenetics – This technology identifies inherited differences (variation) 
between individuals in drug metabolism and response. It can be applied in clinical trials 
and prescribing practices [281, 282]. 
Gene sequencing – Sequencing of pathogen genomes provides ways to identify new 
antimicrobials. These technologies can accelerate the process of drug discovery and fight 
against infectious diseases [280-282].  
Biotechnology Diagnostics – This technology includes both in vitro diagnostics and 
in vivo diagnostics. Modified molecular technologies provide affordable and simple 
diagnosis of infectious diseases [280-282]. 
138 
4.2.3 Strategy Level – Technology Development Strategies  
The Strategy Level defines how technologies should be developed and implemented. 
As an industrializing country, China faces the decisions of “Make” or “Buy”, or 
somewhere in between [259]. According to the findings from the literature review section, 
the following strategies are defined to describe the situation: 
Indigenous Innovation – This strategy relies on the host country’s local technology 
base and available innovation resources to build up indigenous competence [74-76]. 
Imitative Innovation – Also known as re-innovation in literature, it is based on 
imitation, adaptation, and improvement of the original innovators’ technology [74] [77] 
[78]. 
Collaborative Innovation – This strategy means the participants cooperate and 
develop new ideas altogether. Competitors may share resources and work together toward 
innovation [74] [79]. 
International Technology Transfer – This includes technology import and 
acquisitions. This is a fast track to save valuable time and resources during the catching-
up process [14] [19] [24] [284]. 
4.2.4 Resource Level – Innovation Resource Alternatives 
Under the condition of a transitional economy, China’s National Innovation system 
carries some characteristics from both a market economy and centrally-planned system. 
Here we need to identify the key contributors toward technology development and 
innovation in the Chinese biopharmaceutical sector. Subsidies and favorable policy 
measures should be designed and prioritized to strengthen the performance of effective 
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innovators. The following innovation resources have been identified by the literature 
review. 
State-Owned Enterprises (SOEs) – SOEs are medium- to large-sized companies left 
by the centrally planned system. These companies constitute the main production 
capacity of the Chinese pharmaceutical industry, but most of them specialize in low-tech 
generics drugs. Compared with foreign counterparts, domestic pharmaceutical companies 
are weaker in terms of technology level and research capabilities [259] [285] [286] [287].  
High-tech Small-to-Medium Enterprises (SMEs) – These smaller companies have 
emerged since the 1980s, when the government started to allow private ownership of 
companies. Many small dedicated biotechnology firms (DBFs) belong to this category. 
They probe into potential technology areas with the purpose of obtaining leadership 
status in some niche sub-sectors [285] [288] [286].  
Multinational Company and subsidiaries (MNCs) – Currently, many top MNCs have 
established subsidiaries in China. These large American and European pharmaceutical 
companies have dominant innovative capability in most technological areas. They act as 
technology leaders in both production and R&D activities in the Chinese pharmaceutical 
sector [279] [288] [289].  
Contract Research Organizations (CROs) and Contract Manufacture Organizations 
(CMOs) – These organizations provide services for both foreign and domestic companies. 
Through learning-by-doing from leading innovators, CROs and CMOs have shown 
increasing capabilities in developing advanced technologies and manufacturing practice 
aligning to international standards [290] [288] [291].  
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University Research Programs (URPs) – Some top research universities are 
emerging forces in pharmaceutical innovation, and they have been producing more 
publications and patents in recent years. Not only do these research universities innovate 
through laboratories, but they also cultivate talented young students for the domestic 
pharmaceutical industry [286] [288].  
Equity Joint Ventures (EJVs) – This is a common way for foreign companies to 
enter the Chinese biopharmaceutical sector, especially during the 1990s. Two or more 
investors share the ownership and control over the equity, property (including IP), and 
operation [288] [292] [287]. 
Public Research Institutes (PRIs) – PRIs and national R&D laboratories are owned 
and managed by government departments. These organizations carry out research 
projects according to government instructions [286] [288].  
Foreign R&D Centers (FR&D) – In recent years, some foreign invested R&D 
centers have been established in China. The biopharmaceutical sector is one of the target 
areas. This has also happened in India in recent years. Foreign R&D Centers are capable 
of carrying out comprehensive research to develop new medicines at the innovation 
frontiers [290] [293]. 
4.3 Model Validation  
After the decision criteria for each level of the hierarchy were prepared by the 
researcher, the model was sent to related experts for validation. The researcher also 
provided background information about the research along with the model. During the 
validation process, each level was tested for the criteria’s preferential independence. The 
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experts were asked to comment about the model construct, and they were allowed to add 
and/or remove criteria as appropriate.  
The prospective technology areas in the biopharmaceutical industry are extracted 
from available foresight reports. There are two major reasons for these technology areas 
to be validated. Firstly, these reports were published a few years ago, and they need to be 
updated and validated according to recent development. For example, the OECD 
forecasting report was published in 2009. If we consider the publication lag, the research 
should be done between 2008 and 2009. Secondly, the OECD report represented the 
findings from a club of developed countries, while this research focuses on emerging 
economies. As discussed above, the rationale of the technology level is to identify global 
trends and customize to local needs and capabilities. These requirements of validation 
were declared in the introduction and instruction sections of related instruments 
(Appendix C). The results are presented in Table 9.  
 
Prospective Technology Areas Votes on Yes 
Recombinant Therapeutic Proteins  13 
Recombinant Vaccines 13 
Monoclonal Antibody 13 
Tissue Engineering 9 
Stem Cell Therapy  9 
Gene Therapy  10 
Antisense Therapy  10 
RNAi 10 
Nanobiotechnology  12 
Synthetic Biology 10 
Bioinformatics 11 
Pharmacogenetics  10 
Gene Sequencing  10 
Biotechnology Diagnostics  12 
Total Votes 13 
Table 9: Validation Results for Prospective Technology Areas 
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For the purpose of this research, most experts believed that the extracted technology 
areas are viable in the biopharmaceutical industry. Based on such feedback, the 
researcher included all identified technology areas in the model. Regarding preferential 
independence, several experts suggested combining two technology areas, i.e. “tissue 
engineering” and “stem cell technology” into “cell and tissue engineering.” The 
researcher contacted other experts about it, and they all agreed to this change.  
The technology development strategies were extracted from related literature, 
including indigenous innovation, imitative innovation, collaborative innovation, and 
international technology transfer. In general, most experts believe that these technology 
development strategies are observable in the biopharmaceutical industry. Table 10 
presents the validation results of technology development strategies.  
 
Technology Development Strategies Votes on Yes 
Indigenous Innovation  12 
Imitative Innovation  13 
Collaborative Innovation  13 
International Technology Transfer  11 
Total Votes 13 
Table 10: Validation Results for Technology Development Strategies 
 
Regarding the resources level, the prepared list of criteria includes: University 
Research Programs; Public Research Institutes; State-Owned Enterprises; High-tech 
SMEs; Equity Joint Ventures; Contract Research/Manufacture Organizations; Foreign 
R&D Centers; MNCs and Subsidiaries. The validation results of the innovation resources 
are summarized in Table 11. Although some resources have more votes than others, most 
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resources’ votes are above 70%. Therefore, all prepared resources are included in the 
research. 
After several iterations, the results were finalized when a consensus was reached. It 
should be acknowledged that the experts’ feedback was very encouraging and 
informative. The validation of decision criteria helped to answer research questions RQ1, 
RQ2, and RQ3, as stated in Section 3.1.  
 
Innovation Resources  Votes on Yes 
University Research Programs 13 
Public Research Institutes 13 
State-owned Enterprises 10 
High-tech Small-to-Medium Enterprises 13 
Equity Joint Ventures 12 
Contract Research/Manufacture Organizations 11 
Foreign R&D Centers 12 
Multinational Companies and Subsidiaries 13 
Total Votes 13 
Table 11: Validation Results for Innovation Resources 
4.4 The Finalized Research Model  
 
 
Figure 17: The Finalized Research Model 
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Based on the validation results, the finalized research model is illustrated in Figure 
17. In summary, there are four levels as described above, and the complete sets of criteria 
associated with each level are listed below (Table 12):  
 
Levels Criteria 
Mission Level (M): 
M: Technological Competitiveness and Innovation in 
Biopharmaceutical Industry 
Technology Level:  
Prospective Technology 
Areas (Tk): 
T1: Recombinant Therapeutic Proteins 
T2: Recombinant Vaccines 
T3: Monoclonal Antibody Technology 
T4: Cell and Tissue Engineering 
T5: Gene Therapy 
T6: Antisense Therapy 
T7: RNAi 
T8: Nanobiotechnology 
T9: Synthetic Biology 
T10: Bioinformatics 
T11: Pharmacogenetics 
T12: Gene Sequencing 
T13: Biotechnology Diagnostics 
Strategy Level: 
Technology Development 
Strategies (Sj) 
S1: Indigenous Innovation   
S2: Imitative Innovation 
S3: Collaborative Innovation 
S4: International Technology Transfer 
Resource Level: 
Innovation Resource 
Alternatives (Ai): 
A1: University Research Programs 
A2: Public Research Institutes 
A3: State-owned Enterprises 
A4: High-tech Small-to-Medium Enterprises 
A5: Equity Joint Ventures 
A6: Contract Research/Manufacture Organizations 
A7: Foreign R&D Centers 
A8: MNCs and Subsidiaries  
Table 12: The Finalized Model Criteria 
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4.5 Formation of Expert Panel 
In this research, the model was applied to the fast-growing biopharmaceutical 
industry in China. The expert panel included policy-makers from government agencies 
and technology management experts from the health industries. Some of the experts were 
stakeholders from the domestic and foreign organizations. These included domestic 
enterprises, top multinational pharmaceutical companies and foreign research institutions. 
Foreign stakeholders were included because of their technology strength and their long-
term investment stakes in the Chinese pharmaceutical market. Domestic 
biopharmaceutical companies were selected to represent local perspective in research and 
development. The idea here is to reach a “Win-Win” situation in technology development.  
A total of 20 experts participated in the research process (Table 13). According to 
the University’s research policy on human subjects, the identities of the experts were 
coded to protect their privacy (Appendix A, B). By following the expert recruitment 
criteria discussed in Chapter 3, the expert panel was divided into three subgroups to 
match the purpose of this research. Subgroup-G experts have backgrounds from various 
Government agencies. All of them are senior officials or researchers from the National 
Medical Policy Research Center, MOH, State Food & Drug Administration, and Center 
of Drug Evaluation. Subgroup-F experts have Foreign backgrounds, and represent the 
interests of various foreign organizations, which include two foreign research institutions 
and three of the top-ten multinational enterprises (Roche, Sanofi-Aventis, and GSK). 
Subgroup-L consists of Local experts from the domestic industry and research 
organizations (non-government & without foreign backgrounds), which include bio-tech 
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SMEs, industrial associations, and public research institutions. Since the experts come 
from diverse sources, they can provide valuable judgment from different perspectives. 
 
Expert Affiliation Subgroup - G Subgroup - F Subgroup - L 
Exp - 1  Management  
  
x  
Exp - 2  Management  
  
x  
Exp - 3  Scientist/Researcher x  
  
Exp - 4  Scientist/Researcher  x  
  
Exp - 5  Official x  
  
Exp - 6  Official x  
  
Exp - 7  Official x  
  
Exp - 8  Official x  
  
Exp - 9  Management  
 
x  
 
Exp - 10  Official x 
  
Exp - 11  Management  
  
x  
Exp - 12  Scientist/Researcher 
 
x  
 
Exp - 13  Scientist/Researcher 
 
x  
 
Exp - 14  Management  
 
x  
 
Exp - 15  Management  
 
x  
 
Exp - 16  Official x  
  
Exp - 17  Management  
 
x  
 
Exp - 18  Management  
  
x  
Exp - 19  Management  
 
x  
 
Exp - 20  Management  
  
x  
Total 
 
8 7 5 
Table 13: Expert Panel and Subgroups 
 
4.6 Data Collection 
The data collection process includes the design of research instruments, validation of 
instruments, the formal quantification judgments, and related iterations. Here we discuss 
the major steps respectively. 
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Three sets of research instruments were developed to quantify the relative weights of 
decision criteria at each level. There are 19 tables of pair-wise comparisons for eight 
input resources, four innovation strategies, and two subgroups of technology areas. Each 
table has 6 to 28 pairs of comparisons for judgment. The confidence level measurement 
used Likert scaling (5 points means very high confidence, 4 points means high 
confidence, 3 points means medium confidence, 2 points means low confidence, and 1 
point means very low confidence). Confidence scores with medium or above scores from 
the experts are acceptable for this research.  
In the research instruments, the pair-wise comparison method (PCM) was used for 
quantifying experts’ judgments. The constant sum (100) method was selected as the 
scaling standard during the quantification process because it is more precise than the 
conventional AHP’s 1-9 scaling. Experts were to compare the relative weight of every 
two elements in the same level regarding their contribution to the element in the higher 
level. An expert may assign any value between 1 ~ 99 to represent the relative weight of 
a criterion. A larger number means a heavier weight of that criterion. For instance, if 
criterion A was assigned with the value of 75, and criteria B assigned with 25, then A is 
three times more important than B. Three sets of judgmental quantification instruments 
were developed for the model. Each set of instruments was designed in accordance with 
the requirements of a specific level. The judgmental quantification instruments are 
attached in the appendices of this dissertation (Appendix D). 
The robustness of the quantification instruments was first validated in several trial 
runs before it was sent to the entire expert panel. This process ensured both usability and 
clarity of the instruments to capture the priorities of criteria in the hierarchy. During the 
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validation process, questions and suggestions on the instruments were collected for 
improvements. Several minor improvements to the instruments were made based on the 
feedback from the trial runs. 
After all of the above preparation steps were completed, the research instruments 
were formally sent to experts for quantification. Different sets of instruments were sent to 
and filled out by different experts according to their expertise and areas of specialty. 
During this process, necessary information and questions regarding the methodology of 
the pair-wise comparisons were conducted through emails and phone calls. Due to 
various reasons, the data collection process was very lengthy. Reminder emails were sent 
repeatedly for feedback. 
Upon receiving all of the completed research instruments from experts, the 
researcher started the data analysis process using the pair-wise comparison software. The 
results were calculated either in matrix or in vector formats. Some important indicators 
and values such as the inconsistencies and disagreements were evaluated. As discussed in 
the methodology section, if the inconsistency value is above 0.1, the input data need to be 
verified with the original expert. In the data collection process, three inconsistencies were 
observed, including one instance in the strategy level and two instances in the resource 
level. Although all inconsistency values were very close to the 0.1 threshold, these inputs 
were reported to the related expert for review. The researcher explained to them about the 
inconsistency measurement, and the experts improved their judgmental inputs. Similarly, 
if significant disagreement values were observed, iterations were also needed to verify 
the results with related experts. These issues are not uncommon for other AHP-based 
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research. In this research, such issues were resolved after several iterations of 
communication with the experts. The aggregated results are presented in the next chapter.  
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Chapter 5 – Results and Data Analysis  
In this section, the results of data collection for each hierarchy level are calculated 
and shown in figures and tables. The data analyses include disagreement measurement 
and sensitivity analysis. The overall contributions of the bottom and intermediate levels 
toward the mission are also calculated and presented.  
5.1 Quantification Results 
All judgmental data collected from the experts were first put into PCM software to 
assess the relative weights of various criteria at different levels of the HDM. The 
inconsistency values of the finalized results were less than 10% or 0.1, which is an 
acceptable level according to available studies [208, 209]. Confidence level was 
measured using the Likert scaling (5 means very high confidence, 4 means high 
confidence, 3 means medium confidence, 2 means low confidence, and 1 point means 
very low confidence). The scores of all levels are very close to 4, indicating that most 
experts have high confidence level.   
5.1.1 Contribution of Technologies to Mission 
The following figure presents the results of the 13 technology areas’ contribution 
toward the overall mission (Figure 18). The arithmetic means of relative priority of the 
technology areas toward the mission are shown as percentages. Individual relative 
priorities, mean values, and inconsistency values of each expert are shown in Table 14 
and 15.  
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Figure 18: Contribution of Technology Areas to Overall Mission 
  
Group 
A 
T1: 
Recombinant 
Therapeutic 
Proteins 
T2: 
Recombinant 
Vaccines 
T3: 
Monoclonal 
Antibody 
T4: 
Cell and 
Tissue 
Engineering 
T5: 
Gene 
Therapy 
T6: 
Antisense 
Therapy 
T7: 
RNAi 
Inconsistency 
Exp1 0.13 0.13 0.21 0.16 0.16 0.10 0.12 0.010 
Exp2 0.28 0.25 0.13 0.06 0.11 0.09 0.09 0.052 
Exp3 0.21 0.21 0.21 0.13 0.10 0.09 0.06 0.014 
Exp5 0.18 0.14 0.22 0.11 0.12 0.11 0.12 0.009 
Exp8 0.35 0.20 0.26 0.07 0.04 0.04 0.04 0.020 
Exp9 0.28 0.28 0.22 0.08 0.08 0.02 0.06 0.020 
Exp11 0.20 0.38 0.21 0.07 0.07 0.04 0.03 0.079 
Exp13 0.26 0.25 0.20 0.10 0.09 0.04 0.07 0.087 
Exp15 0.18 0.16 0.25 0.16 0.08 0.06 0.12 0.007 
Exp18 0.23 0.11 0.25 0.09 0.13 0.10 0.10 0.035 
Mean 0.23 0.21 0.22 0.10 0.10 0.07 0.08 
 
Table 14: Contribution of Technology Areas to Mission, Group A 
  
Group 
B 
T1: 
Recombinant 
Therapeutic 
Proteins 
T8: 
Nano-
biotech 
T9: 
Synthetic 
Biology 
T10:  
Bio-
informatics 
T11: 
Pharmaco-
genetics 
T12:  
Gene 
Sequencing 
T13: 
Biotech 
Diagnostics 
Inconsistency 
Exp1 0.13 0.19 0.13 0.15 0.09 0.15 0.17 0.016 
Exp2 0.36 0.15 0.10 0.10 0.10 0.11 0.08 0.020 
Exp3 0.16 0.15 0.11 0.16 0.11 0.16 0.16 0.013 
Exp5 0.26 0.10 0.15 0.12 0.13 0.08 0.17 0.014 
Exp8 0.33 0.10 0.09 0.08 0.16 0.09 0.16 0.024 
Exp9 0.33 0.19 0.04 0.08 0.08 0.07 0.21 0.014 
Exp11 0.41 0.10 0.09 0.12 0.05 0.10 0.13 0.026 
Exp13 0.26 0.19 0.06 0.09 0.10 0.10 0.21 0.042 
Exp15 0.17 0.10 0.11 0.14 0.19 0.15 0.14 0.008 
Exp18 0.26 0.15 0.10 0.07 0.13 0.17 0.13 0.065 
Mean 0.27 0.14 0.10 0.11 0.11 0.12 0.16 
 
Table 15: Contribution of Technology Areas to Mission, Group B 
0%
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14%
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In the above tables, the priority judgment of the 13 technology areas was split into 
two groups. The purpose was to reduce the large number of pair-wise comparisons which 
may induce a heavy workload for the experts. This process is referred to as chained 
comparison and had been applied in available studies [252] [294]. The rationale of the 
process is that each group shares a common important comparison element, which will be 
utilized to normalize all other elements in each group. In this case, T1 was chosen during 
the validation process as the common important criterion of the two groups. The 
normalized values were calculated and are shown in Table 16 below. 
 
 Technology Areas Contribution 
T1: Recombinant Therapeutic Proteins 14% 
T2: Recombinant Vaccines 13% 
T3: Monoclonal Antibody 13% 
T4: Cell and Tissue Engineering 6% 
T5: Gene Therapy 6% 
T6: Antisense Therapy 4% 
T7: RNAi 5% 
T8: Nanobiotechnology 7% 
T9: Synthetic Biology 5% 
T10: Bioinformatics 6% 
T11: Pharmacogenetics 6% 
T12: Gene Sequencing 7% 
T13: Biotechnology Diagnostics 8% 
Table 16: The Normalized Results 
 
According to the results, T1 Recombinant Therapeutic Proteins has the highest 
contribution (14%) toward the mission. T2 Recombinant Vaccines and T3 Monoclonal 
Antibody Technology tie for the second and third places at 13%. T6 Antisense Therapy 
contributes the least at 4% toward the mission (Table 16). 
Recombinant therapeutic proteins are used to treat many non-communicable diseases 
such as hematology, diabetes, endocrinology, and oncology. The technology to make 
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recombinant therapeutic proteins was among the most promising biotechnologies for 
improving health in developing countries. With the number of affluent people in China, 
the prevalence of chronic disease is growing at staggering rates due to increased levels of 
hypertension, diabetes, and obesity. This offers a huge demand for drug development in 
the local market [295]. Affordable and sustainable sources of therapeutic proteins for 
treating chronic disease are critical to developing countries like China [280]. 
Recombinant vaccines can be used to effectively treat infectious diseases. Vaccines 
are widely considered as essential for disease prevention in both developing and 
developed countries. Recombinant vaccines have proven to be cheaper as well as safer in 
testing and production than inactivated or attenuated vaccines [283]. With a large 
population, the outlook for vaccines remains bright in China. The growth rate of the 
Chinese vaccine market is around 20%, and its size will reach CNY 12 billion by 2013 
[296]. Focusing on this area is absolutely critical for domestic needs in China. 
Monoclonal Antibody is one of the fastest growing areas in the biopharmaceutical 
industry. The value of the global therapeutic mAb market exceeded US $17 billion in 
2007, and many mAb applications become blockbuster drugs [297]. If China wants to be 
competitive and innovative in the world’s biotech arena, mAb is an area that cannot be 
overlooked.  
5.1.2 Contribution of Development Strategies to Technologies Areas 
This section presents the results of the relative contribution of strategies toward the 
prospective technology areas. The results are illustrated in sequential order from T1 to 
T13. The experts’ individual judgments for each technology area are also included. These 
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findings give us the answer for “which strategy is better for the development of the target 
technology.”  
 
5.1.2.1 Strategies for T1: Recombinant Therapeutic Proteins 
  
T1: 
Recombinant 
Therapeutic 
Proteins 
S1: 
Indigenous 
Innovation 
S2: 
Imitative 
Innovation 
S3: 
Collaborative 
Innovation 
S4:  
Int’l Tech 
Transfer 
Inconsistency 
Exp4 0.43 0.35 0.16 0.07 0.013 
Exp6 0.24 0.33 0.24 0.18 0.004 
Exp11 0.25 0.43 0.20 0.12 0.005 
Exp12 0.19 0.40 0.15 0.26 0.031 
Exp15 0.18 0.39 0.22 0.22 0.032 
Exp16 0.40 0.26 0.14 0.20 0.002 
Exp19 0.33 0.21 0.20 0.26 0.001 
Exp20 0.36 0.29 0.16 0.19 0.009 
Mean 0.30 0.33 0.18 0.19   
Table 17: Contribution of Strategies to T1 Recombinant Therapeutic Proteins 
  
 
Figure 19: Contribution of Strategies to T1 Recombinant Therapeutic Proteins 
    
As shown in the results (Figure 19), S2 Imitative innovation strategy (33%) ranked 
the first for T1 Recombinant Therapeutic Proteins, followed by S1 Indigenous innovation 
strategy (30%) at the second position. S3 Collaborative innovation and S4 International 
technology transfer ranked relatively low at 18% and 19% respectively. It should be 
noted that the rankings of imitative innovation strategy and indigenous innovation 
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strategy are relatively close, meaning that China should focus on catching up with leading 
innovators, and also try to indigenously develop novel drugs in the area of recombinant 
therapeutic proteins (Table 17). 
 
5.1.2.2 Strategies for T2 Recombinant Vaccines 
  
T2: 
Recombinant 
Vaccines 
S1: 
Indigenous 
Innovation 
S2: 
Imitative 
Innovation 
S3: 
Collaborative 
Innovation 
S4:  
Int’l Tech 
Transfer 
Inconsistency 
Exp4 0.21 0.54 0.21 0.05 0.080 
Exp6 0.32 0.33 0.21 0.14 0.034 
Exp11 0.27 0.41 0.16 0.16 0.031 
Exp12 0.38 0.19 0.30 0.13 0.035 
Exp15 0.33 0.27 0.22 0.18 0.008 
Exp16 0.48 0.17 0.17 0.18 0.007 
Exp19 0.39 0.15 0.30 0.16 0.005 
Exp20 0.46 0.21 0.18 0.15 0.023 
Mean 0.36 0.28 0.22 0.14   
Table 18: Contribution of Strategies to T2 Recombinant Vaccines 
  
 
Figure 20: Contribution of Strategies to T2 Recombinant Vaccines 
 
 
For T2 Recombinant Vaccines, S1 Indigenous innovation strategy ranked highest at 
36%. S2 Imitative Innovation ranked second place at 28%, while S3 Collaborative 
Innovation ranked third at 22%. Lastly, S4 International Technology Transfer ranked the 
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lowest at 14%. The results indicate that China should focus on developing innovative 
products, and building up indigenous competence in the vaccine area (Table 18 and 
Figure 20). 
 
5.1.2.3 Strategies for T3 Monoclonal Antibody Technology 
  
T3: 
Monoclonal 
Antibody 
S1: 
Indigenous 
Innovation 
S2: 
Imitative 
Innovation 
S3: 
Collaborative 
Innovation 
S4:  
Int’l Tech 
Transfer 
Inconsistency 
Exp4 0.16 0.68 0.10 0.06 0.044 
Exp6 0.24 0.36 0.26 0.14 0.004 
Exp11 0.16 0.67 0.13 0.04 0.038 
Exp12 0.30 0.28 0.27 0.15 0.045 
Exp15 0.18 0.22 0.33 0.27 0.008 
Exp16 0.36 0.29 0.19 0.16 0.027 
Exp19 0.27 0.25 0.30 0.18 0.010 
Exp20 0.31 0.32 0.28 0.09 0.003 
Mean 0.25 0.38 0.23 0.14  
Table 19: Contribution of Strategies to T3 Monoclonal Antibody Technology 
  
 
Figure 21: Contribution of Strategies to T3 Monoclonal Antibody Technology 
 
 
For T3 Monoclonal Antibody Technology, S2 Imitative innovation strategy ranked 
the highest at 38%. S1 Indigenous innovation ranked second at 25% and S3 Collaborative 
innovation was third at 23%. Again, S4 International Technology Transfer ranked the 
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lowest at only 14%. The results indicate that China should focus on catching up with 
foreign leaders in the area of monoclonal antibody technologies (Table 19 and Figure 21).  
 
5.1.2.4 Strategies for T4 Cell and Tissue Engineering 
  
T4:  
Cell & Tissue 
Engineering 
S1: 
Indigenous 
Innovation 
S2: 
Imitative 
Innovation 
S3: 
Collaborative 
Innovation 
S4:  
Int’l Tech 
Transfer 
Inconsistency 
Exp4 0.49 0.31 0.15 0.05 0.008 
Exp6 0.24 0.36 0.26 0.14 0.004 
Exp11 0.09 0.48 0.26 0.17 0.046 
Exp12 0.23 0.24 0.31 0.22 0.063 
Exp15 0.25 0.18 0.30 0.27 0.004 
Exp16 0.37 0.34 0.21 0.08 0.015 
Exp19 0.26 0.22 0.29 0.23 0.025 
Exp20 0.15 0.36 0.30 0.19 0.008 
Mean 0.26 0.31 0.26 0.17  
Table 20: Contribution of Strategies to T4 Cell and Tissue Engineering 
  
 
Figure 22: Contribution of Strategies to T4 Cell and Tissue Engineering 
 
 
For T4 Cell and Tissue Engineering, S2 Imitative innovation strategy ranked the 
highest at 31%. In second place, S1 Indigenous innovation and S3 Collaborative 
innovation tied with each other at 26%. S4 International Technology Transfer ranked the 
lowest at 17%. The results indicate that China should favor the imitative option, but the 
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indigenous and collaborative approaches are also quite viable for the current conditions 
(Table 20 and Figure 22). 
 
5.1.2.5 Strategies for T5 Gene Therapy   
  
T5: 
Gene 
Therapy 
S1: 
Indigenous 
Innovation 
S2: 
Imitative 
Innovation 
S3: 
Collaborative 
Innovation 
S4:  
Int’l Tech 
Transfer 
Inconsistency 
Exp4 0.31 0.47 0.14 0.07 0.015 
Exp6 0.24 0.36 0.26 0.14 0.004 
Exp11 0.07 0.63 0.21 0.09 0.013 
Exp12 0.27 0.23 0.30 0.19 0.007 
Exp15 0.24 0.21 0.38 0.16 0.017 
Exp16 0.34 0.31 0.20 0.15 0.012 
Exp19 0.29 0.26 0.27 0.18 0.011 
Exp20 0.27 0.35 0.21 0.18 0.022 
Mean 0.25 0.35 0.25 0.15  
Table 21: Contribution of Strategies to T5 Gene Therapy 
  
 
Figure 23: Contribution of Strategies to T5 Gene Therapy 
 
 
For T5 Gene Therapy, S2 Imitative innovation strategy received the highest ranking 
at 35%. S1 Indigenous innovation and S3 Collaborative innovation tied again for second 
place, but at 25% in this case. S4 International Technology Transfer ranked the lowest at 
15%. The results indicate that China should focus on catching up with advanced countries 
in the area of gene therapy. 
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5.1.2.6 Strategies for T6 Antisense Therapy 
  
T6: 
Antisense 
Therapy 
S1: 
Indigenous 
Innovation 
S2: 
Imitative 
Innovation 
S3: 
Collaborative 
Innovation 
S4:  
Int’l Tech 
Transfer 
Inconsistency 
Exp4 0.35 0.35 0.19 0.12 0.018 
Exp6 0.13 0.47 0.22 0.18 0.045 
Exp11 0.08 0.64 0.19 0.09 0.019 
Exp12 0.08 0.31 0.31 0.31 0.001 
Exp15 0.26 0.16 0.38 0.19 0.009 
Exp16 0.30 0.34 0.20 0.16 0.006 
Exp19 0.18 0.28 0.30 0.23 0.014 
Exp20 0.23 0.35 0.22 0.20 0.003 
Mean 0.20 0.36 0.25 0.19  
Table 22: Contribution of Strategies to T6 Antisense Therapy 
  
 
Figure 24: Contribution of Strategies to T6 Antisense Therapy 
 
 
For T6 Antisense Therapy, S2 Imitative innovation strategy ranked first at 36%. S3 
Collaborative innovation ranked second at 25%. S1 Indigenous innovation ranked third at 
20%, while S4 International Technology Transfer ranked slightly lower at 19%. The 
results indicate that China should focus on catching up with foreign countries in the area 
of antisense therapy (Table 22 and Figure 24). 
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5.1.2.7 Strategies for T7 RNAi  
  
T7: 
RNAi 
S1: 
Indigenous 
Innovation 
S2: 
Imitative 
Innovation 
S3: 
Collaborative 
Innovation 
S4:  
Int’l Tech 
Transfer 
Inconsistency 
Exp4 0.35 0.35 0.19 0.12 0.018 
Exp6 0.15 0.44 0.25 0.16 0.032 
Exp11 0.06 0.55 0.26 0.12 0.002 
Exp12 0.25 0.26 0.29 0.20 0.001 
Exp15 0.22 0.18 0.33 0.27 0.008 
Exp16 0.32 0.34 0.16 0.17 0.003 
Exp19 0.28 0.24 0.30 0.17 0.001 
Exp20 0.26 0.39 0.22 0.13 0.012 
Mean 0.24 0.34 0.25 0.17   
Table 23: Contribution of Strategies to T7 RNAi 
  
 
Figure 25: Contribution of Strategies to T7 RNAi 
 
 
For T7 RNAi, S2 Imitative innovation strategy ranked first place at 34%. S3 
Collaborative innovation and S1 Indigenous innovation ranked closely for second and 
third places at 25% and 24% respectively. S4 International Technology Transfer ranked 
the lowest at 17%. The results also indicate that China should focus on catching up with 
advanced countries in the area of RNAi (Figure 25). 
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5.1.2.8 Strategies for T8 Nanobiotechnology   
  
T8:  
Nanobiotech 
S1: 
Indigenous 
Innovation 
S2: 
Imitative 
Innovation 
S3: 
Collaborative 
Innovation 
S4:  
Int’l Tech 
Transfer 
Inconsistency 
Exp4 0.25 0.43 0.22 0.10 0.004 
Exp6 0.10 0.46 0.19 0.24 0.056 
Exp11 0.06 0.66 0.21 0.07 0.017 
Exp12 0.24 0.29 0.27 0.20 0.015 
Exp15 0.23 0.18 0.33 0.26 0.005 
Exp16 0.28 0.33 0.18 0.21 0.003 
Exp19 0.27 0.28 0.24 0.21 0.005 
Exp20 0.23 0.35 0.23 0.19 0.006 
Mean 0.21 0.37 0.23 0.19   
Table 24: Contribution of Strategies to T8 Nanobiotechnology 
  
 
Figure 26: Contribution of Strategies to T8 Nanobiotechnology 
 
 
For T8 Nanobiotechnology, S2 Imitative innovation strategy ranked first at 37%. S3 
Collaborative innovation ranked second at 23%. S1 Indigenous innovation ranked third at 
21%. S4 International Technology Transfer ranked fourth at 19%. The results are obvious 
that China should focus on catching up with leading innovators in the area of 
nanobiotechnology (Table 24 and Figure 26). 
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5.1.2.9 Strategies for T9 Synthetic Biology 
  
T9: 
Synthetic 
Biology 
S1: 
Indigenous 
Innovation 
S2: 
Imitative 
Innovation 
S3: 
Collaborative 
Innovation 
S4:  
Int’l Tech 
Transfer 
Inconsistency 
Exp4 0.33 0.47 0.12 0.07 0.005 
Exp6 0.38 0.22 0.26 0.14 0.079 
Exp11 0.07 0.67 0.19 0.07 0.018 
Exp12 0.15 0.37 0.28 0.20 0.018 
Exp15 0.22 0.18 0.39 0.22 0.032 
Exp16 0.36 0.30 0.19 0.15 0.003 
Exp19 0.24 0.36 0.25 0.15 0.007 
Exp20 0.23 0.34 0.27 0.16 0.019 
Mean 0.25 0.36 0.24 0.15  
Table 25: Contribution of Strategies to T9 Synthetic Biology 
  
 
Figure 27: Contribution of Strategies to T9 Synthetic Biology 
 
 
For T9 Synthetic Biology, S2 Imitative innovation strategy ranked first at 36%. S1 
Indigenous innovation and S3 Collaborative innovation have relatively close priority at 
25% and 24% respectively. S4 International Technology Transfer ranked the lowest at 
15%. The results indicate that China should focus on catching up with leaders in the area 
of synthetic biology (Table 25 and Figure 27). 
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5.1.2.10 Strategies for T10 Bioinformatics 
  
T10:  
Bio-
informatics 
S1: 
Indigenous 
Innovation 
S2: 
Imitative 
Innovation 
S3: 
Collaborative 
Innovation 
S4:  
Int’l Tech 
Transfer 
Inconsistency 
Exp4 0.41 0.34 0.15 0.10 0.005 
Exp6 0.24 0.36 0.26 0.14 0.004 
Exp11 0.10 0.50 0.27 0.13 0.018 
Exp12 0.35 0.20 0.23 0.22 0.008 
Exp15 0.24 0.18 0.33 0.24 0.004 
Exp16 0.45 0.25 0.18 0.12 0.034 
Exp19 0.34 0.21 0.31 0.14 0.019 
Exp20 0.37 0.23 0.25 0.15 0.031 
Mean 0.31 0.28 0.25 0.16  
Table 26: Contribution of Strategies to T10 Bioinformatics 
  
 
Figure 28: Contribution of Strategies to T10 Bioinformatics 
 
 
For T10 Bioinformatics, S1 Indigenous innovation strategy ranked highest at 31%. 
S2 Imitative Innovation ranked second place at 28%. S3 Collaborative Innovation ranked 
third at 25%. S4 International Technology Transfer ranked the lowest at 16%. The results 
indicate that China should focus on developing new applications, and building up 
indigenous competence in the area of bioinformatics (Table 26 and Figure 28). 
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5.1.2.11 Strategies for T11 Pharmacogenetics 
  
T11: 
Pharmaco-
genetics 
S1: 
Indigenous 
Innovation 
S2: 
Imitative 
Innovation 
S3: 
Collaborative 
Innovation 
S4:  
Int’l Tech 
Transfer 
Inconsistency 
Exp4 0.33 0.41 0.17 0.09 0.006 
Exp6 0.22 0.30 0.22 0.25 0.004 
Exp11 0.04 0.60 0.25 0.11 0.042 
Exp12 0.27 0.24 0.30 0.19 0.021 
Exp15 0.25 0.22 0.33 0.20 0.012 
Exp16 0.29 0.37 0.18 0.16 0.014 
Exp19 0.23 0.26 0.29 0.23 0.027 
Exp20 0.27 0.35 0.21 0.18 0.008 
Mean 0.24 0.34 0.24 0.18   
Table 27: Contribution of Strategies to T11 Pharmacogenetics 
 
 
Figure 29: Contribution of Strategies to T11 Pharmacogenetics 
 
 
For T11 Pharmacogenetics, S2 Imitative innovation strategy ranked first at 34%. S1 
Indigenous innovation and S3 Collaborative innovation tied for second place at 24%. S4 
International Technology Transfer ranked the last at 18%. The results indicate that China 
should focus on catching up with foreign leaders in the area of pharmacogenetics (Table 
27 and Figure 29). 
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5.1.2.12 Strategies for T12 Gene Sequencing 
  
T12:  
Gene 
Sequencing 
S1: 
Indigenous 
Innovation 
S2: 
Imitative 
Innovation 
S3: 
Collaborative 
Innovation 
S4:  
Int’l Tech 
Transfer 
Inconsistency 
Exp4 0.40 0.26 0.17 0.17 0.000 
Exp6 0.29 0.30 0.27 0.14 0.021 
Exp11 0.07 0.45 0.29 0.19 0.009 
Exp12 0.19 0.30 0.26 0.25 0.001 
Exp15 0.18 0.22 0.33 0.27 0.008 
Exp16 0.27 0.31 0.26 0.16 0.014 
Exp19 0.20 0.27 0.32 0.21 0.005 
Exp20 0.15 0.36 0.26 0.23 0.028 
Mean 0.22 0.31 0.27 0.20  
Table 28: Contribution of Strategies to T12 Gene Sequencing 
 
 
Figure 30: Contribution of Strategies to T12 Gene Sequencing 
 
 
For T12 Gene Sequencing, S2 Imitative innovation strategy ranked first at 31%. S3 
Collaborative innovation ranked second at 27%. S1 Indigenous innovation ranked third at 
22%. S4 International Technology Transfer ranked fourth at 20%. The results indicate 
that China should focus more on imitative innovation, and also try the collaborative 
approach in the area of gene sequencing (Table 28 and Figure 30). 
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5.1.2.13 Strategies for T13 Biotechnology Diagnostics 
  
T13: 
Biotech 
Diagnostics 
S1: 
Indigenous 
Innovation 
S2: 
Imitative 
Innovation 
S3: 
Collaborative 
Innovation 
S4:  
Int’l Tech 
Transfer 
Inconsistency 
Exp4 0.37 0.37 0.17 0.09 0.002 
Exp6 0.20 0.30 0.22 0.27 0.004 
Exp11 0.10 0.56 0.15 0.19 0.024 
Exp12 0.21 0.32 0.23 0.23 0.004 
Exp15 0.18 0.20 0.39 0.24 0.022 
Exp16 0.27 0.35 0.24 0.15 0.035 
Exp19 0.15 0.31 0.33 0.21 0.016 
Exp20 0.19 0.33 0.28 0.20 0.001 
Mean 0.21 0.34 0.25 0.20  
Table 29: Contribution of Strategies to T13 Biotechnology Diagnostics 
  
 
Figure 31: Contribution of Strategies to T13 Biotechnology Diagnostics 
 
 
For T13 Biotechnology Diagnostics, S2 Imitative innovation strategy ranked the 
highest at 34%. S3 Collaborative innovation ranked second at 25%. S1 Indigenous 
innovation ranked third at 21%. S4 International Technology Transfer ranked the lowest 
at 20%. The results indicate that China should focus on catching up with foreign leaders 
in the area of biotechnology diagnostics (Table 29 and Figure 31). 
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 Technology Areas 
S1:  
Indigenous 
Innovation 
S2:  
Imitative 
Innovation 
S3:  
Collaborative 
Innovation 
S4:  
Int’l Tech 
Transfer 
T1: Recombinant Therapeutic 
Proteins 
0.30 0.33 0.18 0.19 
T2: Recombinant Vaccines 0.36 0.28 0.22 0.14 
T3: Monoclonal Antibody 0.25 0.38 0.23 0.14 
T4: Cell and Tissue Engineering 0.26 0.31 0.26 0.17 
T5: Gene Therapy 0.25 0.35 0.25 0.15 
T6: Antisense Therapy 0.20 0.36 0.25 0.19 
T7: RNAi 0.24 0.34 0.25 0.17 
T8: Nanobiotechnology 0.21 0.37 0.23 0.19 
T9: Synthetic Biology 0.25 0.36 0.24 0.15 
T10: Bioinformatics 0.31 0.28 0.25 0.16 
T11: Pharmacogenetics 0.24 0.34 0.24 0.18 
T12: Gene Sequencing 0.22 0.31 0.27 0.20 
T13: Biotechnology Diagnostics 0.21 0.34 0.25 0.20 
Table 30: Summary of Strategy Level 
 
 
Lastly, as a short summary of the strategy level, the above results show that imitative 
innovation strategy should be selected for 11 out of the 13 technology areas. The 
remaining two technology areas belong to the indigenous innovation strategy. For most 
cases, the ranks of collaborative innovation strategy and indigenous innovation strategy 
are relatively close, which even tied for the second place in several areas. International 
technology transfer received relatively low priority for most technology areas (Table 30).   
5.1.3 Contribution of Resources to Strategies 
The following tables present the results of the relative contribution of the input 
resources toward the innovation strategies. These findings answer the question “What 
innovation resources can contribute more to the technological development strategy?” or 
“What innovation resources should be emphasized in policy development toward the 
preferred innovation strategy?”  
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5.1.3.1 Indigenous Innovation 
  
S1: 
Indigenous 
Innovation 
A1: 
URPs 
A2: 
PRIs 
A3: 
SOEs 
A4: 
SMEs 
A5: 
EJVs 
A6: 
CROs 
A7: 
FR&D 
A8: 
MNCs 
Inconsistency 
Exp7 0.07 0.11 0.05 0.13 0.13 0.15 0.18 0.19 0.013 
Exp8 0.05 0.06 0.09 0.14 0.16 0.18 0.16 0.16 0.016 
Exp10 0.17 0.15 0.07 0.09 0.09 0.09 0.13 0.21 0.012 
Exp11 0.20 0.16 0.03 0.17 0.04 0.07 0.06 0.27 0.071 
Exp14 0.09 0.08 0.04 0.09 0.12 0.13 0.17 0.29 0.005 
Exp17 0.10 0.08 0.06 0.13 0.15 0.05 0.24 0.19 0.012 
Exp18 0.06 0.04 0.07 0.21 0.13 0.14 0.17 0.19 0.063 
Exp19 0.12 0.08 0.06 0.29 0.11 0.08 0.16 0.10 0.008 
Exp20 0.14 0.11 0.08 0.25 0.15 0.12 0.10 0.06 0.029 
Mean 0.11 0.10 0.06 0.17 0.12 0.11 0.15 0.18 
 
Table 31: Contribution of Resources to Indigenous Innovation 
  
 
Figure 32: Contribution of Resources to Indigenous Innovation 
 
In Table 31, the results show that A8 Multinational companies and subsidiaries (18%) 
contribute the most toward Indigenous Innovation, followed by A4 High-tech SMEs 
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(17%). Their priority rankings are very close, which indicate both resources should be 
encouraged for the improvement of China’s indigenous innovation capability (Figure 32).  
A deeper inspection of recent studies reveals that the above findings are reasonable. 
Research claimed that “MNCs pave the way for an innovative pharmaceutical industry in 
China” [298]. MNCs’ penetration will set the quality standards for local industries. They 
will initially absorb and be responsible for the training of local talents. MNCs’ 
investment in local businesses will also be a substantial source of capital for Chinese 
R&D. As opportunities provided by domestic players improve, the migration of skilled 
talents from conglomerates will nurture the thriving small businesses [298].  
Biotech SMEs constitute the largest group of players in the Chinese 
biopharmaceutical sector [299]. Almost all of the private SMEs emerged during the 
1990’s and 2000’s. Private ownership of companies was not allowed in China until the 
mid 1980’s. The majority of biotech SMEs consists of spinoffs from other institutions 
such as universities, research institutes, SOEs, and MNCs. In recent years, an increasing 
number of firms were founded by foreign-trained returnees from developed countries. 
Biotech SMEs have gradually become more influential players in the local industry. The 
innovation capability of SMEs will largely decide the competitiveness of China’s 
biopharmaceutical industry. 
 
5.1.3.2 Imitative Innovation 
As presented in Table 32 and Figure 33, the experts think that A4 High-tech SMEs 
(23%) contribute more to imitative Innovation, followed by A1 University Research 
Programs (17%) and A2 Public Research Institutes 13%.  
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S2: 
Imitative 
Innovation 
A1: 
URPs 
A2: 
PRIs 
A3: 
SOEs 
A4: 
SMEs 
A5: 
EJVs 
A6: 
CROs 
A7: 
FR&D 
A8: 
MNCs 
Inconsistency 
Exp7 0.12 0.10 0.06 0.14 0.11 0.14 0.18 0.16 0.012 
Exp8 0.06 0.06 0.08 0.18 0.16 0.17 0.16 0.15 0.004 
Exp10 0.13 0.10 0.06 0.18 0.09 0.12 0.14 0.19 0.011 
Exp11 0.16 0.23 0.06 0.35 0.06 0.09 0.04 0.02 0.044 
Exp14 0.20 0.18 0.17 0.22 0.08 0.07 0.05 0.04 0.034 
Exp17 0.24 0.15 0.12 0.19 0.10 0.05 0.07 0.08 0.012 
Exp18 0.16 0.08 0.10 0.19 0.14 0.14 0.10 0.09 0.050 
Exp19 0.21 0.15 0.08 0.28 0.11 0.06 0.06 0.05 0.006 
Exp20 0.23 0.09 0.07 0.31 0.07 0.09 0.08 0.06 0.013 
Mean 0.17 0.13 0.09 0.23 0.10 0.10 0.10 0.09 
 
Table 32: Contribution of Resources to Imitative Innovation 
 
  
Figure 33: Contribution of Resources to Imitative Innovation 
 
High-tech SMEs may contribute more toward imitation for several reasons [299]: 
aggressive thinking and action; flexible business strategy; low operational cost and high 
efficiency; better control in designated territory; and good service provision. University 
Research Programs and Public Research Institutes are ranked high because they possess a 
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huge number of biotechnical R&D personnel as well as considerable technical capability 
and experience [295]. Such factors are essential elements for technological learning in 
high-tech areas.  
 
5.1.3.3 Collaborative Innovation 
  
S3: 
Collaborative 
Innovation 
A1: 
URPs 
A2: 
PRIs 
A3: 
SOEs 
A4: 
SMEs 
A5: 
EJVs 
A6: 
CROs 
A7: 
FR&D 
A8: 
MNCs 
Inconsistency 
Exp7 0.11 0.12 0.08 0.14 0.14 0.14 0.14 0.15 0.013 
Exp8 0.05 0.09 0.09 0.13 0.17 0.15 0.16 0.16 0.008 
Exp10 0.13 0.10 0.07 0.13 0.11 0.13 0.16 0.18 0.016 
Exp11 0.13 0.22 0.10 0.34 0.07 0.10 0.04 0.02 0.023 
Exp14 0.08 0.07 0.10 0.12 0.11 0.14 0.14 0.25 0.016 
Exp17 0.19 0.15 0.12 0.24 0.08 0.10 0.05 0.06 0.012 
Exp18 0.16 0.10 0.10 0.21 0.14 0.10 0.09 0.10 0.020 
Exp19 0.16 0.13 0.10 0.18 0.13 0.13 0.11 0.08 0.012 
Exp20 0.15 0.12 0.11 0.17 0.08 0.16 0.09 0.12 0.011 
Mean 0.13 0.12 0.10 0.18 0.11 0.13 0.11 0.12 
 
Table 33: Contribution of Resources to Collaborative Innovation 
 
  
Figure 34: Contribution of Resources to Collaborative Innovation 
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In Table 33 and Figure 34, the results show that A4 High-tech SMEs contributed the 
most toward collaborative innovation at 18%. A1 University Research Programs and A6 
Contract Research/Manufacturing Organizations tied at 13% and ranked in second place.  
High-tech SMEs are often very active players in collaborative activities. SMEs need 
to seek complementary resources due to limited company size, financial funding, and 
research capacity [299]. Cooperation with other players is among the best choices for 
them. Universities are well known to be specialized in the area of basic research. Both 
domestic and foreign players collaborate with Chinese universities in early-stage 
preclinical studies. Contract Research/Manufacturing Organizations are more focused on 
providing clinical trial or production services for other players.  
 
5.1.3.4 International Technology Transfer 
  
S4:  
Int’l Tech 
Transfer 
A1: 
URPs 
A2: 
PRIs 
A3: 
SOEs 
A4: 
SMEs 
A5: 
EJVs 
A6: 
CROs 
A7: 
FR&D 
A8: 
MNCs 
Inconsistency 
Exp7 0.08 0.09 0.09 0.14 0.15 0.15 0.15 0.15 0.007 
Exp8 0.05 0.07 0.08 0.15 0.16 0.15 0.18 0.17 0.007 
Exp10 0.11 0.09 0.08 0.16 0.11 0.13 0.15 0.17 0.009 
Exp11 0.05 0.07 0.18 0.06 0.15 0.12 0.12 0.25 0.078 
Exp14 0.05 0.03 0.02 0.05 0.05 0.09 0.16 0.56 0.030 
Exp17 0.10 0.08 0.06 0.13 0.15 0.05 0.24 0.19 0.012 
Exp18 0.09 0.10 0.20 0.09 0.18 0.15 0.11 0.09 0.049 
Exp19 0.05 0.06 0.08 0.10 0.12 0.13 0.19 0.28 0.028 
Exp20 0.07 0.06 0.10 0.13 0.11 0.11 0.16 0.26 0.011 
Mean 0.07 0.07 0.10 0.11 0.13 0.12 0.16 0.24 
 
Table 34: Contribution of Resources to International Technology Transfer 
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Figure 35: Contribution of Resources to International Technology Transfer 
 
In Table 34 and Figure 35, the results show that A8 MNCs contributed the most 
toward international technology transfer at 24%, followed by A7 Foreign R&D Centers at 
16%. A5 Equity Joint Ventures ranked third at 13%.  
As seen from the literature review, most China-related technology transfer studies 
deal with multinational companies, which are the most important technology carriers in 
the international technology transfer process [71]. Foreign R&D Centers and Joint 
Ventures were also ranked high because they have better access to foreign technologies. 
However, in recent years, there have been more cases of technical transactions from 
domestic players to foreign players. Many MNCs have acquired domestic companies or 
research outcomes to broaden their research pipelines [300]. International technology 
transfer has become a mutual process to benefit both sides in the Chinese 
biopharmaceutical sector. 
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5.1.4 Overall Contributions 
After validating the values of relative priority at each level, the contribution of lower 
level elements toward the overall mission can be calculated by vector and matrix 
manipulations. The following matrix calculations demonstrate the process and results. 
This includes: Innovation Strategies to Mission [S/M], Resource Alternatives to 
Prospective Technology Areas [A/T], and Resource Alternatives to Mission [A/M]. The 
other two matrixes represent Strategies to Technology Areas [S/T] and Resource 
Alternatives to Strategies [A/S]. 
 
Contribution of Strategies to Mission: 
[S/M] = [S/T] x [T/M]       Equation (1) 
0.30 0.36 0.25 0.26 0.25 0.20 0.24 0.21 0.25 0.31 0.24 0.22 0.21 
 
0.14 
 
0.26 
0.33 0.28 0.38 0.31 0.35 0.36 0.34 0.37 0.36 0.28 0.34 0.31 0.34 
 
0.13 = 0.33 
0.18 0.22 0.23 0.26 0.25 0.25 0.25 0.23 0.24 0.25 0.24 0.27 0.25 
 
0.13 
 
0.23 
0.19 0.14 0.14 0.17 0.15 0.19 0.17 0.19 0.15 0.16 0.18 0.20 0.20 
 
0.06 
 
0.17 
              
0.06 
  
              
0.04 
  
              
0.05 
  
              
0.07 
  
              
0.05 
  
              
0.06 
  
              
0.06 
  
              
0.07 
  
              
0.08 
  
 
 
 
 
 
175 
Contribution of Resource Alternatives to Technology Areas: 
[A/T] = [A/S] x [S/T]        Equation (2) 
0.11 0.17 0.13 0.07 
 
0.30 0.36 0.25 0.26 0.25 0.20 0.24 0.21 0.25 0.31 0.24 0.22 0.21 
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Contribution of Resource Alternatives to Mission: 
[A/M] = [A/S] x [S/T] x [T/M] = [A/T] x [T/M]    Equation (3) 
0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13  0.14  0.13 
0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11  0.13 
 
0.11 
0.08 0.08 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.08 0.09 0.09 0.09  0.13 = 0.09 
0.18 0.18 0.19 0.18 0.18 0.18 0.18 0.18 0.19 0.18 0.18 0.18 0.18  0.06  0.18 
0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11  0.06  0.11 
0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11  0.04  0.11 
0.13 0.13 0.12 0.13 0.12 0.12 0.12 0.12 0.12 0.13 0.13 0.13 0.13  0.05  0.13 
0.15 0.15 0.14 0.15 0.14 0.14 0.14 0.14 0.14 0.15 0.15 0.15 0.15  0.07  0.15 
             
 0.05 
  
             
 0.06 
  
             
 0.06 
                0.07   
              0.08   
 
176 
5.1.4.1 Overall Contribution of Strategies to Mission 
The relative contribution of the strategies to the mission can be calculated by 
multiplying the arithmetic mean of the strategic priority and the mean values of the 
relative contribution of technology areas to mission. According to Matrix [S/M], the 
results are presented in Figure 36. 
 
 
 
The above results show that technology development strategy should focus more on 
imitative innovation (33%). Indigenous innovation (26%) is regarded as the second best 
option to improve national competitive capability and to obtain high industry value for 
China. Collaborative innovation ranked third at 23%. Lastly, international technology 
transfer contributed 17% to the overall mission. 
Imitative innovation strategy has the highest overall ranking because it ranks highest 
for 11 technology areas out of the total 13 areas. This conforms to the fact that China has 
limited capability in developing novel drugs. Referring to Figure 16, generic drugs are 
the mainstay of China's pharmaceutical industry, and that is unlikely to change in the 
short term. While the government encourages and relies upon innovation to meet industry 
Figure 36: Contribution of Strategies to Mission 
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targets, China will probably continue to rely upon widespread prescriptions of generics in 
public insurance plans to reduce the overall healthcare expenditures, and the current 
R&D capability also limits the possibility of launching domestic patented drugs in the 
near future [301]. It is more realistic for the country to focus on catching up with 
advanced countries in the high-tech areas. Biosimilars offer one legal way of widening 
access and enabling better value to be obtained for latecomer countries like China. Here, 
the need to broaden healthcare coverage to large populations must be balanced against 
limited budgets and growing demand for innovative drugs [302]. 
5.1.4.2 Overall Contribution of Resource Alternatives to the Mission 
The relative contribution of bottom level resources toward the mission can be 
calculated by multiplying the arithmetic mean of the resources to strategies, strategies to 
technology areas, and technology areas to mission. The results are presented in Figure 37. 
 
 
Figure 37: Contribution of Resources to Mission 
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From the above results, we can observe that A4 High-tech SMEs contributed about 
18% and ranked first toward the overall mission, indicating its important position in 
technological innovation. A8 MNCs ranked second in overall contribution at 15%. Lastly, 
A3 SOEs are ranked surprisingly low with 9% in overall contribution, indicating an area 
for improvement in terms of innovative performance. 
There are several reasons for high-tech SMEs to rank the highest. Firstly, biotech 
SMEs have a higher contribution toward indigenous innovation. After a burst of growth 
for 20 years, SMEs have become the mainstay players in China’s biopharmaceutical 
sector. China is now home to more than 700 biopharmaceutical companies, among which 
over 500 are small enterprises with net assets of less than US$10 million [303] [304]. The 
capabilities of these SMEs have a significant impact on China’s indigenous innovation. 
Secondly, SMEs contribute more toward the imitative innovation strategy, which has 
been identified as the most preferred strategy in China’s biopharmaceutical sector today. 
As discussed in the above sections, biotech SMEs are more flexible and efficient in 
product development. They have cost advantages and are more focused in specialty high-
tech areas. Thirdly, SMEs contribute more toward collaborative innovation. Due to 
limited scale, biotech SMEs actively cooperate with other players for complementary 
resources. The areas of cooperation include all aspects such as financial investment, joint 
research, and production. 
Multinational companies and subsidiaries ranked second toward the overall mission, 
indicating that foreign investments are important sources in China’s current innovation 
ecosystems. Firstly, MNCs ranked very high in terms of international technology transfer. 
These companies have brought some of the latest technologies into the local market. 
179 
MNCs played important roles in upgrading the local industrial structure during the last 
two decades. Secondly, MNCs also ranked high for indigenous innovation. MNCs are 
expected to lead the way for the innovative biopharmaceutical industry in China [298]. 
Through demonstration effects, MNCs set the industrial standards according to 
internationally accepted practice. Employee training and turnovers also benefited the 
domestic players in the long run [160]. In fact, without the open door policy and foreign 
investment from MNCs, the local industries would not have achieved what is happening 
today. Therefore, it can be predicted that the presence of MNCs will continue to 
contribute to technological innovations in China. 
5.2 Measurement of Disagreement 
It is natural to have different opinions among the experts during the research process. 
The diverse social backgrounds and working experiences of the experts may cause 
significant differences in opinions or perspectives toward any research topic. This section 
addresses such disagreement issues at each level of the research model. 
According to the methdology illustrated in Section 3.6, the intraclass correlation 
coefficient ICR  was calculated to measure the disagreement among experts. Shrout and 
Fleiss (1979) developed a statistical procedure to test the hypothesis about whether or not 
there is an absolute disagreement among the judges [271]. F-test was applied in the 
calculation process. The application of this methodology on HDM was first done by N. 
Gerdsri (2004), and expanded by P. Gerdsri (2009) [210, 211] [208, 209]. 
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5.2.1 Technology Level 
Referring to the data presented in Section 5.1.1, the following hypothesis was tested 
for disagreement among the experts:  
H0: ICR  = 0 there is disagreement 
H1: ICR  > 0 there is statistically significant evidence that there is some level of 
agreement 
The calculation process of the intraclass correlation coefficient and F-test was done 
through SPSS software (Appendix E). The results are shown in Table 35.  
The coefficient for the ten experts in Group A is 0.67, and for Group B it is 0.57. 
Both values are relatively high (scale 0 to 1). Therefore, it can be argued that there is high 
agreement among the group of experts. F-test was further applied to approve this 
argument. The process was done through computing the FBS value and comparing it to 
the F-critical value. The FBS value of Group A is 18.08. The F-critical with df1 = 6 and 
df2 = 6*9 = 54 at the 0.01 level is less than 3.29. While df2 = 54 is not provided in the 
table, an even larger value of df2 = 40 is used. This is a more conservative value which 
makes it more difficult to obtain significance. Since the FBS value is larger than F-critical 
(0.01), the null hypothesis can be rejected. This result confirms that there is statistically 
significant agreement in Group A at F-test 0.01 level. Similarly, the FBS value of Group B 
is 12.11, which is also larger than F-critical (0.01); the null hypothesis is also rejected. 
The result confirms that significant agreement exists in Group B at F-test 0.01 level. 
 
   
P-value  FBS Fcritical(0.01) F-test Results 
Group A <0.001  18.08 3.29 H0 rejected at 0.01 level 
Group B <0.001  12.11 3.29 H0 rejected at 0.01 level 
Table 35: Calculation of Disagreement at the Technology Level 
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Since the null hypotheses in both tables were rejected at the 0.01 level, we may 
conclude that the experts reached a very high level of agreement for the technology level. 
Although the experts come from different sources and have different backgrounds, their 
perceptions about prospective technology areas for China are very similar. 
5.2.2 Strategy Level 
Referring to the data presented in Section 5.1.2, the intraclass correlation coefficient 
and F-test were calculated for the strategy level (Table 36). The results show that ICR
coefficients range from 0.20 to 0.49, indicating that a certain degree of agreement exists 
among the experts in all examined technology areas. F-test was further applied to 
compare the FBS value and the F-critical value with df1 = 3 and df2 = 21. As we examine 
the results from Table 36, the results have the following features:  
1) All of the FBS values are larger than F-critical at the 0.1 level. This means 
disagreements among experts for all technology areas can be rejected at the 0.1 level.  
2) There are 11 of 13 technology areas where the FBS value is larger than F-critical 
(0.05). This indicates that the disagreements for these 11 areas can be rejected at the 0.05 
level. The two exceptions are T4 Cell and Tissue Engineering and T12 Gene Sequencing, 
where the values of FBS are smaller than the F-critical (0.05). The results indicate that 
disagreements for these two areas cannot be rejected at the 0.05 level. 
3) There are four technology areas, where the FBS values are larger than the F-critical 
(0.01), indicating that disagreements for these four areas can be rejected at the 0.01 level. 
These areas include T1 Recombinant Therapeutic Proteins, T2 Recombinant Vaccines, 
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T5 Gene Therapy, and T8 Nanobiotechnology. For the remaining nine technology areas, 
where the FBS values are smaller than the F-critical (0.01), disagreements cannot be 
rejected at this highest level at 0.01. 
 
  P-value  FBS Fcritical(0.01) F-test results 
T1 0.002  6.80 4.87 H0 rejected at 0.01 level 
T2 0.003  6.21 4.87 H0 rejected at 0.01 level 
T3 0.011  4.79 4.87 
H0 rejected at 0.05 level, but 
cannot be rejected at 0.01 level 
T4 0.084  2.53 4.87 
H0 rejected at 0.1 level, but 
cannot be rejected at 0.05 level 
T5 0.008  5.16 4.87 H0 rejected at 0.01 level 
T6 0.023  3.89 4.87 
H0 rejected at 0.05 level, but 
cannot be rejected at 0.01 level 
T7 0.015  4.41 4.87 
H0 rejected at 0.05 level, but 
cannot be rejected at 0.01 level 
T8 0.009  4.94 4.87 H0 rejected at 0.01 level 
T9 0.015  4.36 4.87 
H0 rejected at 0.05 level, but 
cannot be rejected at 0.01 level 
T10 0.029  3.67 4.87 
H0 rejected at 0.05 level, but 
cannot be rejected at 0.01 level 
T11 0.022  3.96 4.87 
H0 rejected at 0.05 level, but 
cannot be rejected at 0.01 level 
T12 0.058  2.92 4.87 
H0 rejected at 0.1 level, but 
cannot be rejected at 0.05 level 
T13 0.022  3.94 4.87 
H0 rejected at 0.05 level, but 
cannot be rejected at 0.01 level 
Table 36: Calculation of Disagreement at the Strategy Level 
 
When compared with the technology level, the strategy level has more disagreement 
issues. Although all null hypotheses can be rejected at the 0.1 level, the degree of 
agreement is relatively low. In many available studies, the 0.05 level has been used as a 
medium range. However, in the above results, two technology areas are still below the 
medium level. Moreover, most technology areas cannot reach the highest 0.01 level. 
Therefore, more discussions are needed below.  
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5.2.2.1 Contribution of Strategies to T4 Cell and Tissue Engineering 
In Table 36, we can see that T4 Cell and Tissue Engineering has a FBS value of 2.53 
which is less than the F-critical at 0.05 level (3.07). This indicates that as a whole group, 
the experts’ disagreement cannot be rejected at the medium level. In this section, the 
experts’ judgmental data will be reevaluated in subgroups for ICR and F-test. The results 
are illustrated in Table 37: 
 
T4 P-value  FBS Fcritical(0.01) F-test results 
Subgroup-G 0.023  6.81 9.78 
H0 rejected at 0.05 level, but 
cannot be rejected at 0.01 level 
Subgroup-F 0.030  6.03 9.78 
H0 rejected at 0.05 level, but 
cannot be rejected at 0.01 level 
Subgroup-L 0.043  10.32 29.5 
H0 rejected at 0.05 level, but 
cannot be rejected at 0.01 level 
Table 37: Subgroup Analysis on T4 Cell and Tissue Engineering 
 
5.2.2.2 Contribution of Strategies to T12 Gene Sequencing  
Another area that has higher disagreement (cannot be rejected at the 0.05 level) is 
T12 Gene Sequencing. Following a similar process, the data was reevaluated in expert 
subgroups. The results are presented in Table 38: 
 
T12 P-value  FBS Fcritical(0.01) F-test results 
Subgroup-G 0.041  5.24 9.78 
H0 rejected at 0.05 level, but 
cannot be rejected at 0.01 level 
Subgroup-F 0.048  4.88 9.78 
H0 rejected at 0.05 level, but 
cannot be rejected at 0.01 level 
Subgroup-L 0.041  10.79 29.5 
H0 rejected at 0.05 level, but 
cannot be rejected at 0.01 level 
Table 38: Subgroup Analysis on T12 Gene Sequencing 
 
The above analyses provides positive results. The disagreement values among 
experts within subgroups improved to have values higher than the 0.05 level. This is true 
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for both T4 and T12. This also indicates that there are certain differences of opinion 
among subgroups which need more exploration.  
5.2.3 Variance among Subgroups 
Due to the disagreement issues raised in the above analyses, this section further 
explores the different perspectives of the three expert subgroups. Tables with 
disagreements that cannot be rejected at the 0.01 level will be reexamined based on each 
expert’s judgmental rankings.  
5.2.3.1 Subgroup-G 
There are 9 technology areas where disagreements cannot be rejected at the 0.01 
level. The judgmental rankings of Subgroup-G experts were first pulled out and 
examined in Table 39. These experts have backgrounds in government agencies. The 
rankings range from 1 – 4, meaning from the highest to the lowest. A smaller mean value 
in the bottom row means a higher average ranking. 
 
Exp4 S1 S2 S3 S4 
 
Exp6 S1 S2 S3 S4 
 
Exp16 S1 S2 S3 S4 
T3 2 1 3 4 
 
T3 3 1 2 4 
 
T3 1 2 3 4 
T4 1 2 3 4 
 
T4 3 1 2 4 
 
T4 1 2 3 4 
T6 1 1 3 4 
 
T6 4 1 2 3 
 
T6 2 1 3 4 
T7 1 1 3 4 
 
T7 4 1 2 3 
 
T7 2 1 4 3 
T9 2 1 3 4 
 
T9 1 3 2 4 
 
T9 1 2 3 4 
T10 1 2 3 4 
 
T10 3 1 2 4 
 
T10 1 2 3 4 
T11 2 1 3 4 
 
T11 3 1 3 2 
 
T11 2 1 3 4 
T12 1 2 3 4 
 
T12 2 1 3 4 
 
T12 2 1 3 4 
T13 1 1 3 4 
 
T13 4 1 3 2 
 
T13 2 1 3 4 
Mean 1.3 1.3 3.0 4.0 
 
Mean 3.0 1.2 2.3 3.3 
 
Mean 1.6 1.4 3.1 3.9 
Table 39: Subgroup-G Ranking Analysis 
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The results reveal that Subgroup-G experts tend to give the highest rank to S2 
Imitative Innovation Strategy. They tend to give a lower rank to S4 International 
Technology Transfer. Expert4 and Expert16 also tend to give a higher rank to S1 
Indigenous Innovation. 
5.2.3.2 Subgroup-F 
The individual judgmental rankings of Subgroup-F experts are presented in Table 40. 
These experts have backgrounds or interests from various foreign organizations. 
 
Exp12 S1 S2 S3 S4 
 
Exp15 S1 S2 S3 S4 
 
exp19 S1 S2 S3 S4 
T3 1 2 3 4 
 
T3 4 3 1 2 
 
T3 2 3 1 4 
T4 3 2 1 4 
 
T4 3 4 1 2 
 
T4 2 4 1 3 
T6 4 1 1 1 
 
T6 2 4 1 3 
 
T6 4 2 1 3 
T7 3 2 1 4 
 
T7 3 4 1 2 
 
T7 2 3 1 4 
T9 4 1 2 3 
 
T9 2 4 1 2 
 
T9 3 1 2 4 
T10 1 4 2 3 
 
T10 2 4 1 2 
 
T10 1 3 2 4 
T11 2 3 1 4 
 
T11 2 3 1 4 
 
T11 3 2 1 3 
T12 4 1 2 3 
 
T12 4 3 1 2 
 
T12 4 2 1 3 
T13 4 1 2 2 
 
T13 3 3 1 2 
 
T13 4 2 1 3 
Mean 2.9 1.9 1.7 3.1 
 
Mean 2.8 3.6 1.0 2.3 
 
Mean 2.8 2.4 1.2 3.4 
Table 40: Subgroup-F Ranking Analysis 
 
The above information reveals that Subgroup-F experts tend to give a higher rank to 
S3 Collaborative Innovation Strategy. Among others, expert15 ranks S3 as the first 
priority for all technology areas.  
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5.2.3.3 Subgroup-L 
The individual judgmental rankings of Subgroup-L experts were pulled out and are 
presented in Table 41. These are experts from the local industry or domestic research 
organizations (non-government and without foreign backgrounds). 
 
Exp11 S1 S2 S3 S4 
 
Exp20 S1 S2 S3 S4 
T3 2 1 3 4 
 
T3 2 1 3 4 
T4 4 1 2 3 
 
T4 4 1 2 3 
T6 4 1 2 3 
 
T6 2 1 3 4 
T7 4 1 2 3 
 
T7 2 1 3 4 
T9 3 1 2 3 
 
T9 3 1 2 4 
T10 4 1 2 3 
 
T10 1 3 2 4 
T11 4 1 2 3 
 
T11 2 1 3 4 
T12 4 1 2 3 
 
T12 4 1 2 3 
T13 4 1 3 2 
 
T13 4 1 2 3 
Mean 3.7 1.0 2.2 3.0 
 
Mean 2.7 1.2 2.4 3.7 
Table 41: Subgroup-L Ranking Analysis 
 
The above results indicate that Subgroup-L experts tend to give a higher rank to S2 
Imitative Innovation Strategy. For example, Expert11 ranked S2 as the first priority for 
all technology areas. Another observation is that the experts are more likely to rank S3 
Collaborative Innovation as the second highest option. 
For the strategy level, the subgroup analysis confirms that experts from different 
subgroups tend to give different weight for different strategies. The experts showed 
certain tendencies in their judgments as a whole in terms of subgroups. These tendencies 
caused some disagreements in the last section. The reasons for such disagreements were 
investigated during the result validation stage, which will be discussed in the next chapter.  
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5.2.4 Resource Level 
Referring to the data presented in Section 5.1.3, the intraclass correlation coefficient 
was calculated and F-test was applied for the resource level. The results show that ICR
coefficients range from 0.12 to 0.42, indicating that agreement exists among the experts 
in all examined tables. F-test was carried out to test the FBS value, and the F-critical value 
at df1 = 7 and df2 = 56. Since df2 = 56 is not provided in the table, an even larger value of 
df2 = 40 is used. This is because we always act conservatively and choose a larger value, 
which makes it more difficult to obtain significance. 
As we examine the data from Table 42, the results show that FBS values are larger 
than the F-critical (0.01) for S1 Indigenous Innovation, S2 Imitative Innovation, and S4 
International Technology Transfer. This indicates that disagreements can be rejected at 
the 0.01 level in these tables. For S3 Collaborative Innovation, FBS = 2.44 is larger than 
the F-critical (0.05) = 2.25, but smaller than the F-critical (0.01) = 3.12. Therefore, the 
null hypothesis can be rejected at the 0.05 level, but it cannot be rejected at the 0.01 level. 
 
  P-value  FBS Fcritical(0.01) F-test Results 
S1 <0.001  4.94 3.12 H0 rejected at 0.01 level 
S2 <0.001  6.76 3.12 H0 rejected at 0.01 level 
S3   0.030  2.44 3.12 
H0 rejected at 0.05 level, but 
cannot be rejected at 0.01 level 
S4 <0.001  6.40 3.12 H0 rejected at 0.01 level 
Table 42: Calculation of Disagreement at the Resource Level 
 
The above results indicate that the contribution of resource alternatives toward 
collaborative innovation has an acceptable but slightly higher disagreement level (0.05 
level). A careful analysis of the data reveals that expert 14 has a very different judgement 
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when compared to others. This expert gave a higher priority value for A8 MNCs but a 
lower value for A4 SMEs. The researcher contacted the experts to verify their 
judgemental inputs. They were confident about their judgements and confirmed that the 
judgemental values represented their opinion regarding the issue. Expert 14 chose to 
retain the original judgement and provided a website to the researcher for more 
information. The website of this MNC clearly indicates that a dedicated organization for 
collaboration and partnering was established in 2009. The Chinese branch is one of the 
four global collaboration centers, while the other three are located in the US, EU, and 
Japan respectively. This fact explained the disaggreement with others. The existance of 
disagreement reveals that even though these experts all have foreign backgrounds, they 
may disagree with each other since they came from different companies or institutions.  
5.2.5 Summary on Disagreement Analysis 
The experts have very low disagreement in the judgment of technology level toward 
mission. It is within a very high acceptable level of 0.01. However, the experts have a 
certain level of disagreement regarding the strategies. By using subgroup analysis, we 
found that there are lower disagreements within subgroups. The analysis also revealed the 
trend of disagreement among subgroups. These disagreements were mainly caused by the 
different backgrounds of the subgroups. For the resource level, the only area with higher 
disagreement is about collaborative innovation. Through contacting the experts, the 
disagreement was explained by the organizational differences.  
Instead of trying to eliminate subjectivity and smooth out the differences, it is more 
important to understand the disagreement. Assessment of disagreement among experts at 
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each level of the model gives valuable insight on the expert’s position on the issues and 
provides even more useful information for policy makers. 
5.3 Sensitivity Analysis 
Since judgments involve subjectivity, the input data always bring uncertainty. 
Sensitivity analysis is necessary to test the robustness and stability of the results. There 
are several types of methods for carrying out sensitivity analysis on a hierarchical 
decision model, including: numerical incremental analysis, simulations, and 
mathematical deduction. Numerical incremental analysis is an iteration-based process 
where different numerical values are applied to the model to test corresponding changes 
in the ranking orders of the decision alternatives. The simulation method can be done 
through software packages such as Crystal Ball. However, the probabilistic input may 
return in stochastic output, which is undeterministic in nature. The method is more 
suitable to verify the results, but not to conduct the sensitivity analysis. 
This study utilizes the sensitivity analysis algorithm for HDM developed in Chen’s 
dissertation and Kocaoglu's research [272] [273]. This is a mathematical deduction type 
method to examine the impact of changes in different levels. The algorithm has been 
applied to the criteria level, which is the technology level. The purpose is find how 
changes in the technology areas will impact the rankings of innovation resources. Here 
the known conditional figures have been adapted from previous matrix calculations in the 
results discussion section (Table 43 and 44). 
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 A1: 
URPs 
A2: 
PRIs 
A3: 
SOEs 
A4: 
SMEs 
A5: 
EJVs 
A6: 
CROs 
A7: 
FR&D 
A8: 
MNCs 
Contribution 0.1279 0.1096 0.0861 0.1821 0.1127 0.1130 0.1257 0.1462 
Ranking 3 7 8 1 6 5 4 2 
Table 43: Contribution and Ranking of the Input Resources to the Mission 
  
 
A1: 
URPs 
A2: 
PRIs 
A3: 
SOEs 
A4: 
SMEs 
A5: 
EJVs 
A6: 
CROs 
A7: 
FR&D 
A8: 
MNCs 
T1 0.1258 0.1078 0.0847 0.1802 0.1135 0.1122 0.1282 0.1509 
T2 0.1256 0.1086 0.0828 0.1806 0.1136 0.1130 0.1286 0.1500 
T3 0.1318 0.1118 0.0862 0.1867 0.1115 0.1122 0.1232 0.1404 
T4 0.1270 0.1094 0.0865 0.1810 0.1129 0.1138 0.1258 0.1467 
T5 0.1300 0.1110 0.0865 0.1845 0.1120 0.1130 0.1240 0.1425 
T6 0.1290 0.1101 0.0884 0.1827 0.1122 0.1133 0.1239 0.1440 
T7 0.1286 0.1101 0.0870 0.1827 0.1124 0.1133 0.1247 0.1446 
T8 0.1292 0.1100 0.0879 0.1831 0.1122 0.1128 0.1242 0.1443 
T9 0.1304 0.1111 0.0864 0.1850 0.1119 0.1127 0.1239 0.1422 
T10 0.1254 0.1086 0.0848 0.1797 0.1135 0.1138 0.1276 0.1494 
T11 0.1280 0.1096 0.0870 0.1820 0.1126 0.1132 0.1252 0.1458 
T12 0.1260 0.1087 0.0881 0.1793 0.1131 0.1143 0.1257 0.1479 
T13 0.1274 0.1092 0.0882 0.1809 0.1127 0.1136 0.1250 0.1464 
Table 44: Intermediate Matrix of Input Resources to Technology 
 
For n = 1 and r = 1, based on the definition 


L
lll
lll oo
*,1
**  , we have the 
following calculations: 
 86.014.0 1    
0.03591462.01821.0210  aaC  
0.0077
1825.0.14540 0.18020.1509
13
2
13
2
1,113
2
13
2
1,21,11,21











l
l
l
l
l
l
l
l o
o
a
o
o
aaaC
 
191 
658.4
0077.0
0359.0
1
0 
C
C
  
We can obtain that 658.41    
Repeating the similar calculation steps for 1n and 7...,3,2r we get the following 
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By finding out the intersection of the above inequality sets, we can obtain the 
perturbation of the weight of the chemical pharmaceutical technology: 
172.014.0 1    
The allowable range of the perturbation on lO is denoted as  ll 21 , , and the 
tolerance of lO  is defined as  llll oo  21 , . From the calculations above, we can 
calculate the result that the tolerance of lO , which is T1 Recombinant Therapeutic 
Proteins, to keep the current ranking of all the input resources is [0, 0.312]. In the HDM 
Sensitivity Analysis algorithm [272], the sensitivity coefficient for lO  is defined as:  
ll
lOsens
21
1
)(
 
  
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After repeating similar steps for each technology area, the results of calculations are 
summarized in Table 45. The related explanations are explained in Table 46. 
 
Criteria 
Range of 
Perturbations 
Tolerance of 
Weights 
Sensitivity 
Coefficient 
T1: Recombinant 
Therapeutic 
Proteins 
[-0.14, 0.172] [0, 0.312] 3.205 
T2: Recombinant 
Vaccines 
[-0.13, 0.306] [0, 0.436] 2.293 
T3: Monoclonal 
Antibody  
[-0.13, 0.794] [0, 0.924] 1.082 
T4: Cell & Tissue 
Engineering 
[-0.06, 0.94] [0, 1] 1 
T5: Gene Therapy [-0.06, 0.94] [0, 1] 1 
T6: Antisense 
Therapy 
[-0.04, 0.96] [0, 1] 1 
T7: RNAi [-0.05, 0.95] [0, 1] 1 
T8: Nano-
biotechnology 
[-0.07, 0.93] [0, 1] 1 
T9: Synthetic 
Biology 
[-0.05, 0.95] [0, 1] 1 
T10: Bioinformatics [-0.06, 0.464] [0, 0.524] 1.908 
T11: Pharmaco-
genetics 
[-0.06, 0.94] [0, 1] 1 
T12: Gene 
Sequencing 
[-0.07, 0.93] [0, 1] 1 
T13: Biotech 
Diagnostics 
[-0.08, 0.92] [0, 1] 1 
Table 45: Sensitivity Analysis on Technologies to the Ranks of Input Resources 
 
The most critical criterion for keeping the current ranking of input resources 
corresponds to the technology area with the biggest sensitivity coefficient. As seen in the 
results, T1 Recombinant Therapeutic Proteins is determined as the most critical criterion 
among the technology areas in keeping current resource rankings, followed by T2 
Recombinant Vaccines. T1 Recombinant Therapeutic Proteins contributes the most 
toward the overall mission, and at the same time it is also the most critical technology 
area to keep the current rankings of resources. 
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Criteria 
Tolerance 
of 
Weights 
Descriptions 
T1: Recombinant 
Therapeutic 
Proteins 
[0, 0.312] 
When the weight of T1 changes to a value larger than 0.312, 
the contribution of Joint Ventures will surpass CROs to 
become the 5th. When the changes are within the range from 
0 to 0.312, the ranks of the input resources remain the same. 
T2: Recombinant 
Vaccines 
[0, 0.436] 
When the weight of T2 is larger than 0.436, the contribution 
of Foreign R&D Centers will surpass University Research 
Programs to become the 3rd. When the changes are within the 
range from 0 to 0.436, the ranks of the input resources remain 
the same. 
T3: Monoclonal 
Antibody  
[0, 0.924] 
When the weight of T3 changes to a value larger than 0.924, 
the contribution of Joint Ventures will surpass CROs to 
become the 5th. When the changes are within the range from 
0 to 0.924, the ranks of the input resources remain the same. 
T10: Bioinformatics [0, 0.524] 
When the weight of T10 is larger than 0.524, the contribution 
of Foreign R&D Centers will surpass University Research 
Programs to become the 3rd. When the changes are within the 
range from 0 to 0.524, the ranks of the input resources remain 
the same. 
Table 46: Explanation of the Results of Sensitivity Analysis 
 
Sensitivity analysis gives more information on how changes in upper level criteria 
can impact on lower level alternatives. In this case, the overall results are not very 
sensitive to changes, especially for the top-ranked strategy criteria and resource 
alternatives. This is primarily due to the high priority in favor of imitative innovation 
strategies for most technology areas and high contribution of certain resources (SMEs 
and MNCs) toward strategies. The results have demonstrated the process of how to assess 
the impact of technology changes on the resource rankings. Sensitivity analysis is a 
useful supplemental tool for policy makers to explore the relationships of the decision 
criteria.  
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Chapter 6 – Discussions and Recommendations 
Based on the data analysis and expert feedback, this chapter focuses on the 
discussions and policy recommendations. During the result validation process, 
aggregated results and a short summary regarding the disagreement issues were sent to 
the expert panel for further review. The experts were asked to validate the findings of this 
research. They provided valuable feedback and opinions, which largely facilitated the 
following discussions and recommendations. These findings are summarized in several 
major aspects according to each level of the model, including: 1) prospective technology 
areas, 2) technology development strategies, and 3) innovation resources. Table 47 
illustrates the main results from the data analysis. 
6.1 Prospective Technology Areas 
With achieving technological competitiveness and sustained innovation as the 
mission, this research examines a number of prospective technology areas in the 
biopharmaceutical industry. Although the experts come from different backgrounds, they 
have reached a high level of agreement in their judgments. The results can be classified 
under three categories: high >10%, medium 6%-10%, and low 1%-5% (Table 47).  
6.1.1 High Priority Technology Areas 
The “high” category is defined where the contribution is larger than 10%. These are 
the technology areas that should be China’s highest priorities for R&D. The 
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recommended areas include T1 Recombinant Therapeutic Proteins, T2 Recombinant 
Vaccines, and T3 Monoclonal Antibody Technology.  
 
C
at
eg
or
y  
Prospective 
Technology Areas  
Preferred Technology 
Development Strategies 
Preferred Innovation Resource Alternatives 
(Top Three) 
H
ig
h 
>
10
%
 
T1: Recombinant 
therapeutic 
proteins 
S2: Imitative 
Innovation    
1. High-tech Small-to-Medium Enterprises 
2. University Research Programs 
3. Public Research Institutes 
T2: Recombinant 
vaccines 
S1: Indigenous 
Innovation     
1. MNCs and Subsidiaries  
2. High-tech Small-to-Medium Enterprises 
3. Foreign R&D Centers 
T3: Monoclonal 
antibody 
technology 
S2: Imitative 
Innovation    
1. High-tech Small-to-Medium Enterprises 
2. University Research Programs 
3. Public Research Institutes 
M
ed
iu
m
 (
6-
10
)%
 
T4: Cell and tissue 
engineering 
S2: Imitative 
Innovation    
1. High-tech Small-to-Medium Enterprises 
2. University Research Programs 
3. Public Research Institutes 
T5: Gene therapy 
S2: Imitative 
Innovation    
1. High-tech Small-to-Medium Enterprises 
2. University Research Programs 
3. Public Research Institutes 
T8: Nano-
biotechnology 
S2: Imitative 
Innovation    
1. High-tech Small-to-Medium Enterprises 
2. University Research Programs 
3. Public Research Institutes 
T10: Bioinformatics 
S1: Indigenous 
Innovation     
1. MNCs and Subsidiaries  
2. High-tech Small-to-Medium Enterprises 
3. Foreign R&D Centers 
T11: Pharmaco-
genetics 
S2: Imitative 
Innovation    
1. High-tech Small-to-Medium Enterprises 
2. University Research Programs 
3. Public Research Institutes 
T12: Gene 
sequencing 
S2: Imitative 
Innovation    
1. High-tech Small-to-Medium Enterprises 
2. University Research Programs 
3. Public Research Institutes 
T13: Biotechnology 
Diagnostics 
S2: Imitative 
Innovation    
1. High-tech Small-to-Medium Enterprises 
2. University Research Programs 
3. Public Research Institutes 
L
ow
 (
1-
5
)%
  
T6: Antisense 
therapy 
S2: Imitative 
Innovation    
1. High-tech Small-to-Medium Enterprises 
2. University Research Programs 
3. Public Research Institutes 
T7: RNAi 
S2: Imitative 
Innovation    
1. High-tech Small-to-Medium Enterprises 
2. University Research Programs 
3. Public Research Institutes 
T9: Synthetic 
biology 
S2: Imitative 
Innovation    
1. High-tech Small-to-Medium Enterprises 
2. University Research Programs 
3. Public Research Institutes 
Table 47: Summary of Findings 
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For T1 Recombinant Therapeutic Proteins, the preferred strategy is imitative 
innovation. The ideal innovation resources include: high-tech SMEs, university research 
programs, and public research institutes. The development of recombinant proteins is 
well known to have relied on blockbuster revenue, primarily derived from 16 brands. For 
example, Amgen's blockbusters Enbrel, Neulasta and Aranesp are the sector's key leading 
blockbusters, with combined sales of more than US$10.8billion in 2010. The expected 
growth during 2012-2014 will be around 13% [305]. Hematology, diabetes, 
endocrinology and oncology are the most valuable therapy areas for recombinant proteins. 
Taking the imitative innovation strategy means that China should focus on developing 
biosimilars in this area; and biotech SMEs, Universities, and Research Institutes should 
play more important roles. 
For T2 Recombinant Vaccines, the preferred strategy is indigenous innovation. The 
recommended innovation leaders include: MNCs and subsidiaries, high-tech SMEs, and 
foreign R&D centers. Vaccines are among the most lucrative segments in the global 
pharmaceutical market. With an average growth of over 13% during 2009-2012, the 
global market for human vaccines is forecasted to reach US$32 billion by the year 2017 
[306]. The US and EU are the two largest vaccine markets in the world. The vaccine 
market in China has the potential to record phenomenal growth in the coming years. The 
growth rate will be around 20% and its size will reach CNY 12 billion by 2013 [296]. 
The quantity and the variety of vaccines produced in China are similar to those of 
developed countries, but China needs to improve the production capability and critical 
technology in order to produce higher quality vaccines [279]. Taking the indigenous 
innovation strategy indicates that China should develop more novel products, and focus 
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on the improvement of local competence. For such a purpose, innovation resources like 
multinationals and subsidiaries, biotech SMEs, and Foreign-invested R&D centers can 
take the lead. 
For T3 Monoclonal antibody technology, the preferred strategy is imitative 
innovation. The recommended innovation leaders include: high-tech SMEs, university 
research programs, and public research institutes. In the global market, the antibody 
bandwagon has been joined by 200 companies with hundreds of new projects and targets 
that have attracted billions of dollars in R&D investment, acquisitions and licensing deals 
leading to monoclonal antibody [277]. The total global monoclonal antibody (mAb) sales 
are forecasted to reach US$49 billion by 2013. The “big ﬁve” mAbs – Avastin, Herceptin, 
Rituxan, Humira, and Remicade – have dominated the market, cornering almost 80 
percent of sales [297]. There has been a great gap between China and Western countries 
in the research, development and manufacture of monoclonal antibody drugs [307]. Since 
the imitative innovation strategy has a higher priority, China should focus on the 
development of biosimilars, especially for the blockbuster drugs. Ideally, biotech SMEs, 
Universities, and Research Institutes should play more important roles in this process. 
6.1.2 Medium Priority Technology Areas 
The “medium” category is defined as being where the contribution ranges from 6% 
to 10%. These technology areas are recommended as medium priorities for China to carry 
out R&D. This list consists of seven technology areas including T4 Cell and tissue 
engineering, T5 Gene therapy, T8 Nanobiotechnology, T10 Bioinformatics, T11 
Pharmacogenetics, T12 Gene sequencing, and T13 Biotechnology Diagnostics. 
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For T4 Cell and tissue engineering, the preferred strategy is imitative innovation. 
The recommended innovation leaders include: high-tech SMEs, university research 
programs, and public research institutes. According to market reports, there are more than 
60 tissue engineering products in the global market and about 30 in clinical trials. China’s 
biomedical materials industry is largely driven by foreign technology, and domestic 
companies accounted for a mere 3% of global market share in 2011 [308]. By following 
the imitative innovation strategy, China should focus on catching up with the advanced 
countries. The results suggest that biotech SMEs, Universities, and Research Institutes 
should play more important roles. 
For T5 Gene therapy, the preferred strategy is imitative innovation. The 
recommended innovation leaders include: high-tech SMEs, university research programs, 
and public research institutes. Gene therapy is a high-tech area with very few available 
products. However, there about 80 gene therapies are in clinical trials [281]. Many 
experts believe that gene therapy will play a significant role in future medical treatment. 
The research recommends imitative innovation strategy, indicating that China should 
focus on learning from advanced countries. The results also suggest that biotech SMEs, 
Universities, and Research Institutes play more important roles. 
For T8 Nanobiotechnology, the preferred strategy is imitative innovation. The 
recommended innovation leaders include: high-tech SMEs, university research programs, 
and public research institutes. The applications of nanobiotechnology in the biomedical 
field are principally directed towards development of novel drug delivery systems. 
According to a market report in 2012, the global nanobiotechnology market will reach 
$6.0 billion by 2017 [309]. As a catching up country in this area, it is recommended that 
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China follow the imitative innovation strategy. The results also suggest that biotech 
SMEs, Universities, and Research Institutes should play more important roles in the 
process. 
For T10 Bioinformatics, the preferred strategy is indigenous innovation. The 
recommended innovation leaders include: MNCs and subsidiaries, high-tech SMEs, and 
foreign R&D centers. The applications in bioinformatics are increasingly powerful, 
allowing researchers to garner more knowledge about more complex organisms and 
systems. The worldwide bioinformatics market was estimated at US$3.0 billion in 2010, 
and the applications will continue to have very rapid growth to 2015 [281]. Today, 
bioinformatics research in China still lags behind the best in the world. There are 
relatively few applications for drug discovery in the domestic market [310]. Since the 
indigenous innovation strategy is recommended, China should focus on developing new 
applications in bioinformatics. To support this strategy, innovators such as MNCs, high-
tech SMEs, and Foreign R&D centers can take the leading roles. 
For T11 Pharmacogenetics, the preferred strategy is imitative innovation. The 
recommended innovation leaders include: high-tech SMEs, university research programs, 
and public research institutes. Pharmacogenetics is a prospective field that could lead to 
personalized medicines. According to market reports, the worldwide pharmacogenetics 
market was estimated at US$3.7 billion in 2009, but there will be a limited number of 
new pharmacogenetic products arriving on the market by 2015 [281]. The experts 
recommend the imitative innovation strategy, indicating that China should focus on 
catching up with advanced countries. The results also suggest that biotech SMEs, 
universities, and research institutes should play more important roles in this process. 
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For T12 Gene sequencing, the preferred strategy is imitative innovation. The 
recommended innovation leaders include: high-tech SMEs, university research programs, 
and public research institutes. Applications of gene sequencing technology will help 
researchers to find genes associated with human disease. China is catching up rapidly in 
the field of gene sequencing. The acquisition in 2012 of a California-based DNA 
sequencing company by a Chinese firm (BGI) led to wide concerns. Some American 
scientists, politicians and industry executives said the takeover represented a threat to 
American competitiveness in DNA sequencing [311]. So far, the experts in this research 
still recommend an imitative innovation strategy, where biotech SMEs, Universities, and 
Research Institutes should take the lead in China’s catching-up process. 
For T13 Biotechnology Diagnostics, the preferred strategy is imitative innovation. 
The recommended innovation leaders include: high-tech SMEs, university research 
programs, and public research institutes. The diagnostics market was estimated at $ 52.4 
billion in 2012, and it is expected to grow at a rate of 7% during 2012-2017 [312]. Roche 
Diagnostics is the dominant leader with 20% market share. Nine of the world’s top 15 
firms are based in the United States. Other firms are based in either Europe or Japan. In 
this research, the experts recommend an imitative innovation strategy for China. The 
country should focus on catching up with advanced countries. The results suggest that 
biotech SMEs, universities, and research institutes play more important roles in this 
process. 
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6.1.3 Low Priority Technology Areas 
The “low” category is where the contribution is equal to or less than 5%. These 
technology areas are regarded as having lower priorities for China. This list consists of 
three technology areas including T6 Antisense therapy, T7 RNAi, and T9 Synthetic 
biology. 
The above three technology areas have one thing in common: there are still very few 
or even no approved applications in the market today. However, these drugs have good 
prospects in that some candidate drugs are already in clinical trials [281]. The related 
studies in China are still in initial stages. The experts recommend an imitative innovation 
strategy for all three technology areas. China should focus on catching up with advanced 
countries. The results also suggest that biotech SMEs, universities, and research institutes 
should play more important roles in this process. 
6.1.4 Summary on Prospective Technology Areas 
The research results of technology levels highlights the directions for investment and 
improvement. For most of the above discussed high-tech areas, the Unites States is the 
dominant leader worldwide. Research has shown that American academic publications 
and patents comprise more than 40% of the world. China and some major European 
countries belong to the second tier in these areas. As a latecomer country in the 
biopharmaceutical industry, China’s innovation capabilities have been steadily growing 
since the mid 1990s. However, China’s technology level is still lagging behind the 
world’s leading standard, and the country needs to take a learning position as discussed in 
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the above analyses. In order to accelerate the catching-up process, the government’s role 
of long-term investment in these identified areas cannot be overemphasized.  
6.2 Technology Development Strategies  
Any static strategy is often less effective for latecomer countries since competitive 
advantage could be accumulated through multiple approaches or sources. From an 
industrial perspective, a country’s technology strategies need to be dynamic for its unique 
but changing developmental contexts. Therefore, policy makers should adopt a 
comprehensive approach to technology strategy using all possible resources, and engage 
various stakeholders in the process of technology development. Such an approach entails 
decision makers becoming more involved in governance initiatives to improve the 
innovation environment, or scaling their influence over the relevant high-tech areas for 
the long-term innovation goals. This involves balancing various technology development 
strategies to build up industrial innovation capacity for competitiveness and future 
success. 
6.2.1 Imitative Innovation and Biosimilars 
Accumulation of technological capacities to compete in the global market has 
become a major concern for China. The research brings to light that imitative innovation 
is still the best option to achieve such a purpose under the current conditions. The experts’ 
judgments give high priority to imitative innovation (33%) in the development of 
biopharmaceutical technologies. This conforms to the fact that technology leaders in 
high-tech areas are mostly foreign enterprises, which mainly belong to the United States 
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and Western Europe. If the latecomers want to catch up with the technological frontiers, 
their strategies are likely to start from imitation. This has been the case for many of the 
East Asian  economies – first for Japan, then for Taiwan, Korea and Singapore – and now 
for China [82]. The results of this research indicate that China’s biopharmaceutical 
industry is at the stage of learning from advanced countries.  
When discussing imitative innovation in the biopharmaceutical industry, biosimilars 
are topics that cannot be circumvented. Novel biologics are noted for their high 
production cost and expensive purchase prices. Biosimilars bring clear potential for 
payers in the emerging pharmaceutical or “pharmerging” markets, such as Brazil, India 
and China [302]. Developing biosimilar products is also a relatively low-risk strategy for 
newcomers entering the health biotech space and generating short-term revenues [313]. 
Of the approximate 150 approved originator biologic drugs on the market today, almost 
half of them have lost or are close to losing their patent protection. This provides an 
external condition for cheaper biosimilar products to enter the market and be available for 
consumers. However, under the current registration regime, biosimilar drugs and new 
biologic drugs are not treated with any differences in China. Both applications require the 
same process for clinical trials. Although the United States does not currently have 
related regulations, India and the European Union have developed abbreviated approval 
processes for biosimilar products [302]. China should consider adopting similar 
approaches to remove or lower the legislative hurdles for the development of biosimilars. 
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6.2.2 India’s Experience in Pharmaceutical Development 
The rise of India’s pharmaceutical industry in the last few decades may provide 
some insight for other emerging economies. The Indian government adopted an imitative 
strategy in the pharmaceutical industry during the 1970s [314]. The weak IPRs regime 
fostered the development of domestic technology capabilities in that period. If an Indian 
domestic company could merely modify the manufacturing process of a foreign medicine, 
the company was allowed to produce the same product without patent infringement [315]. 
This strategy established low cost leadership advantage among local companies and 
increased domestic social welfare due to the lowered drug prices. It was remarkable 
achievement that new drugs can be introduced to India only within four to five years after 
their introduction in foreign countries. However, the negative effect was that most MNCs 
chose to leave the Indian market for afraid of patent infringement.  
As a large number of medicines went off patent protection during the late 1980s, 
Indian medicines further experienced a rapid growth of exports to the world market. 
Moreover, an interesting effect was that the increased technological capabilities of Indian 
pharmaceutical companies have brought back the FDI from the Western developed 
countries. New joint ventures or R&D centers were setup mainly draw upon trained 
manpower and research infrastructure available in the country, despite the fact that the 
Indian patent regime did not provide strong patent protection [316]. By introduction and 
assimilation of advanced technologies from abroad, the Indian pharmaceutical companies 
have emerged as competitive suppliers in the world.  
The Indian experience highlights the fact that government strategy may lead to 
industrial success. However, India’s imitative strategy can no longer be duplicated by 
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other emerging economies because the global innovation environment has changed 
significantly in recent years. Many countries have joined WTO and endorsed the TRIPS 
Agreement, which requires strengthened IPR protection. Therefore, direct replication of 
foreign products will not be applicable, and even India has to make a change in recent 
years. Nowadays, emerging economies should focus on re-innovation or imitative 
innovation, which is beyond pure replication. In summary, the Indian experience in 
pharmaceutical development strengthened the findings in this research. 
6.2.3 Indigenous Innovation, Collaborative Innovation, and Novel Drugs 
Indigenous innovation strategy ranks second at 26%, followed by collaborative 
innovation strategy at 23%. These strategies cannot be overlooked as optional choices for 
China’s current technology capabilities. China should try to develop its indigenous 
strengths and also collaborate with leading countries. In most technology areas, China 
belongs to the second cohort among the worldwide biopharmaceutical communities. 
Therefore, the country cannot afford to totally rely on indigenous innovation. The open-
door policy in the last 30 years has proven that foreign elements are extremely important 
resources for the local industries. China would not have achieved the current technology 
level if the doors were closed for FDI and MNCs. As a long term goal, indigenous 
innovation strategy should be encouraged in China. Past experiences from other countries 
have repeatedly demonstrated that an emerging economy will ultimately move from the 
imitative stage to the innovative stage [82].  
Although the collaborative innovation strategy did not rank the highest for any 
specific technology areas, it has been regarded as an increasingly important strategy in 
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recent years. In reality, some industrial players have come up with new channels to 
develop novel drugs through bridging collaborative and indigenous innovation. For 
example, Chinese-based SinoPharm struck a cooperation deal with American-based 
Harbor Biosciences to develop novel drugs in the area of therapeutic protein drugs. The 
two sides share resources in terms of financial investment, technology know-how, and 
research facilities. Regarding the research outcomes, SinoPharm has exclusive rights in 
China, while Harbor Biosciences maintains rights in other countries. This type of 
collaboration is very attractive to both parties: the foreign player benefits from lowered 
investment and more research resources, while the Chinese player is able to gain access 
to advanced R&D techniques and essentially obtain their very own novel drugs [298] 
[300]. 
6.2.4 International Technology Transfer 
Compared with other strategies, international technology transfer ranks relatively 
low in the overall contribution toward mission. MNCs and Foreign R&D Centers are the 
major contributors for this strategy. The Chinese industries have benefited substantially 
from international technology transfer deals during the 1980s and 1990s. The MNCs 
transferred many technologies which helped China to upgrade its industries. However, as 
local technology capability matured, the reliance on foreign technologies decreased. In 
recent years, there have been many cases where foreign companies began acquiring 
domestic firms or technologies [304]. International technology transfer deals no longer 
travel in one direction from abroad to local, but also from home to abroad. Nevertheless, 
in high-tech areas such as the biopharmaceutical industry, foreign players still play more 
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important roles in international technology transfer in China. From a government 
perspective, China needs to establish effective macro-level technology policies to guide 
and promote technology transfer activities in high-tech areas.  
6.2.5 Disagreement on Technology Development Strategies 
The experts’ judgments recorded a relatively high disagreement regarding the 
strategy level. Experts with different backgrounds suggested different strategies for China 
to follow. Government experts have higher expectations for imitative innovation or 
indigenous innovation. Indeed, due to noticeable gaps between China and the global 
innovation frontiers, it is more realistic to expect some learning and imitative activities. 
This process happened to other countries during their catching up stages, such as Japan in 
the 1960’s and South Korea in the 1970s. India’s pharmaceutical industry grew very fast 
during the 1970’s when the government adopted similar strategies to imitate foreign 
drugs [314]. However, in today’s more globalized environment, China’s strategy should 
focus on re-innovation or imitative innovation, which goes beyond simple imitation. The 
domestic industrial experts have suggested more on imitative innovation strategy, 
indicating the catching up trends in the industry. They also have higher expectations for 
collaborative innovation, which confirms that collaborations are necessary for domestic 
companies. Although the foreign experts suggested relying more on collaborative 
innovation, the reality is that some MNCs have limited collaborations with domestic 
players, as seen from the results of resource levels. Their major concerns are loss of 
technology edge or IPR. However, the results have demonstrated that foreign players 
have the motive or interests to collaborate with domestic players.  
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The global biotech communities are well aware of the advantages and attractions 
China can offer. As China’s economy grows and incomes rise, it can be anticipated that 
people will increase their spending on healthcare and medicines. This brings great 
opportunities not only for domestic companies, but also for multinationals. The 
government should welcome global partners to jointly share the development and 
prosperity of the nation's emerging industry. To facilitate internationalization of China's 
biopharmaceutical industry, policy makers should plan to establish ideal conditions for 
attracting foreign innovators. Promoting research collaboration between domestic 
companies and their overseas counterparts will benefit the technology learning process, 
as well as the mission of sustained industrial growth. For its innovation goals to be met, 
China needs to have more integrated strategies for technology development. Past 
experiences revealed that the country needs to be more integrated into the global 
innovation networks. This means keeping an open-door policy and encouraging foreign 
investment in high-tech areas. 
6.3 Supportive Innovation Resources 
This case application provides the Chinese biopharmaceutical industry a 
performance report of various innovators with regard to their contribution toward global 
strategies and technology objectives. This will assist policy makers in determining which 
infrastructure items require improvement or investment. Based on the feedback from 
result validation, the research suggests improving the conditions and environment for 
innovation. The result analyses indicate that High-tech SMEs are the most important 
contributors for China’s biopharmaceutical industry in the current development stage. 
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The second group of important contributors is considered to be the MNCs and 
subsidiaries. The Foreign R&D Centers and University Research Programs tie for the 
third place toward mission. These important innovation resources will be discussed in 
this section.  
6.3.1 High-tech SMEs 
Owing to the narrowed gaps of competitive advantages in recent years, many 
emerging biotech SMEs have entered the race for technology development. These 
companies have certain advantages over large established enterprises, including greater 
flexibility, better efficiency, less bureaucracy, and profit-seeking behaviors which allow 
them to succeed in the fast-changing markets. Many biotech SMEs in the Chinese 
biopharmaceutical sector share similar advantages and traits. For example, they are more 
successful in some specialized high-tech areas, and most of them are very eager or active 
in collaborative innovations with other players. This is mainly due to the reality that 
SMEs are usually not strong as standalone innovators. They need to search for 
complementary resources to cover their deficiencies in certain aspects.  
Despite a clear evidence of progress in recent years, biotech SMEs still have some 
key issues to be addressed. One of the main challenges faced by biotech SMEs is to 
obtain funding, not only for their business purposes but also for their R&D activities. 
With lower research inputs, most biotech SMEs are not well prepared to compete 
globally in many high-tech fields. The government should provide services to expand 
biotech SMEs’ networking with other players so that interactions can create a synergy 
where knowledge, expertise, and experiences are shared. This is also a measure to avail 
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biotech SMEs with complementary resources and related activities that they lacked. 
Moreover, the government has the ability to alleviate biotech SMEs’ tax burdens, and 
induce them to invest more in R&D activities with incentives.  
6.3.2 Multinational Companies and Subsidiaries 
MNCs’ technological strength, institutional heritage, and their global coverage 
generate specific advantages for their operations in the Chinese biopharmaceutical sector. 
MNCs are in a better competing position because they are better endowed with both 
R&D capacities and funding capital. Chiesa and Chiaroni (2005) found that the presence 
of foreign pharmaceutical firms can make a number of important contributions to the 
success of the industrial networks of the host country. For example, these firms have 
better expertise in developing and protecting intellectual property with high commercial 
potential, they have well-established marketing and distribution channels, and they are 
experienced in both shaping and working within strict regulatory guidelines [317]. 
Domestic players in the host country may benefit from technology spillover through 
MNCs’ demonstration effects, labor turnover, and overall industrial structure upgrading 
(both upstream and downstream) [160, 318]. These are essential factors to build up a 
better innovation ecosystem for the biopharmaceutical industry in China.  
The research results have revealed that there are certain disagreements on whether 
MNCs collaborate with other players. According to the feedback from result validation, 
the contributions of MNCs toward collaborative innovation are uneven. One expert 
claimed that her company has initiated many partnership programs in recent years, which 
indicates higher contribution. On the other hand, several other experts argued that their 
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collaborative programs are limited in clinical trials which do not contribute much to 
innovation. Most of the MNCs in China focus on the collaborations with domestic 
players in the late-stage clinical trials, which are required by domestic regulations. The 
Chinese government does not allow First-in-Human clinical research for foreign drugs in 
China. Even if the drug is approved for marketing in a foreign country, the drug company 
still needs to restart all three phases of clinical trials locally. Although some MNCs also 
collaborate with Chinese universities and research institutes in early-stage discoveries, 
the cases are relatively few, and the MNCs would eventually acquire the research 
outcomes to enrich their own product pipelines. Therefore, the government should 
provide more favorable policies to facilitate and support collaboration between MNCs 
and domestic players, especially in early-stage drug discovery. This presupposes that 
both sides will benefit from cooperation or even competition with their counterparts. The 
trend of globalization and industrial liberalization needs such a change in attitude or 
business orientation where even competitors can cooperate with each other to achieve 
mutual success [319]. From a foreign perspective, MNCs also need to achieve a better 
balance between their demands in exploiting the potential Chinese market and utilizing 
the plentiful local resources. 
6.3.3 University Research Programs 
According to the results, the contribution of University Research Programs ties with 
that of Foreign R&D Centers for third place. This is mainly due to a university’s higher 
contribution toward collaborative innovation and imitative innovation. University 
programs are more oriented toward basic research. Many biotech startups and spinoffs 
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were created to take advantages of discoveries in academic research. MNCs collaborate 
with top Chinese universities in early-stage drug discoveries. Many universities also have 
academic connections with foreign research institutions. Moreover, university 
partnerships are not limited to R&D. They are important for training future talents with 
advanced research techniques, as well as providing companies the opportunity to recruit a 
highly qualified workforce [313]. In the past two decades, Chinese universities have 
trained about 100,000 biotech researchers. Nearly 1,000 universities and colleges in 
China offer biology-related courses, and more than 500 universities and colleges offer 
biology-related programs. More than 20,000 university students graduated each year in 
biology-related fields before 2006 [320]. Universities provide the foundations for China 
to catch up with developed countries. 
6.3.4 Foreign R&D Centers 
Foreign R&D Centers also contribute the third highest toward the overall mission. 
This is largely due to their contributions toward international technology transfer and 
indigenous innovation. In recent years, more and more foreign-invested R&D centers 
have been established in China. This is a new approach to R&D in that it builds Chinese 
portals to the global biotech communities. On the one hand, these innovation centers have 
stringent ties with research resources in their own countries. On the other hand, they hire 
and train many domestic scientists and researchers to carry out local R&D projects. The 
vast population and different disease patterns in China provide a convenient condition for 
the application of new technologies. There are plenty of opportunities for both early-stage 
drug discovery and late-stage clinical trials. These organizations bring some of the latest 
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research techniques, routines, and practices to China. Many of these research centers 
focus on finding specific biomarkers and genes related to diseases that are more prevalent 
in China and Asian regions. This is an important aspect because they contribute to 
indigenous innovation as well as technology transfer. 
6.3.5 Other Innovation Resources 
Although the research model can be utilized to identify a single best contributor 
toward the mission, the research goal is far beyond such a finding. The technology 
development process in reality involves complementary technologies which can be 
developed by different innovators in the innovation systems. In other words, the current 
model is not merely for choosing the only innovator for each candidate technology. For 
example, when the model proposes high-tech SMEs, as the best contributing resource 
toward the overall mission of competitiveness and innovation, it should not be interpreted 
that other innovators are excluded from the development strategy; rather, they just 
contribute less than the ideal option but still remain as contributors. Because rankings 
provide guidelines and direction for the design of technology policies to leverage 
investment input, such as time, effort, human capital, and related monetary support.  
6.4 Policy Recommendations 
Based on the above discussions and experts’ feedback, major areas of policy 
recommendations include: 1) Establishing a clear vision for technology objectives and 
implementation strategies in the biopharmaceutical sector; 2) Creating actors or 
organizations with responsibility for promoting or executing such strategies; 3) Nurturing 
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a collaborative environment and innovation ecosystem. 4) Providing service platforms, 
education, and training; and 5) Legislating support and financial incentives for innovators 
at a micro or organizational level. 
6.4.1 Establishing a Clear Vision for Technology Objectives and Strategies 
In the development of high-tech industries in emerging economies, the synergies of 
two major aspects need to be considered, which will reap some of the benefits of 
globalization while remaining responsive to local market needs. Technology objectives 
and strategies serve to provide direction and schemes for the making of innovation policy 
within the sectoral regime. This research suggests that emerging economies must set clear 
technology goals before formulating their global strategies. The decision makers have the 
roles of clarifying the vision for those undertaking risky R&D activities in the high-tech 
areas, determining proper regulations, and industrial standards to maintain the desired 
boundaries of research activities, and making sure that an effective innovation 
environment is provided with appropriate market mechanisms. The concern is to enhance 
competitiveness for the industry’s present needs in globalization and local applications. 
A major achievement of the Technology Level results is that the experts with diverse 
backgrounds have reached unanimous agreement for prospective technology areas in 
China. This means that the identified high-tech areas are in need of attention not only for 
the local biotech community to upgrade but also for the overseas stakeholders to invest. 
These high priority areas include Recombinant Therapeutic Proteins, Recombinant 
Vaccines, and Monoclonal Antibody Technology. As a large country, China should not 
give up developing other technologies, but the focus here is to make priorities based on 
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both global trends and local needs. The long-term objective is to develop a full-fledged 
biopharmaceutical sector that ranks among the higher end of the global industrial value 
chain.  
6.4.2 Creating Actors and Organizations to Improve Innovation Capacity  
Global strategies often require substantial supporting resources during the 
implementation processes. This research suggests that policy makers actively consider 
the strategic need and ensure adequate resources are provided. The results bring to light 
that China should strive to build an enterprise-centered innovation system for the 
biopharmaceutical sector. The change from a structural and institutional context of 
scientific research to an entrepreneurial mode may be beneficial for the 
biopharmaceutical industry in the long run. This concern needs to be taken for policy 
making.  
To build a more competitive biopharmaceutical Industry, the government can 
strengthen the development of enterprises by enhancing the factors that lead them to 
business success. Research shows that institutional support, especially support from the 
government, can play a major role in SMEs’ competitiveness development within the 
domestic market [319]. The actions can include executing an elite promotion program to 
support a number of flagship enterprises, and motivate them toward innovation. In order 
to stimulate innovation in the identified priority high-tech areas, policies can be designed 
to encourage Chinese scientists overseas to return to China and contribute their 
experience and expertise to the local industry. Domestic scientists should be encouraged 
to participate in the commercialization process or even to become technological 
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entrepreneurs themselves. Policy responses should be developed with regard to 
supporting innovation and investment in high-tech areas.  
6.4.3 Nurturing a Collaborative Environment and Innovation Ecosystem 
A major concern of the government is to improve the innovation ecosystem in the 
biopharmaceutical sector. The research results showed that both indigenous innovation 
and collaborative innovation are contributing strategies for the biopharmaceutical 
industry in China. Under the present conditions and status of China’s biopharmaceutical 
industry, imitative innovation is the preferred strategy. However, increasing international 
collaboration, as well as appropriate competition, is crucial for technological innovations 
and scientific breakthroughs. With increased partnerships and collaborations, both 
domestic and foreign actors cooperate to carry out scientific research that leads to 
innovations. 
The situation of limited collaborations between foreign and domestic biotech 
companies has been discussed in the literature. There are suggestions that foreign firms 
should adjust their IP strategies and change from a defensive position of filing and 
enforcing patents to a more active exploitation of the commercial value of their 
technologies in China [321]. First, large MNCs usually have a broad range of non-
commercialized patents where they are willing to open their innovation processes through 
patent transactions. Chinese firms may have opportunities either to buy or in-license 
some of the foreign state-of-the-art technologies. Second, smaller or medium-sized 
foreign firms usually have more specific and state-of-the-art technologies. They may 
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consider out-licensing such technologies before their IPs are infringed by Chinese firms 
[321].  
In short, the foreign firms should be encouraged to employ an open innovation 
strategy. In China’s context, the government can play a decisive role in promoting 
innovation activities in the high-tech areas. Measures can include setting up appropriate 
institutional frameworks, opening up more business opportunities, and providing 
generous incentives for various innovators. Policy makers must have a strong 
commitment to establish a more innovative environment for various players. Promoting 
the development of new ventures and encouraging foreign investment from MNCs are 
not only very necessary, but also represent the current needs and future trends for high-
tech development. 
6.4.4 Providing Service Platforms, Education, and Training 
In order to support innovation, the government can provide various services and 
facilities. These include clinical trial facilities and R&D service platforms that align with 
international best practices. The government should promote the development of biotech 
contract research services for clinical trial phase I & II, and establish biotech contract 
manufacturing services for clinical trial phase III. The government can also provide 
support through education, information propaganda, and procurement programs. The 
need for high quality scientists and engineers arises from both industry and research 
institutes. The investment in the higher education system should keep up with rapidly 
growing demand. The availability of human resources will ultimately contribute to the 
increase of industrial competitiveness.  
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6.4.5 Legislating Support and Financial Incentives for Innovators 
The nature of innovation networks in China is different from those in developed 
countries such as the United States and EU. The infrastructure and supporting systems are 
mainly policy driven. Favorable policies and economic support from the government are 
key factors to drive continuous growth in the long run. Substantial investments may be 
required in reforming established SOEs, cultivating startups, and supporting various 
academic/research institutes. Another area that needs improvement is the efficiency of the 
drug evaluation process and reviewing mechanism. The bureaucratic nature of decision 
making due to the involvement of government agencies has deterred the progress of 
technological development and cooperation. Such barriers should be simplified or 
removed completely. For example, the registration procedures for biosimilars could be 
simplified according to related practices in advanced foreign countries. 
Policies can serve to arouse the market participants’ interests in high-tech areas 
through fiscal incentives. Such measures may include offering support to SMEs in 
preferred research areas through investment incentives or low-interest loans. The 
government can provide startups with special funding to lower their burden of initial sunk 
cost. Lastly, the competitiveness of companies also depends on how well the companies 
handle their networks of complementary relationships with other players in the biotech 
sector. Institutional setup, active collaboration, and financial support from the 
government will enhance the companies’ capabilities with regard to innovation and 
competitiveness [319].  
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Chapter 7 – Conclusions  
With the implications and recommendations discussed in the last Chapter, this 
Chapter summarizes and concludes the project in several major aspects including: 
contributions, assumptions, limitations, and future research directions. 
7.1 Research Contribution 
The research contribution is summarized in Table 48 and explained below. 
 
Research Gaps  Research Outcomes  
1. Latecomers face the dilemma of ‘‘make or buy’’ 
decisions in high tech development [12] [84] [258] 
[259].Technology export control at various levels 
complicates their problems [16] [80] [138]. 
This research has identified four types of viable 
strategies for technology development in the 
emerging economies and latecomer countries.  
2. Latecomer countries and emerging economies 
need to identify the “windows of opportunity” for 
catching-up and leapfrogging [27] [29]. 
Identified and categorized thirteen prospective 
high-tech areas for the biopharmaceutical 
industry in China.  
3. International technology transfer activities may 
not necessarily result in sustained innovation, 
technology diffusion not efficient and spillover not 
obvious  [23] [25] [34]. 
The research has suggested more effective 
technology development strategies, including 
imitative innovation, indigenous innovation, 
and collaborative innovation strategies.  
4. Different attitudes toward appropriate 
technology. Common concerns exist but different 
interests and motivations are obvious among the 
stakeholders [30] [32] [37]. 
This research has identified the areas of 
disagreement or agreement in different 
hierarchy levels.  
5. Globalization brought new challenges in the 
research of innovation systems, innovation 
resources are across boundary [7] [72] [260].  
This research has identified eight types of input 
resources to support technological innovations 
in China’s biopharmaceutical industry.  
6. Transitional innovation systems: allocation of 
innovation resources is not effectively linked to 
national or regional tech development strategies 
[196] [197]. 
This research has prioritized the innovation 
resources to support the identified technology 
development strategies in China’s 
biopharmaceutical industry.  
7. No viable framework has been developed to deal 
with technology policy problems in latecomer 
countries. A decision model for the implementation 
mechanism of selected technologies is needed in 
such countries [180] [208] [261]. 
This research has developed a comprehensive 
research framework that links various 
technologies, strategies, and resources to assist 
technology policy decision in emerging 
economies.  
Table 48: Research Contribution 
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7.1.1 Contribution to Technology Management Literature 
Catching up and leapfrogging development in high-tech industries is a complicated 
issue for latecomer countries. It is a great challenge for decision makers because of 
limited innovation capacities and input resources. The literature review has revealed the 
necessity for proactive technology posture, strategy adaptation, and resource allocation to 
gain competitive advantage and innovation capability. However, little was known about 
the inner relationships and their combined impact on competitiveness. This research 
serves to fill the gap in the technology management literature. The findings of this 
research have identified prospective technology areas, effective innovation strategies, and 
resource allocation mechanisms. Along with the trend of globalization, technological 
innovations are more scattered around the world. The model helps latecomer countries to 
deal with the ‘‘make or buy’’ dilemma in technology development. The research process 
has considered the interests of both domestic and foreign stakeholders by incorporating 
multiple perspectives during data collection. It also combined a top-down and bottom-up 
approach to consider the needs and concerns of both governments and enterprises. 
Experts from diverse sources provided their valuable judgments for the research. 
7.1.2 Contribution to Methodology 
Conventional technology assessment methods are applied to evaluate and assign 
priority to technology alternatives for economic, social, or environmental objectives. 
However, such methods are not an appropriate means for determining a workable 
solution during the implementation stages. The biopharmaceutical industry encompasses 
many high-tech areas and complex aspects, and the realization mechanism of a particular 
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area may involve interconnected decision elements such as technology, strategy, and 
resources. Because of the many criteria involved and the different perceptions of experts 
with different backgrounds, this study has employed the HDM method proposed by 
Dundar Kocaoglu in 1976 to construct a new framework for the assessment of innovation 
potential in the biopharmaceutical sector  [252]. 
 AHP provides an effective methodology allowing the collective decision making 
process among various experts to be systematically integrated. It consolidates different 
opinions brought by experts’ backgrounds, and presents the results in an aggregated 
manner. Moreover, the disagreement among experts can be measured by the calculation 
of the intra-class coefficient and F-test. Through exploring the variance of opinions 
among different experts, policy makers can understand the exact area of disagreement 
and make tradeoffs accordingly. This provides an effective decision making mechanism 
for resource allocation, implementation strategy, and technology directions.  
7.1.3 Contribution to the Biopharmaceutical Industry 
The case application contributes to policy development in China’s bio-
pharmaceutical industry in time and in need. China is resolute to reform its health sector 
and promote innovations in high-tech areas. However, policy controversy exists in 
China’s pharmaceutical industry, and technological innovation is remarkably difficult 
[278]. Moreover, globalized competition has significantly complicated the innovation 
environments for local companies. Since the biopharmaceutical industry is noted for high 
regulatory control, the government plays an important role in guiding industrial 
development. The case study's most important contribution lies in its having consolidated 
222 
the valuable inputs of policy makers, industry representatives, and specialists from 
various biopharmaceutical fields to provide policy directions encompassing innovation 
resources, technology development strategies, and prospective high-tech areas. The 
resulting information allows the comparison of each innovator's level of development and 
provides a robust basis for policy improvement in the biopharmaceutical sector. 
In summary, this research continues and broadens the related technology 
management research in academic literature, and it develops a new analytic framework to 
deal with real world problems in the Chinese biopharmaceutical sector. Findings and 
implications of the research can provide new perspectives for high-tech development in 
other emerging economies. 
7.2 Assumptions and Limitations 
This section discusses some research assumptions and limitations, and how such 
issues were addressed in this research process.  
7.2.1 Research Assumptions 
The research has several assumptions in the area of AHP model development and 
expert recruitment. The development of an AHP model has its assumptions. The impact 
relationships between adjacent levels were assumed to be linear and unidirectional. The 
decision criteria at each level were assumed to be preferentially independent. To cope 
with such assumptions, the research model was conceptually developed based on a 
comprehensive literature review. The model structure was further tested in a pilot study. 
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The finalization of criteria and level of relationships were validated by the experts before 
the data collection process.  
The appropriate selection of experts is critical for the success of this research. The 
experts were assumed to be knowledgeable in their fields. Individual biases were 
assumed to be balanced in the expert panel and subgroups, and they had minimal effect 
on the overall quantification measurement. In order to meet such assumptions, experts 
were recruited according to their professional backgrounds and industrial experience. The 
researcher tried to minimize the biases by inviting experts from diverse sources including 
government agencies, domestic industrial associations, and foreign organizations. 
Moreover, the influential biases were avoided since the experts did not know who else 
participated in the research.  
7.2.2 Limitations 
Several limitations need to be clarified for this research. The experts provide their 
opinions based on their perception of reality, as well as their professional backgrounds 
and experience. The research process evaluated their judgmental preferences at a certain 
period of time, and the results only reflected their perceptions during that period of time. 
Their judgments may change over time due to other influencing factors such as social or 
economic changes. The model has been demonstrated through a case application in the 
biopharmaceutical sector. However, due to industrial differences, the research criteria 
may need to be modified for applications in other industries. 
This research is not to find a panacea for all the problems related to technology 
policy. The objective is to develop an analytic approach to assist policy design in 
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building a more effective innovation infrastructure to support technology implementation. 
The model may yield different outcomes for different countries, different political 
institutions, and different development stages. The idiosyncrasies of ideological 
frameworks are beyond the consideration of this research. 
7.3 Future Research 
The limitations discussed above leave some room for future research. Further 
exploration may lead to one or more of the following directions. 
7.3.1 Other Emerging Economies and Industries. 
Although the research framework has been demonstrated with a case study in 
China’s biopharmaceutical sector, additional research can be applied to other emerging 
economies such as Brazil, India, and Russia. Addressing industry-specific characteristics 
and examining the influence of regional characteristics would clearly be a future direction. 
The types and number of technologies and resources may vary from industry to industry, 
and from country to country. More criteria and alternatives could be identified and 
included in new models to reflect the reality according to different conditions. 
Policymakers can tailor this framework to the needs of particular sectors in the host 
country. The related research outcomes can provide insights for designing policies to 
improve the country’s innovation capacity. 
225 
7.3.2 Enterprise-Level Applications 
Selection of appropriate technology for a rapidly evolving market environment is a 
complicated issue at both the industrial and enterprise level. It should be acknowledged 
that the experts provided valuable feedback and suggestions, which was incisive, 
intelligent, and very thoughtful. One of them suggested that the model can be applied at 
both the industrial level and enterprise level. The future is uncertain and enterprises are 
engaged in the effort to sustain innovation. Many decision makers have the question 
"How do enterprises innovate consistently?" The difficulties of this go into making the 
right decisions about how many resources to pour into innovation, and how to choose the 
right products to innovate around. Enterprises leverage various innovation resources, but 
funding is relatively internal and constrained by various factors. It is crucial to have a 
discipline of execution around the innovation process. The research model can therefore 
serve to help enterprises in making balanced investments, innovating in the right areas, 
and making the right bets for the future. 
7.3.3 Deployment of Policy Tools 
The application of an analytical hierarchical structure gave meaningful results in 
identifying the effective innovation resources and comparing the relative importance of 
strategies. The purpose of this research, as well as the model, is to guide policy directions 
that will build up the innovation capability for the country. However, more specific 
policy tools and measures are not discussed in detail. Follow up policy research can focus 
on the development of favorable policy tools to support the identified criteria. For 
example, the results suggest that High-tech SMEs and MNCs have more contributions 
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toward the overall mission of competitiveness and innovation. These research outcomes 
can lead future work to the deployment of more specific policy tools to support the 
identified players. Moreover, technology policies should also be revised in a dynamic 
manner to keep up with the rapid trend of globalization and trade liberalization.  
227 
Bibliography 
[1] K. Annan, "Science for all nations," Science, vol. 303, p. 925, 2004. 
[2] C. Freeman, Technology Policy and Economic Performance: Lessons from Japan. 
London: Pinter, 1987. 
[3] T. Galama and J. Hosek, "U.S. Competitiveness in Science and Technology," 
RAND, 2008. 
[4] K. Fukuda and C. Watanabe, "Japanese and US perspectives on the National 
Innovation Ecosystem," Technology in Society, vol. 30, pp. 49-63, 2008. 
[5] S. Radosevic, International Technology Transfer and Catch-Up in Economic 
Development. Cheltenham: Edward Elgar, 1999. 
[6] J. Zhouying, "Globalization, technological competitiveness and the 'catch-up' 
challenge for developing countries: Some lessons of experience," International 
Journal of Technology Management and Sustainable Development, vol. 4, pp. 35-
46, 2005. 
[7] J. Bessant and J. Tidd, Innovation and Entrepreneurship. West Sussexs, England: 
John Wiley & Sons, 2007. 
[8] T. Altenburg, H. Schmitz, and A. Stamm, "Breakthrough? China’s and India’s 
transition from production to innovation," World Development, vol. 36, pp. 325-
344, 2008. 
[9] W. Sun, J. Peng, J. Ma, and W. Zhong, "Evolution and performance of Chinese 
technology policy: An empirical study based on "market in exchange for 
technology" strategy," Journal of Technology Management in China, vol. 4, pp. 
195 - 216, 2009. 
[10] L. Chan, "Technology transfer to China: Case of the high-speed rail industry," in 
Portland International Conference on Management of Engineering and 
Technology Portland: IEEE, 2009, pp. 2858-2867. 
[11] M. Rock, J. T. Murphy, R. Rasiah, P. van Seters, and S. Managi, "A hard slog, not 
a leap frog: Globalization and sustainability transitions in developing Asia," 
Technological Forecasting and Social Change, vol. 76, pp. 241-254, 2009. 
[12] K. Eggleston, J. Wang, and K. Rao, "From plan to market in the health sector? 
China's experience," Journal of Asian Economics, vol. 19, pp. 400-412, 2008. 
[13] K. Hoffman and N. Girvan, "Managing international technology transfer: a 
strategic approach for developing countries," IDRC, 1990. 
[14] M. Farhang, "Managing Technology Transfer to China," International Marketing 
Review, vol. 14, pp. 92-106, 1997. 
[15] N. M. Reddy and L. Zhao, "International technology transfer: A review," 
Research Policy, vol. 19, pp. 285-307, 1990. 
[16] A. S. Erickson and K. A. Walsh, "National security challenges and competition: 
Defense and space R&D in the Chinese strategic context," Technology in Society, 
vol. 30, pp. 349- 361, 2008. 
[17] C. Perez and L. Soete, "Catching up in technology: Entry barriers and windows of 
opportunity," in Technical Change and Economic Theory, G. Dosi, Ed. London 
UK: Pinter, 1988, pp. 458-479. 
228 
[18] I. Dunmade, "Indicators of sustainability: assessing the suitability of a foreign 
technology for a developing economy," Technology in Society, vol. 24, pp. 461-
471, 2002. 
[19] J. C. Guan, C. K. Mok, R. C. M. Yam, K. S. Chin, and K. F. Pun, "Technology 
transfer and innovation performance: Evidence from Chinese firms," 
Technological Forecasting & Social Change, vol. 73, pp. 666-678, 2006. 
[20] X. M. Wang and X. Zhou, "A new strategy of technology transfer to China," 
International Journal of Operations & Production Management, vol. 19, pp. 527-
537, 1999. 
[21] D. Leonard-Barton, Wellspring of Knowledge Building and Sustaining the 
Sources of Innovation. Cambridge, MA: Harvard Business School Press, 1995. 
[22] M. Hobday, Innovation in East Asia: The Challenge to Japan Cheltenham: 
Edward Elgar, 1995. 
[23] X. Chen and C. Sun, "Technology transfer to China: Alliances of Chinese 
enterprises with Western technology exporters," Technovation, vol. 20, pp. 353-
362, 2000. 
[24] A. D. Meyer, "Technology transfer into China: Preparing for a new era," 
European Management Journal, vol. 19, pp. 140-144, 2001. 
[25] X. Fu and Y. Gong, "Indigenous and Foreign Innovation Efforts and Drivers of 
Technological Upgrading: Evidence from China," World Development, vol. 39, 
pp. 1213-1225, 2011. 
[26] J. A. Mathews, "National system of economic learning: The case of technology 
diffusion management in East Asia," International Journal of Technology 
Management, vol. 22, pp. 455-479, 2001. 
[27] K. Lee and C. Lim, "Technological regimes, catching-up and leapfrogging: The 
findings from the Korean industries," Research Policy, vol. 30, pp. 459-483, 2001. 
[28] D. Ernst and L. Kim, "Global Production Networks, Knowledge Diffusion and 
Local Capability Formation," Research Policy, vol. 31, pp. 1417-1429, 2002. 
[29] K. Lee, "Making a technological catch-up: Barriers and opportunities," Asian 
Journal of Technology Innovation, vol. 13, pp. 97-131, 2005. 
[30] C. A. Un and A. Cuervo-Cazurra, "Do subsidiaries of foreign MNEs invest more 
in R&D than domestic firms?," Research Policy, vol. 37, pp. 1812-1828, 2008. 
[31] P. Bruun and D. Bennett, "Transfer of technology to China: A Scandinavian and 
European perspective," European Management Journal, vol. 20, pp. 98-106, 2002. 
[32] X. Gao, P. Zhang, and X. Liu, "Competing with MNEs: developing 
manufacturing capabilities or innovation capabilities," Journal of Technology 
Transfer, vol. 32, pp. 87-107, 2007. 
[33] J. Dedrick, K. L. Kraemer, and T. Tsai, "ACER: An IT company learning to use 
information technology to compete," IT in Business, Center for Research on 
Information Technology and Organization, University of California, October 
1999. 
[34] F. Lemoine and D. Unal-Kesenci, "Assembly trade and technology transfer: The 
case of China," World Development, vol. 32, pp. 829-850, 2004. 
229 
[35] M. Nieto and P. Quevedo, "Absorptive capacity, technological opportunity, 
knowledge spillovers, and innovative effort," Technovation, vol. 25, pp. 1141 -
1157, 2005. 
[36] G. F. Farris, "Research on innovation management and technology transfer in 
China," Journal of Technology Transfer, vol. 32, pp. 123-126, 2007. 
[37] J. Edler, "International research strategies of multinational corporations: A 
German perspective," Technological Forecasting & Social Change, vol. 71, pp. 
599-621, 2004. 
[38] A. Marin and M. Bell, "Technology spillovers from foreign direct investment 
(FDI): The active role of MNC subsidiaries in Argentina in the 1990s," Journal of 
Development Studies, vol. 42, pp. 678-697, May 2006. 
[39] C. A. D. Benedetto, R. J. Calantone, and C. Zhang, "International technology 
transfer: Model and exploratory study in the People's Republic of China," 
International Marketing Review, vol. 20, pp. 446 - 462, 2003. 
[40] M. Porter and S. Stern, "National innovative capacity," in The Global 
Competitiveness Report 2001-2002, M. E. Porter, J. D. Sachs, P. K. Cornelius, J. 
W. McArthur, and K. Schwab, Eds. New York: Oxford University Press, 2002, pp. 
102-118. 
[41] R. Rothwell, "Towards the fifth-generation innovation process," International 
Marketing Review, vol. 11, pp. 7-31, 1994. 
[42] G. F. Nemet, "Demand-pull, technology-push, and government-led incentives for 
non-incremental technical change," Research Policy, vol. 38, pp. 700-709, 2009. 
[43] C. Freeman, "The Greening of Technology and Models of Innovation " 
Technological Forecasting and Social Change, vol. 53, pp. 27-39, 1996. 
[44] M. P. Hekkert, R. A. A. Suurs, S. O. Negro, S. Kuhlmann, and R. E. H. M. Smits, 
"Functions of Innovation Systems: A new approach for analysing technological 
change," Technological Forecasting and Social Change, vol. 74, pp. 413-432, 
2006. 
[45] C. Edquist, Systems of Innovation: Technologies, Institutions and Organizations. 
London: Pinter, 1997. 
[46] B. A. Lundvall, B. Johnson, E. S. Andersen, and B. Dalum, "National systems of 
production, innovation and competence building," Research Policy, vol. 31, pp. 
213-231, 2002. 
[47] R. Smits and S. Kuhlmann, "The rise of systemic instruments in innovation 
policy," International Journal of Foresight and Innovation Policy, vol. 1, pp. 1-26, 
2004. 
[48] C. Edquist, The systems of Innovation Approach and Innovation Policy: An 
Account of the State of the Art. Aalborg: DRUID, 2001. 
[49] B. Elzen and A. Wieczorek, "Transitions towards sustainability through System 
Innovation," Technological Forecasting and Social Change, vol. 72, pp. 651-661, 
2005. 
[50] B. A. Lundvall, Introduction. National Systems of Innovation - Toward a Theory 
of Innovation and Interactive Learning. London: Pinter, 1992. 
[51] R. R. Nelson and K. Nelson, "Technology, institutions, and innovation systems," 
Research Policy, vol. 31, pp. 265-272, 2002. 
230 
[52] J. Niosi, P. Saviotti, B. Bellon, and M. Crow, "National systems of innovation: In 
search of a workable concept," Technology in Society, vol. 15, pp. 207-227, 1993. 
[53] S. Metcalfe, "The economic foundations of technology policy: Equilibrium and 
evolutionary perspectives," in Handbook of the Economics of Innovation and 
Technical Change, P. Stoneman, Ed. London: Blackwell, 1995, pp. 409-512. 
[54] P. Krugman, "Increasing returns and economic geography," Journal of Political 
Economy, vol. 99, pp. 483-99, 1991. 
[55] P. Cooke, M. Uranga, and G. Etxebarria, "Regional innovation systems: 
Institutional and organizational dimensions," Research Policy, vol. 26, pp. 475-
491, 1997. 
[56] M. Storper, The Regional World: Territorial Development in a Global Economy. 
New York: The Guilford Press, 1997. 
[57] H.J.Braczyk, P. Cooke, and M. Heidenreich, Regional Innovation Systems. 
London: Routledge, 1998. 
[58] D. Doloreux, "What should we know about regional systems of innovation?," 
Technology in Society, vol. 24, pp. 243-263, 2002. 
[59] H. Etzkovitz and L. Leydersdorff, "The dynamics of innovation: from National 
Systems and “Mode 2” to a Triple Helix of university - industry - government 
relations," Research Policy, vol. 29, pp. 109-123, 2000. 
[60] B. T. Asheim and M. Gertler, "The geography of innovation: Regional innovation 
systems," in The Oxford Handbook of Innovation, J. Fagerberg, Mowery, D., and 
Nelson, R. , Ed. Oxford: Oxford University Press, 2005, pp. 291-317. 
[61] J. Zysman, "How institutions create historically rooted trajectories of growth," 
Industrial and Corporate Change, vol. 3, pp. 243-283, 1994. 
[62] S. Breschi and F. Malerba, "Sectoral innovation systems: Technological regimes, 
Schumpeterian dynamics, and spatial boundaries," in Systems of Innovation: 
Technologies, Institutions and Organization, C. Edqvist, Ed. London: Pinter, 
1997, pp. 130-153. 
[63] F. Malerba, "Sectoral systems of innovation and production," Research Policy, 
vol. 31, pp. 247-264, 2002. 
[64] F. Malerba, "Sectoral systems:  How and why innovation differs across sectors," 
in The Oxford Handbook of Innovation, J. Fagerberg, D. C. Mowery, and R. 
Nelson, Eds. Oxford: Oxford University Press, 2005. 
[65] B. Carlsson, S. Jacobsson, M. Holmen, and A. Rickne, "Innovation systems: 
Analytical and methodological issues," Research Policy, vol. 31, pp. 233-45, 
2002. 
[66] B. Carlsson and R.Stankiewicz, "On the nature, function and composition of 
technological systems," Journal of Evolutionary Economics, vol. 1, pp. 93-118, 
1991. 
[67] B. Carlsson, Technological Systems and Industrial Dynamics: Economics of 
Science, Technology and Innovation. Boston: Kluwer Academic Publishers, 1997. 
[68] S. Chung, "Building a national innovation system through regional innovation 
systems," Technovation, vol. 22, pp. 485-491, 2002. 
[69] UNCTD, Science, Technology and Innovation Policy Review. New York: United 
Nations Conference on Trade and Development, 2005. 
231 
[70] P. Fan, "Catching up through developing innovation capability evidence from 
China’s Telecom-equipment industry," Technovation, vol. 26, pp. 359-368, 2006. 
[71] M. Blomstrom and A. Kokko, "Foreign investment as a vehicle for international 
technology transfer," in Creation and Transfer of Knowledge: Institutions and 
Incentives, G. B. Navaretti, P. Dasgupta, K.-G. Maler, and D. Sniscalco, Eds. 
Berlin: Springer, 1998. 
[72] B. Carlsson, "Internationalization of innovation systems: A survey of the 
literature," Research Policy, vol. 35, pp. 56-67, 2006. 
[73] NRC, S&T Strategies of Six Countries: Implications for the United States. 
Washington, DC: The National Academies Press, 2010. 
[74] J. Yang and W. Shu, "On the choice of technological innovation strategy of 
Chinese enterprises at present," China-USA Business Review, vol. 4, pp. 63-66, 
2005. 
[75] W. Lazonick, "Indigenous innovation and economic development: Lessons from 
China’s leap into the information age," Industry and Innovation, vol. 11, pp. 273-
297, 2004. 
[76] C. Jin, "Towards Indigenous Innovation: Pathways for Chinese Firms," Workshop 
of Technology Innovation and Economic Development, 2005. 
[77] C. J. Cheng and E. C. C. Shiu, "Re-innovation: The construct, measurement, and 
validation," Technovation, vol. 28, pp. 658-666, 2008. 
[78] T. Mukoyama, "Innovation, imitation, and growth with cumulative technology," 
Journal of Monetary Economics, vol. 50, pp. 361-380, 2003. 
[79] X. Wang and J. Li, "Innovation network in harvest," in International Conference 
on Technology Innovation, Risk Management, and Supply Chain Management. 
Beijing, 2007, pp. 420-424. 
[80] G. Overton, "Confronting photonics: are controls on exports of high-power lasers 
hurting US manufacturers," Laser Focus World, vol. 4, pp. 59-61, 2008. 
[81] L. Pereira and G. A. Plonski, "Shedding light on technological development in 
Brazil," Technovation, vol. 29, pp. 451-464, Jun-Jul 2009. 
[82] L. Kim, Imitation to Innovation: The Dynamics of Korea's Technological 
Learning. Cambridge, MA.: Harvard Business School Press, 1997. 
[83] M. C. Hu and J. A. Mathews, "China's national innovative capacity," Research 
Policy, vol. 37, pp. 1465-1479, Oct 2008. 
[84] M. Tang and C. Hussler, "Betting on indigenous innovation or relying on FDI: 
The Chinese strategy for catching-up," Technology in Society, vol. 33, pp. 23-35, 
2011. 
[85] E. B. Viotti, "National Learning Systems: A new approach on technological 
change in late industrializing economies and evidences from the cases of Brazil 
and Korea (R.O.)," Technological Forecasting and Social Change, vol. 69, pp. 
653-680, 2002. 
[86] MOES, "National innovation system and state innovation policy of the Russian 
Federation," Ministry of Education and Science of the Russian Federation. 2009. 
[87] A. Sokolov, "Russian Critical Technologies 2015," The European Foresight 
Monitoring Network Foresight Brief No.079, 2006. 
232 
[88] S. Srinivas and J. Sutz, "Developing countries and innovation: Searching for a 
new analytical approach," Technology in Society, vol. 30, pp. 129-140, 2008. 
[89] D. Byerlee and K. Fischer, "Accessing modern science: Policy and institutional 
options for agricultural biotechnology in developing countries," World 
Development, vol. 30, pp. 931-948, 2002. 
[90] R. Bendis and E. Byler, "Creating a National Innovation Framework: Building a 
Public-Private Support System to Encourage Innovation," Science Progress, vol. 
April, 2009. 
[91] B. R. Martin, "Foresight in science and technology," Technology Analysis & 
Strategic Management, vol. 7, pp. 139-168, 1995. 
[92] A. L. Porter and W. B. Ashton, "Foresight in the USA," in The Handbook of 
Technology Foresight, L. Georghiou, H. Cassingena, J, M. Keenan, I. Miles, and 
R. Popper, Eds. Cheltenham: Edward Elgar, 2008, pp. 154-169. 
[93] C. S. Wagner and S. W. Popper, "Identifying critical technologies in the United 
States: A review of the Federal effort," Journal of Forecasting, vol. 22, pp. 113-
128, 2003. 
[94] T. Kuwahara, K. Cuhls, and L. Georghiou, "Foresight in Japan," in The Handbook 
of Technology Foresight, L. Georghiou, H. Cassingena, J, M. Keenan, I. Miles, 
and R. Popper, Eds. Cheltenham: Edward Elgar, 2008, pp. 170-183. 
[95] NISTEP, "The 8th Science and Technology Foresight Survey - Future Science 
and Technology in Japan, Delphi Report," National Institute of Science and 
Technology Policy (NISTEP), Report 97, Tokyo: Japan 2005. 
[96] L. Georghiou and M. Keenan, "Evaluation of national foresight activities: 
assessing rationale, process and impact," Technological Forecasting and Social 
Change, vol. 73, pp. 761-777, 2006. 
[97] R. Johnston, "The State and Contribution of  International Foresight: New 
Challenges," in The Role of Foresight in the Selection of Research Policy 
Priorities, IPTS Seminar, Seville, 2002. 
[98] R. Johnston, "Priority Setting for Future Critical and Key Industrial Technologies 
as Driving Forces for Economic Development and Competitiveness " in 
Technology Foresight Summit 2007, Budapest, Hungary, 2007. 
[99] L. Georghiou, "Third generation foresight - integrating the socio-economic 
dimension," in Proceedings of the International Conference on Technology 
Foresight, NISTEP, Japan 2001. 
[100] L. Georghiou, "Foresight: Concept and Practice as a Tool for Decision Making," 
Expert Papers, Technology Foresight Summit 2003. Budapest, Hungary, 2003. 
[101] L. Georghiou, "Future of Foresighting for Economic Development," in 
Technology Foresight Summit 2007, Budapest, Hungary, 2007. 
[102] B. R. Martin and R. Johnston, "Technology foresight for wiring up the national 
innovation system: Experiences in Britain, Australia, and New Zealand," 
Technological Forecasting and Social Change, vol. 60, pp. 37-54, 1999. 
[103] K. Blind, K. Cuhls, and H. Grupp, "Current foresight activities in central Europe," 
Technological Forecasting and Social Change, vol. 60, pp. 15-35, 1999. 
233 
[104] C. A. d. F. Porto, E. Marques, and A. B. A. Santos, "Prospective in Brazil: The 
power to build the future," Technological Forecasting & Social Change, vol. 77, 
pp. 1550-1558, 2010. 
[105] C. Canongia, "Synergy between Competitive Intelligence (CI), Knowledge 
Management (KM) and Technological Foresight (TF) as a strategic model of 
prospecting - The use of biotechnology in the development of drugs against breast 
cancer," Biotechnology Advances, vol. 25, pp. 57-74, 2007. 
[106] M. d. M. Santo, G. M. Coelho, D. M. d. Santos, and L. F. Filho, "Text mining as a 
valuable tool in foresight exercises: A study on nanotechnology," Technological 
Forecasting & Social Change, vol. 73, pp. 1013-1027, 2006. 
[107] R. Popper, "Production Chains 2016 - The Brazilian Technology Foresight 
Program," The European Foresight Monitoring Network Foresight Brief. No.15, 
2005. 
[108] D. M. Santos and L. F. Filho, "The Role of Foresight Experience in the Promotion 
of Brazil's National Innovation System," National Council of Scientific and 
Technological Development & Center for Strategic Management and Studies, 
Brazil, 2007. 
[109] R. Popper and J. Medina, "Foresight in Latin America," in The Handbook of 
Technology Foresight, L. Georghiou, H. Cassingena, J, M. Keenan, I. Miles, and 
R. Popper, Eds. Cheltenham: Edward Elgar, 2008, pp. 265-268. 
[110] J. M. Pereira, G. F. Marcelino, and I. Kruglianskas, "Brazilian new patterns of an 
industrial, technological and foreign trade policy," Journal of Technology 
Management & Innovation, vol. 1, pp. 17-28, 2006. 
[111] R. Gouvea and S. Kassicieh, "Using resources in R&D policy planning: Brazil, 
the Amazon and biotechnology," Technological Forecasting & Social Change, 
vol. 72, pp. 535-547, 2005. 
[112] E. D. Zanotto, "Scientific and technological development in Brazil: The widening 
gap," Scientometrics, vol. 55, pp. 383-391, 2002. 
[113] V. S. Efmov and A. V. Lapteva, "Practices of exploring the future: Russian 
foresight," Journal of Siberian Federal University. Humanities & Social Sciences, 
vol. 3, pp. 143-153, 2010. 
[114] D. Yakov, C. Alexander, and S. Yury, "Forecasting of long-term innovation 
development in Russian economy sectors: Main results, lessons and policy 
conclusions," in The 4th International Seville Conference on Future-Oriented 
Technology Analysis. Seville, Spain, 2011. 
[115] M. Ksenofontov, "Technology foresight in the Russian Federation: Background 
and agenda for the future," in International Practice in Technology Foresight. 
United Nations Industrial Development Organization, Vienna: United Nations 
Publications, 2002, pp. 77-88. 
[116] N. Gaponenko, "Russian Nanotechnology 2020," The European Foresight 
Monitoring Network Foresight Brief No.075, 2007. 
[117] I. Eliseeva, "Benchmarking Russian Science and Technology Productivity," in 
Liberalizing Research in Science and Technology: Studies in Science Policy, N. 
Asheulova, B. K. Pattnaik, E. Kolchinsky, and G. Sandstrom, Eds. St. Petersburg: 
Russian Academy of Sciences, 2010, pp. 332-339. 
234 
[118] R. Chidambaram, "India needs to have technology foresight to emerge as leader," 
The Hindu, vol. Aug 22, 2006. 
[119] S. Mishra, S. G. Deshmukh, and P. Vrat, "Matching of technological forecasting 
technique to a technology," Technological Forecasting & Social Change, vol. 69, 
pp. 1-27, 2002. 
[120] D. Bhatnagar, "Knowledge network in action: New paradigms from India," in The 
12th International Conference on Technology Policy and Innovation. Porto, 
Portugal, 2009. 
[121] S. Mani, "Institutional support for investment in domestic technologies: An 
analysis of the role of government in India," Technological Forecasting & Social 
Change, vol. 71, pp. 855-863, 2004. 
[122] A. Mallik, "National security challenges and competition for India: Defence and 
space R&D in a strategic context," Technology in Society, vol. 30, pp. 362-370, 
2008. 
[123] CAS, Technology Foresight towards 2020 (in Chinese). Beijing: Kexue Press, 
2006. 
[124] R. Mu, Z. Ren, S. Yuan, and Y. Qiao, "Technology foresight towards 2020 in 
China: The practice and its impacts," Technology Analysis & Strategic 
Management, vol. 20, pp. 287-307, 2008. 
[125] MOST, Technology Foresight Report: Energy, Resources, Environment, and 
Advanced Manufacturing Technology (in Chinese). Beijing: Kexue Press, 2004. 
[126] A. Havas, "Evolving foresight in a small transition economy," Journal of 
Forecasting, vol. 22, pp. 179-201, 2003. 
[127] D. A. Bromley, "Technology policy," Technology in Society, vol. 26, pp. 455-468, 
2004. 
[128] M. Dodgson, D. Gann, and A. Salter, The Management of Technological 
Innovation: Strategy and Practice. Oxford, Britain: Oxford University Press, 
2008. 
[129] B. R. Inman and D. F. Burton(Jr.), "Technology and Competitiveness: The New 
Policy Frontier," Foreign Affairs, vol. 69, pp. 116-134, 1990. 
[130] T. A. Hemphill, "US innovation policy: creating (and expanding) a national 
agenda for global competitiveness," Innovation: Management, Policy, & Practice, 
2006. 
[131] G. W. Bush, "American Competitiveness Initiative," Domestic Policy Council 
Office of Science and Technology Policy, 2006. 
[132] W. J. Clinton, "Science and Technology Shaping the Twenty-First Century," 
Office of Science and Technology Policy, 1997. 
[133] S. Lall, "Reinventing Industrial Strategy: The Role of Government Policy in 
Building Industrial Competitiveness," United Nations Conference on Trade and 
Development (UNCTAD), vol. 28, 2004. 
[134] B. Obama, "A Strategy for American Innovation - Driving Towards Sustainable 
Growth and Quality Jobs," Executive Office of the President, National Economic 
Council, Office of Science and Technology Policy, 2009. 
[135] Y. Yasunaga, M. Watanabe, and M. Korenaga, "Application of technology 
roadmaps to governmental innovation policy for promoting technology 
235 
convergence," Technological Forecasting and Social Change, vol. 76, pp. 61-79, 
2009. 
[136] J. B. Reynolds, "Export controls and economic sanctions," The International 
Lawyer, vol. 36, 2002. 
[137] C. F. Corr, "The wall still stands! Complying with export controls on technology 
transfers in the post-cold war, post-9/11 era," Houston Journal of International 
Law, vol. 25, p. 441, 2003. 
[138] R. DeVol and P. Wong, "Jobs for America - Investments and policies for 
economic growth and competitiveness," Milken Institute, vol. January, 2010. 
[139] M. R. Byrne, "Protecting national security and promoting foreign investment: 
Maintaining the Exon-Florio balance," Ohio State Law Journal, vol. 67, p. 849, 
2006. 
[140] J. C. Stagg, "Scrutinizing foreign investment: How much congressional 
involvement is too much," Iowa Law Review, vol. 93, p. 325, 2007. 
[141] J.-H. J. Yun, "The development of technological capability and the transformation 
of inward FDI in Korea from 1962 to 2000," Innovation and Technology in Korea, 
pp. 33-54, 2007. 
[142] K. Kiyota and T. Okazaki, "Foreign technology acquisition policy and firm 
performance in Japan, 1957-1970: Macro-aspects of industrial policy," CIRJE 
Discussion Papers, 2005. 
[143] M. Hobday, H. Rush, and J. Bessant, "Approaching the innovation frontier in 
Korea: the transition phase to leadership," Research Policy, vol. 33, pp. 1433-
1457, 2004. 
[144] F. Narin and J. D. Frame, "The growth of Japanese science and technology," 
Science, vol. 245, pp. 600-605, 1989. 
[145] M. Hobday, "Technological Learning in Singapore: A Test Case of 
Leapfrogging," Journal of Development Studies, vol. 30, pp. 831-858, 1994. 
[146] S. Ghazinoory, A. Divsalar, and A. S. Sooﬁ, "A new deﬁnition and framework for 
the development of a national technology strategy: The case of nanotechnology 
for Iran," Technological Forecasting & Social Change, vol. 76, pp. 835-848, 2009. 
[147] J. A. Alic, "Policies for innovation: Learning from the past," in The Role of 
Government in Technology Innovation: Insights for Government Policy in the 
Energy sector, V. Norberg-Bohm, Ed. Cambridge, MA: Belfer Center for Science 
and International Affairs, Harvard University, 2002. 
[148] A. Reid and V. Peter, "Sectoral Innovation Systems: The Policy Landscape in the 
Eu25," Mapping of Sectoral Innovation Policy, Technopolis Group. 2008. 
[149] X. Zhong and X. Yang, "Science and technology policy reform and its impact on 
China's national innovation system," Technology in Society, vol. 29, pp. 317-325, 
2007. 
[150] J. Song, "Awakening: Evolution of China's science and technology policies," 
Technology in Society, vol. 30, pp. 235-241, 2008. 
[151] R. Mu and W. Qu, "The development of science and technology in China: A 
comparison with India and the United States," Technology in Society, vol. 30, pp. 
319-329, 2008. 
236 
[152] P. Fan and C. Watanabe, "Promoting industrial development through technology 
policy: Lessons from Japan and China," Technology in Society, vol. 28, pp. 303-
320, 2006. 
[153] MOST, "Ministry of Science and Technology of People's Republic of China," 
[Online: available www.most.gov.cn ], [Accessed: 8-30-2009]. 
[154] G. Hutschenreiter and G. Zhang, "China's quest for innovation-driven growth - 
the policy dimension " Journal of Industry Competition and Trade, vol. 7, pp. 
245-254, 2007. 
[155] J. Wu and N. Pangarkar, "Rising to the global challenge: Strategies for firms in 
emerging markets," Long Range Planning, vol. 39, pp. 295-313, 2006. 
[156] P. Fan, "Catching up through developing innovation capability: evidence from 
China's telecom-equipment industry," Technovation, vol. 26, pp. 359-368, 2006. 
[157] W. S. Siu, T. L. Lin, W. C. Fang, and Z. C. Liu, "An institutional analysis of the 
new product development process of small and medium enterprises (SMEs) in 
China, Hong Kong and Taiwan," Industrial Marketing Management, vol. 35, pp. 
323-335, Apr 2006. 
[158] X. D. Chen and G. Reger, "The role of technology in the investment of German 
firms in China," Technovation, vol. 26, pp. 407-415, Mar 2006. 
[159] J. Duanmu and F. M. Fai, "A processual analysis of knowledge transfer: From 
foreign MNEs to Chinese suppliers," International Business Review, vol. 16, pp. 
449-473, 2007. 
[160] X. Liu and T. Buck, "Innovation performance and channels for international 
technology spillovers: Evidence from Chinese high-tech industries," Research 
Policy, vol. 36, pp. 355-366, 2007. 
[161] K. Motohashi and X. Yun, "China's innovation system reform and growing 
industry and science linkages," Research Policy, vol. 36, pp. 1251-1260, Oct 2007. 
[162] K. Chen and M. Kenney, "Universities/Research institutes and regional 
innovation systems: The cases of Beijing and Shenzhen," World Development, vol. 
35, pp. 1056-1074, Jun 2007. 
[163] X. Liu and H. Zou, "The impact of greenﬁeld FDI and mergers and acquisitions 
on innovation in Chinese high-tech industries," Journal of World Business, vol. 
43, pp. 352-364, 2008. 
[164] K. Fisher-Vanden and G. H. Jefferson, "Technology diversity and development: 
Evidence from China's industrial enterprises," Journal of Comparative Economics, 
vol. 36, pp. 658-672, 2008. 
[165] J. Zheng, A. Bigsten, and A. Hu, "Can China's growth be sustained? A 
productivity perspective," World Development, vol. 37, pp. 874-888, 2009. 
[166] W. Hong, "Decline of the center: The decentralizing process of knowledge 
transfer of Chinese universities from 1985 to 2004," Research Policy, vol. 37, pp. 
580-595, May 2008. 
[167] S. Girma and Y. D. Gong, "FDI, linkages and the efficiency of state-owned 
enterprises in China," Journal of Development Studies, vol. 44, pp. 728-749, 2008. 
[168] J. Y. Kim and L. Y. Zhang, "Formation of foreign direct investment clustering: A 
new path to local economic development? The case of Qingdao," Regional 
Studies, vol. 42, pp. 265-280, 2008. 
237 
[169] K. Asakawa and A. Som, "Internationalization of R&D in China and India: 
Conventional wisdom versus reality," Asia Pacific Journal of Management, vol. 
25, pp. 375-394, 2008. 
[170] S. Girma and Y. D. Gong, "Putting people first? Chinese state-owned enterprises' 
adjustment to globalisation," International Journal of Industrial Organization, vol. 
26, pp. 573-585, Mar 2008. 
[171] K. Kiyota, T. Matsuura, S. Urata, and Y. Wei, "Reconsidering the backward 
vertical linkages of foreign affiliates: Evidence from Japanese multinationals," 
World Development, vol. 36, pp. 1398-1414, Aug 2008. 
[172] L. G. Ying, "The shape of ideas production function in transition and developing 
economies: Evidence from China," International Regional Science Review, vol. 
31, pp. 185-206, Apr 2008. 
[173] H. Kroll and I. Liefner, "Spin-off enterprises as a means of technology 
commercialisation in a transforming economy - Evidence from three universities 
in China," Technovation, vol. 28, pp. 298-313, May 2008. 
[174] Y. Zhou, "Synchronizing export orientation with import substitution: Creating 
competitive indigenous high-tech companies in China," World Development, vol. 
36, pp. 2353-2370, 2008. 
[175] G. Bin, "Technology acquisition channels and industry performance: An industry-
level analysis of Chinese large- and medium-size manufacturing enterprises," 
Research Policy, vol. 37, pp. 194-209, Mar 2008. 
[176] S. Girma, Y. Gong, and H. Gorg, "What Determines Innovation Activity in 
Chinese State-owned Enterprises? The Role of Foreign Direct Investment," World 
Development, vol. 37, pp. 866-873, Apr 2009. 
[177] D. Chen, W. Newburry, and S. H. Park, "Improving sustainability: An 
international evolutionary framework," Journal of International Management vol. 
15, pp. 317-327, 2009. 
[178] K. S. Swan and B. B. Allred, "Does 'the China Option' influence subsidiary 
technology sourcing strategy," Journal of International Management, vol. 15, pp. 
169-180, 2009. 
[179] F. Hatani, "The logic of spillover interception: The impact of global supply chains 
in China," Journal of World Business, vol. 44, pp. 158-166, 2009. 
[180] J. C. Guan, R. C. M. Yam, E. P. Y. Tang, and A. K. W. Lau, "Innovation strategy 
and performance during economic transition: Evidences in Beijing, China," 
Research Policy, vol. 38, pp. 802-812, 2009. 
[181] J. P. H. Fan, R. Morck, L. C. Xu, and B. Yeung, "Institutions and Foreign Direct 
Investment: China versus the Rest of the World," World Development, vol. 37, pp. 
852-865, Apr 2009. 
[182] C. Huang and N. Sharif, "Manufacturing dynamics and spillovers: The case of 
Guangdong Province and Hong Kong, Macau, and Taiwan (HKMT)," Research 
Policy, vol. 38, pp. 813-828, Jun 2009. 
[183] L. Brandt and E. Thun, "The fight for the middle: Upgrading, competition, and 
industrial development in China," World Development, vol. 38, pp. 1555-1574, 
2010. 
238 
[184] H. Kroll and D. Schiller, "Establishing an interface between public sector applied 
research and the Chinese enterprise sector: Preparing for 2020," Technovation, 
vol. 30, pp. 117-129, 2010. 
[185] J. Lu, Z. Tao, and Z. Yang, "The costs and benefits of government control: 
Evidence from China's collectively-owned enterprises," China Economic Review, 
vol. 21, pp. 282-292, 2010. 
[186] K. Motohashi and Y. Yuan, "Productivity impact of technology spillover from 
multinationals to local firms: Comparing China's automobile and electronics 
industries," Research Policy, vol. 39, pp. 790-798, 2010. 
[187] X. Tian, "Managing FDI technology spillovers: A challenge to TNCs in emerging 
markets," Journal of World Business, vol. 45, pp. 276-284, 2010. 
[188] K. Kimura, "Is there hope for firms facing the technology gap? A case of China's 
mobile industry," Journal of Contemporary China, vol. 20, pp. 833-847, 2011. 
[189] H. Liu and Y. Jiang, "Technology transfer from higher education institutions to 
industry in China: Nature and implications," Technovation, vol. 21, pp. 175-188, 
2001. 
[190] OECD, "Reviews of Innovation Policy: China," Synthesis Report, Organization 
for Economic Co-Operation and Development (OECD), 2008. 
[191] G. H. Jefferson, H. Bai, X. Guan, and X. Yu, "R&D performance in Chinese 
industry," Economics of Innovation and New Technology, vol. 15, pp. 345-366, 
2006. 
[192] CEC/CEDA, Top 500 Chinese Enterprises Development Report 2010. Beijing: 
Enterprise Management Publishing, 2010. 
[193] A. Fosfuri, "Patent protection, imitation and the mode of technology transfer," 
International Journal of Industrial Organization, vol. 18, pp. 1129-1149, 2000. 
[194] W. G. Park and D. C. Lippoldt, "Technology transfer and the economic 
implications of the strengthening of intellectual property rights in developing 
countries," OECD Trade Policy Working Papers, 2008. 
[195] S. Nagaoka, "Does strong patent protection facilitate international technology 
transfer? Some evidence from licensing contracts of Japanese firms," Journal of 
Technology Transfer, vol. 34, pp. 128-144, Apr 2009. 
[196] A. Tylecote, "Twin innovation systems, intermediate technology and economic 
development: history and prospect for China," Innovation: Management, Policy & 
Practice, vol. 8 pp. 62-83, 2006. 
[197] X. B. Li, "China's regional innovation capacity in transition: An empirical 
approach," Research Policy, vol. 38, pp. 338-357, Mar 2009. 
[198] O. Gassmann and Z. Han, "Motivations and barriers of foreign R&D activities in 
China," R&D Management, vol. 34, pp. 423-437, 2004. 
[199] J. Li and D. R. Yue, "Managing Global Research and Development in China: 
Patterns of R&D Configuration and Evolution," Technology Analysis & Strategic 
Management, vol. 17, pp. 317-337, 2005. 
[200] A. Salo and J.-P. Salmenkaita, "Embedded foresight in RTD programs," 
International Journal of Technology, Policy and Management, vol. 2, pp. 167-193, 
2002. 
239 
[201] M. A. Oner and O. Saritas, "A systems approach to policy analysis and 
development planning: Construction sector in the Turkish 5-year development 
plans," Technological Forecasting & Social Change, vol. 72, pp. 886-911, 2005. 
[202] A. Porter, "Technology futures analysis: Toward integration of the field and new 
methods," Technological Forecasting & Social Change, vol. 71, pp. 287-303, 
2004. 
[203] R. Popper, "Foresight methodology," in The Handbook of Technology Foresight, 
L. Georghiou, H. Cassingena, J, M. Keenan, I. Miles, and R. Popper, Eds. 
Cheltenham: Edward Elgar, 2008, pp. 44-88. 
[204] A. Porter, "Technology futures analysis: Toward integration of the field and new 
methods," Technology Futures Analysis Working Group, Technological 
Forecasting & Social Change, vol. 71, pp. 287-303, 2004. 
[205] EFMN, "Mapping foresight: Revealing how Europe and other world regions 
navigate into the future," European Foresight Monitoring Network, 2009. 
[206] M. Keenan, "Combining foresight methods for impacts," in NISTEP 3rd 
International Conference on Foresight, Tokyo, Japan, 2007. 
[207] V. A. Banuls and J. L. Salmeron, "A scenario-based assessment model - SBAM," 
Technological Forecasting & Social Change, 2006. 
[208] P. Gerdsri, "A Systematic Approach to Developing National Technology Policy 
and Strategy for Emerging Technologies," Portland State University, 2009. 
[209] P. Gerdsri and D. F. Kocaoglu, "HDM for Developing National Emerging 
Technology Strategy and Policy Supporting Sustainable Economy: A Case Study 
of Nanotechnology for Thailand's Agriculture," in Portland International 
Conference on Management of Engineering and Technology Portland: IEEE, 
2008. 
[210] N. Gerdsri, "An Analytical Approach on Building a Technology Development 
Envelope (TDE) for Roadmapping of Emerging Technologies," Portland State 
University, 2004. 
[211] N. Gerdsri and D. F. Kocaoglu, "A Quantitative Model for the Strategic 
Evaluation of Emerging Technologies," in Portland International Conference on 
Management of Engineering and Technology Portland: IEEE, 2004. 
[212] T. U. Daim, G. Rueda, H. Martin, and P. Gerdsri, "Forecasting emerging 
technologies: Use of bibliometrics and patent analysis," Technological 
Forecasting & Social Change, vol. 73, pp. 981-1012, 2006. 
[213] M. Bengisu and R. Nekhili, "Forecasting emerging technologies with the aid of 
science and technology databases," Technological Forecasting & Social Change, 
vol. 73, pp. 835-844, 2006. 
[214] T. A. Tran and T. Daim, "A taxonomic review of methods and tools applied in 
technology assessment," Technological Forecasting & Social Change, vol. 75, pp. 
1396-1405, 2008. 
[215] C. M. Josee and V. Eijndhoven, "Technology assessment: Product or process," 
Technological Forecasting and Social Change, vol. 54, pp. 269-286, 1997. 
[216] S. Lall, "Technological capabilities and industrialization," World Development, 
vol. 20, pp. 165-186, 1992. 
240 
[217] P. M. Romer, "Increasing returns and long-run growth," The Journal of Political 
Economy, vol. 94, pp. 1002-1037, 1986. 
[218] P. Aghion and P. Howitt, "A model of growth through creative destruction," 
Econometrica, vol. 60, pp. 323-351, 1992. 
[219] K. Kojima, "The "flying geese" model of Asian economic development: origin, 
theoretical extensions, and regional policy implications," Journal of Asian 
Economics, vol. 11, pp. 375-401, 2000. 
[220] R. Hayter and D. Edgington, "Flying Geese in Asia: The Impacts of Japanese 
MNCs as a Source of Industrial Learning," Tijdschrift voor Ekonomische en 
Sociale Geografie, vol. 95, pp. 3-26, 2004. 
[221] J. Child, "Strategic choice in the analysis of action, structure, organizations and 
environment: retrospect and prospect," Organization Studies, vol. 18, pp. 43-76, 
1997. 
[222] M. Tuominen, A. Rajala, and K. Moller, "How does adaptability drive firm 
innovativeness?," Journal of Business Research, vol. 57, pp. 495-506, 2004. 
[223] A. S. Cui, D. A. Griffith, S. T. Cavusgil, and M. Dabic, "The influence of market 
and cultural environmental factors on technology transfer between foreign MNCs 
and local subsidiaries: a Croatian illustration," Journal of World Business, pp. 
100-111, 2006. 
[224] P. Bruun and R. N. Mefford, "A framework for selecting and introducing 
appropriate production technology in developing countries," International 
Journal of Production Economics, vol. 46-47, pp. 197-209, 1996. 
[225] L. Platt and G. Wilson, "Technology development and the poor marginalized: 
context, intervention and participation," Technovation, pp. 393-401, 1999. 
[226] P. F. Basch, "Technology transfer to the developing world: does new technology 
have any relevance for developing countries?," Tubercle and Lung Disease, vol. 
74, pp. 353-358, 1993. 
[227] I. Hipkin, "Determining technology strategy in developing countries," Omega, vol. 
32, pp. 245-260, 2004. 
[228] G. Blalock and P. J. Gertler, "How firm capabilities affect who benefits from 
foreign technology," Journal of Development Economics, vol. 90, pp. 192 - 199, 
2009. 
[229] Z. Griliches, "Issues in assessing the contribution of R&D to productivity 
growth," Bell Journal of Economics, vol. 10, pp. 92-116, 1979. 
[230] A. B. Jaffe, "Technological Opportunity and Spillovers of R&D: Evidence from 
Firms' Patents, Profits, and Market Value," The American Economic Review, vol. 
76, pp. 984-1001, 1986. 
[231] C. Watanabe, K. Matsumoto, and J. Y. Hur, "Technological diversification and 
assimilation of spillover technology: Canon's scenario for sustainable growth," 
Technological Forecasting and Social Change, vol. 71, pp. 941-959, 2004. 
[232] J. Bjorn, S. Johannes, and K. Ingmar, "Industry level technology gaps and 
complimentary knowledge stocks as determinants of intra-MNC knowledge 
flow," Journal of Economics and Business, vol. 8, pp. 137-156, 2005. 
[233] S. Luckraz, "Process Spillovers and Growth," Journal of Optimization Theory and 
Applications, vol. 139, pp. 315-335, Nov 2008. 
241 
[234] I. Alvarez and J. Molero, "Technology and the generation of international 
knowledge spillovers: An application to Spanish manufacturing firms," Research 
Policy, vol. 34, pp. 1440-1452, Nov 2005. 
[235] F. H. P. Oliveira, F. G. Jayme, and M. B. Lemos, "Increasing returns to scale and 
international diffusion of technology: An empirical study for Brazil (1976-2000)," 
World Development, vol. 34, pp. 75-88, Jan 2006. 
[236] D. Chudnovsky, A. Lopez, and G. Rossi, "Foreign direct investment spillovers 
and the absorptive capabilities of domestic firms in the Argentine manufacturing 
sector (1992-2001)," Journal of Development Studies, vol. 44, pp. 645-677, 2008. 
[237] S. Girma and H. Gorg, "The role of the efficiency gap for spillovers from FDI: 
Evidence from the UK electronics and engineering sectors," Open Economies 
Review, vol. 18, pp. 215-232, Apr 2007. 
[238] M. Lai, H. Wang, and S. Zhu, "Double-edged effects of the technology gap and 
technology spillovers: Evidence from the Chinese industrial sector," China 
Economic Review, vol. 20, pp. 414-424, 2009. 
[239] P. Criscuolo and R. Narula, "A novel approach to national technological 
accumulation and absorptive capacity: Aggregating Cohen and Levinthal," The 
European Journal of Development Research, vol. 20, pp. 56-73, 2008. 
[240] R. R. Nelson, "The changing institutional requirements for technological and 
economic catch up," International Journal of Technological Learning, Innovation 
and Development, vol. 1, pp. 4-12, 2007. 
[241] D. Rodrik, A. Subramanian, and F. Trebbi, "Institutions rule: The primacy of 
institutions over geography and integration in economic development," Journal of 
Economic Growth, vol. 9, pp. 131-165, 2004. 
[242] N. Dalkey and O. Helmer, "An experimental application of the Delphi method to 
the use of experts," Management Science, vol. 9, pp. 458-467, 1963. 
[243] H. A. Linstone and M. Turoff, The Delphi method: Techniques and Applications. 
Reading, MA: Addison-Wesley, 2002. 
[244] V. S. Lai, B. K. Wong, and W. Cheung, "Group decision making in a multiple 
criteria environment: A case using the AHP in software selection," European 
Journal of Operational Research, vol. 137, pp. 134-144, 2002. 
[245] M. K. Rayens and E. J. Hahn, "Building consensus using the policy Delphi 
method," Policy, Politics, & Nursing Practice, vol. 4, pp. 308-315, 2000. 
[246] G. Rowe and G. Wright, "The Delphi techniques as a forecasting tool: Issues and 
analysis," International Journal of Forecasting, vol. 15, pp. 353-375, 1999. 
[247] E. R. Doke and N. E. Swanson, "Decision variables for selecting prototyping in 
information systems development: A Delphi study of MIS managers," 
Information & Management, vol. 29, pp. 173-182, 1995. 
[248] J. P. Martino, Technological Forecasting for Decision-Making, 3rd ed. New York: 
McGraw-Hill, 1993. 
[249] T. Saaty, The Analytical Hierarchy Process: Planning, Priority Setting, Resource 
Allocation. New York: McGraw-Hill, 1980. 
[250] A. L. Comrey, "A proposed method for absolute ratio scaling," Psychometrika, 
vol. 15, pp. 317-325, 1950. 
242 
[251] J. P. Guilford, Psychometric Methods. New York: McGraw Hill Book Company, 
INC., 1954. 
[252] D. F. Kocaoglu, "A Systems Approach to the Resource Allocation Process in 
Police Patrol," University of Pittsburgh, 1976. 
[253] P. T. Harker and L. G. Vargas, "The theory of ratio scale estimation: Saaty’s 
Analytic Hierarchy Process," Management Science, vol. 33, pp. 383-403, 1987. 
[254] E. H. Forman and S. I. Gass, "The Analytic Hierarchy Process - an exposition," 
Operations Research, vol. 49(4), pp. 469-485, 2001. 
[255] R. A. Taha, B. C. Choi, P. Chuengparsitporn, A. Cutar, Q. Gu, and K. Phan, 
"Application of hierarchical decision modeling for selection of laptop," in 
Portland International Conference on Management of Engineering and 
Technology Portland: IEEE, 2007. 
[256] T. Pandejpong and D. F. Kocaoglu, "Strategic decision: Process for technology 
selection in the petrochemical industry," in Portland International Conference on 
Management of Engineering and Technology Portland: IEEE, 2003. 
[257] O. S. Vaidya and S. Kumar, "Analytic hierarchy process: An overview of 
applications," European Journal of Operational Research, vol. 169, pp. 1-29, Feb 
16 2006. 
[258] N. Sharif, "Technological dimensions of international cooperation and sustainable 
development," Technological Forecasting and Social Change, vol. 42, pp. 367-
383, 1992. 
[259] S. White, "Competition, capabilities, and the make, buy, or ally decisions of 
Chinese State-Owned firms," The Academy of Management Journal, vol. 43, pp. 
324-341, 2000. 
[260] J. Tidd, "Challenges of Innovation, Globalization and Development," The 5th 
International Symposium on Management of Technology, 2007. 
[261] A. M. A. Baez, "A decision model for technology assemssment to reduce the 
international digital divide in emerging economies," in Department of 
Engineering and Technology Management: Portland State University, 2005. 
[262] R. Kaplinsky, "Revisiting the revisited terms of trade: Will China make a 
difference," World Development, vol. 34, pp. 981-995, 2006. 
[263] E. E. Learner, "A flat world, a level playing field, a small world after all, or none 
of the above? A review of Thomas L. Friedman's The World is Flat," Journal of 
Economic Literature, vol. 45, pp. 83-126, 2007. 
[264] F. Saliola and A. Zanfei, "Multinational firms, global value chains and the 
organization of knowledge transfer," Research Policy, vol. 38, pp. 369-381, 2009. 
[265] D. Autor, F. Levy, and R. Murnane, "The skill content of recent technological 
change: An empirical exploration," Quarterly Journal of Economics, vol. 118, pp. 
1279-1334, 2003. 
[266] F. Robert-Nicoud, "Offshoring of routine tasks and (de) industrialization: Threat 
or opportunity and for whom," Journal of Urban Economics, vol. 63, pp. 517-535, 
2008. 
[267] A. M. A. Baez and D. F. Kocaoglu, "ICT and the reduction of the internal digital 
divide in a developing country," in Portland International Conference on 
Management of Engineering and Technology Portland: IEEE, 2005. 
243 
[268] E. Aho, "Proposal for Finland's National Innovation Strategy," The Ministry of 
Trade and Industry, Finland, 2008. 
[269] D. F. Kocaoglu, "A participative approach to program evaluation," Transactions 
on Engineering Management, IEEE vol. 30, 1983. 
[270] D. J. Sheskin, Handbook of Parametric and Nonparametric Statistical Procedures: 
Chapman & Hall / CRC Publisher, 2007. 
[271] P. E. Shrout and J. L. Fleiss, "Intraclass Correlation: Uses in Assessing Rater 
Reliability," Psychological Bulletin, vol. 86, pp. 420-428, 1979. 
[272] H. Chen, "Sensitivity Analysis for Hierarchical Decision Models," in Department 
of Engineering and Technology Management: Portland State University, 2007. 
[273] H. Chen, J. C. Ho, and D. F. Kocaoglu, "A strategic technology planning 
framework: A case of Taiwan's semiconductor foundry industry," IEEE 
Transactions on Engineering Management, vol. 56, 2009. 
[274] E. Babbie, The Practice of Social Research (6th ed.). Belmont, CA: Wadsworth, 
1992. 
[275] C. Bieri, "Global Pharma & Biotech M&A Report," IMAP, 2012. 
[276] E. Giniat, P. Fung, A. Weir, and N. Meyring, "China's Pharmaceutical Industry - 
Poised for the Giant Leap," KPMG Advisory (China) Limited, 2011. 
[277] K. Maggon, "Monoclonal antibody gold rush," Current Medicinal Chemistry, vol. 
14, pp. 1978-1987, 2007. 
[278] Q. Sun, M. A. Santoro, Q. Meng, C. Liu, and K. Eggleston, "Pharmaceutical 
policy in China," Health Affairs, vol. 27, pp. 1042-1050, 2008. 
[279] P. Han, "China's growing biomedical industry," Biologicals, vol. 37, pp. 169-172, 
2009. 
[280] A. S. Daar, H. Thorsteinsdóttir, D. K. Martin, A. C. Smith, S. Nast, and P. A. 
Singer, "Top ten biotechnologies for improving health in developing countries," 
United Nations Educational, Scientific and Cultural Organization (UNESCO) 
2006. 
[281] A. Arundel, D. Sawaya, and I. Valeanu, "Human health biotechnologies to 2015," 
Organization for Economic Co-Operation and Development (OECD), 2009. 
[282] OECD, "The Bioeconomy to 2030: Designing a Policy Agenda," Organization for 
Economic Co-Operation and Development, 2009. 
[283] C. D. Chin, "Biotechnology for global health: Solutions for the developing 
world," Consilience, vol. 1, pp. 1-12, 2008. 
[284] L. A. Salicrup and L. Fedorkova, "Challenges and opportunities for enhancing 
biotechnology and technology transfer in developing countries," Biotechnology 
Advances, vol. 24, pp. 69-79, 2006. 
[285] Y. Jiang, Y. Wang, and X. Yan, "Chinese pharmaceutical companies: an 
emerging industry," Drug Discovery Today, vol. 6, pp. 610-612, 2001. 
[286] K. Wang, J. Hong, D. Marinova, and L. Zhu, "Evolution and governance of the 
biotechnology and pharmaceutical industry of China," Mathematics and 
Computers in Simulation, vol. 79, pp. 2947-2956, 2009. 
[287] P. Nolan and G. Yeung, "Big business with Chinese characteristics: Two paths to 
growth of the firm in China under reform," Cambridge Journal of Economics, vol. 
25, pp. 443-465, 2001. 
244 
[288] R. Boutellier and F. Ullman, "China's unique position in discovery and preclinical 
research," Drug Discovery Today, vol. 12, pp. 4-7, 2007. 
[289] P. N. Ghauri and P. M. Rao, "Intellectual property, pharmaceutical MNEs and the 
developing world," Journal of World Business, vol. 44, pp. 206-215, 2009. 
[290] R. Lawrence, "New opportunities in Asia: A focus on India and China," Drug 
Discovery Today, vol. 10, pp. 89-91, 2005. 
[291] R. Singh, "Clinical research in China and India: A paradigm shift in drug 
development," Drug Discovery Today, vol. 11, pp. 675-676, 2006. 
[292] P. Lee, "Opening the door to the Chinese pharmaceutical market," Chemistry 
Today, vol. 26, pp. 76-81, 2008. 
[293] O. Gassmann, G. Reepmeyer, and M. v. Zedtwitz, Leading Pharmaceutical 
Innovation: Trends and Drivers for Growth in the Pharmaceutical Industry. 
Berlin: Springer, 2008. 
[294] J. W. Ra, "Analysis of expert judgments in hierarchical decision process," 
University of Pittsburgh, 1988. 
[295] Z. Li and X. Zhu, "China's Biotechnology Industry: Barriers to Overcome and 
Opportunities to Exploit," Tech Monitor, pp. 31-36, March 2011. 
[296] WiCON, "Pharma China 2012," WiCON International Group LLC., January 2012. 
[297] J. Bird, "Monoclonal Antibodies Report: 2008 Update," Datamonitor Group, 2008. 
[298] Bioassociate, "Pharmerging markets: China - the next major innovative pharma 
market," Bioassociate Consulting & Management Ltd., December 2012. 
[299] Z. Li, "Participation of Biotechnology SMEs in the International Value Chain," 
Tech Monitor, pp. 17-21, July 2012. 
[300] B. Nasto, "Biotech in China: Special feature on China's emerging biotech 
industry," Nature Biotechnology, pp. 1-16, December 2011. 
[301] Y. Wu, "The next phase: Opportunities in China's pharmaceuticals market," 
Deloitte Touche Tohmatsu CPA Ltd., 2011. 
[302] IMS, "Shaping the biosimilars opportunity: A global perspective on the evolving 
biosimilars landscape," IMS Health, 2011. 
[303] F. Bruschi, M. Dundar, P. B. Gahan, K. Gartland, M. Szente, M. P. Viola-Magni, 
and Y. Akbarova, "Biotechnology worldwide and the European Biotechnology 
Thematic Network Association (EBTNA)," Current Opinion in Biotechnology, 
vol. 22, pp. 7-14, 2011. 
[304] Q. V. Xia, "Analysis of future directions and growth of biotechnology in China," 
Asia Biotech, vol. 12, pp. 1-6, 2008. 
[305] S. Maheshwari, "Global protein therapeutics market: Beefing up towards 
futuristic growth," pharmaphorum, October 2011. 
[306] GIA, "Human Vaccines: A Global Strategic Business Report," Global Industry 
Analysts, Inc., 2012. 
[307] X. Hu, Q. Ma, and S. Zhang, "Biopharmaceuticals in China," Biotechnology 
Journal, vol. 1, pp. 1215-1224, 2006. 
[308] M. Hvistendahl, "China's Push in Tissue Engineering," Science, vol. 338, pp. 900-
902, 2012. 
[309] GIA, "Nanobiotechnology: A Global Strategic Business Report," Global Industry 
Analysts, Inc., 2012. 
245 
[310] L. Wei and J. Yu, "Bioinformatics in China: A personal perspective," Plos 
Computational Biology, vol. 4, pp. 1-11, 2008. 
[311] A. Pollack, "U.S. clears DNA firm's acquisition by Chinese," The New York 
Times, December 30, 2012. 
[312] RNCOS, "In-Vitro Diagnostics Market Analysis to 2017," RNCOS Industry 
Research Solutions, 2013. 
[313] S. E. Frew, S. M. Sammut, A. F. Shore, J. K. Ramjist, S. Al-Bader, Rahim Rezaie, 
A. S. Daar, and P. A. Singer, "Chinese health biotech and the billion-patient 
market," Nature Biotechnology, vol. 26, pp. 37-53, 2008. 
[314] M. D. Janodia, D. Sreedhar, V. S. Ligade, A. Pise, and N. Udupa, "Facets of 
Technology Transfer: A Perspective of Pharmaceutical Industry," Journal of 
Intellectual Property Rights, vol. 13, pp. 28-34, 2008. 
[315] N. Kumar, "Intellectual property rights, technology and economic development: 
Experiences of Asian countries," RIS Discussion Paper, vol. 25, 2002. 
[316] N. Kumar and A. Aggarwal, "Liberalization, outward orientation and in-house 
R&D activity of multinational and local ﬁrms: A quantitative exploration for 
Indian manufacturing," Research Policy, vol. 34, pp. 441-460, 2005. 
[317] V. Chiesa and D. Chiaroni, Industrial Clusters in Biotechnology: Driving Forces, 
Development Processes and Management Practices. London: Imperial College 
Press, 2005. 
[318] E. X. Fan, "Technological spillovers from foreign direct investment," Asian 
Development Review, vol. 20, pp. 34-56, 2003. 
[319] G. B. Awuah and M. Amal, "Impact of globalization: The ability of less 
developed countries' (LDCs') firms to cope with opportunities and challenges," 
European Business Review, vol. 23, pp. 120-132, 2011. 
[320] Y. Zhou, "Opportunities in Biopharmaceutical Outsourcing to China," BioProcess 
International, pp. 16-23, January 2007. 
[321] Y. Li, E. Meijer, G. Duysters, and M. d. Rochemont, "Patent transactions with 
China in a new era: A European perspective," Journal of Knowledge-based 
Innovation in China, vol. 3, pp. 136-156, 2011. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
246 
Appendix A – Human Subject Agreement 
 
Informed Consent Form 
Policy Choice Framework for Sustainable Technological Innovation 
 
Dear [Expert’s Name], 
You are invited to participate in a research study conducted by Leong Chan from Portland State 
University, Engineering and Technology Management Department. The researcher hopes to 
identify the innovation resources that contribute to the technological competitiveness of an 
industry. This project is being conducted in partial fulfillment for the requirements of a PhD’s 
degree under supervision by Dr. Tugrul Daim. You are invited as a possible participant because 
you have innovation management experience in the industry that the researcher is examining in 
the study. 
If you decide to participate, you will be asked to provide judgments through pair-wise 
comparisons among the model criteria in the research instrument. This is a numerical 
quantification process, thus it presents no hazard to the participants. The task takes about 15 to 30 
minutes to complete. You will not receive any direct benefit from taking part in this study, but the 
study may help to increase knowledge which may help others in the future.  
Your name and responses will be confidential and will not be shared with any third party. Any 
data linked to your identification will be kept confidential by storing in secured places only 
accessible by the researcher. The data will be stored in the researcher’s computer and backed up 
in university’s secured server. The data will be destroyed within one year after the completion of 
research. Participation in this research is totally voluntary. You have the right to withdraw at any 
time or refuse to participate entirely. You may also withdraw from this study at any time without 
affecting your relationship with the researcher or any institute.  
If you have concerns or problems about your participation in this study or your rights as a 
research subject, please contact the Human Subjects Research Review Committee, Office of 
Research Strategic Partnerships, 1600 SW Fourth Avenue, Suite 620, Portland, OR, 97201, (503) 
725 3423. If you have any questions about the study itself, contact Leong at 1802 SW 11th Ave 
#404, Portland, OR, 97201, (503) 442 8428. 
Your signature indicates that you have read and understand the above information and agree to 
take part in this study. Please understand that you may withdraw your consent at any time without 
penalty, and that by signing, you are not waiving any legal claims, rights or remedies. The 
researcher will provide you with a copy of this form for your records. 
 
 
Signature:       Date: 
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Appendix B – Subject Recruitment Letter 
 
Policy Choice Framework for Sustainable Technological Innovation 
 
Dear Sir or Madam, 
My name is Leong Chan, and I am a Ph.D. student at Department of Engineering and Technology 
Management (ETM), Portland State University. I am conducting a research to develop a policy 
choice framework for sustainable technological innovation, and would like to invite you to 
participate. You are being asked to take part because you are considered as an expert in the area 
of innovation management due to your qualification and professional experience. I am impressed 
with your expertise in innovation management, and I hope that your expert judgment will help me 
to better understand the innovation mechanism from different perspectives. Your participation 
will help to increase the knowledge in policy decisions to foster technological innovation. This 
study is being conducted in partial fulfillment of the requirements for a doctoral degree in 
Technology Management at Portland State University. 
If you decide to participate, an Informed Consent Form will be sent to you for signature before 
the research. I will be sending some data collection instruments to you after I receive the signed 
form. You will be asked to provide your opinions by doing some pair-wise comparisons among 
the research criteria. The research instrument will take about 15-30 minutes to complete. When 
you return the research instruments, I will quantify the judgmental data and prioritize the related 
research criteria. The result can demonstrate what strategies and resources are more important in 
policy decisions.  
There is no risk for the involvement in this research. No identifiable data is collected, and will not 
be reported. All data will remain confidential by the researcher. The data obtained from the 
participants will only be reported in the aggregate format, and the individual information will be 
kept confidential. All responses will be concealed, and no one other than the researcher will have 
access to them. The information will be deleted or destroyed by the researcher within one year 
after the completion of this research. 
The benefits for participation include two things: 1) at the end of the research, a copy of the 
aggregated results will be provided to you at no cost; 2) through your participation as an expert, 
researcher, and decision-maker, we will all learn more about how innovation resources contribute 
to technology policy decisions, which will ultimately lead to the benefit of whole society. 
Participation in this research is completely voluntary. You have the right to withdraw at any time 
or refuse to participate entirely and it will not affect your relationship with the investigator or any 
institute.  
248 
If you have questions regarding this study, you may contact Leong Chan at leong@pdx.edu, 1802 
SW 11th Ave #404, Portland, OR, 97201, (503) 442 8428. If you have concerns or problems 
about your participation in this study or your rights as a research subject, please contact the 
Human Subjects Research Review Committee, Research and Strategic Partnerships, Market 
Center Building, 6th Floor, 1600 SW 4th Ave, Portland, OR 97201, (503) 725-4288 / 1-877-480-
4400.  
  
Sincerely,  
 
Leong Chan 
Ph.D. student  
Department of Engineering and Technology Management  
Portland State University 
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Appendix C – Validation Instruments 
 
Validation Instrument I A  
Identification and validation of Prospective Technology Areas in the Biopharmaceutical 
Industry 
 
1. Introduction 
Identification and investment on prospective technology areas are crucial for improving 
competiveness in the biopharmaceutical industry. Emerging countries not only need to 
identify global technology trends, but also have to adapt to local needs and capabilities. 
The purpose of this instrument is to identify and validate such technology areas. 
A preliminary list of technology areas has been prepared according to comprehensive 
literature review. The following list contains the prospective technology areas in the 
biopharmaceutical industry as suggested by OECD’S forecasting report. However, the 
lists might need to be updated and validated because it was originally published in 2009.  
2. Instructions 
In the following table, you are invited to validate the technology areas and provide 
suggestions. The goal is to identify a list of prospective high tech areas to enhance 
competitiveness from a global perspective.  
In your opinion, if you think the technology is novel and prospective in the future, please 
check the YES column; or if you think a technology is matured enough or less 
prospective, please check the NO column.  
Moreover, you can suggest new technology areas that you think as prospective in the 
biopharmaceutical industry. Please kindly provide your opinions in the following table. 
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3. List of prospective technology areas and your opinions: 
Prospective Technology Areas  
Prospective 
in future? 
Yes No 
Recombinant therapeutic proteins - treat many non-communicable diseases; 
provide affordable and sustainable sources for treatment of chronic disease.   
Recombinant vaccines - vaccines produced using recombinant DNA 
technology; can be used to effectively treat infectious diseases.   
Monoclonal antibody technology - used for both therapeutic treatment and 
diagnostic tests. Most are concerned with immunological and oncology targets.   
Tissue engineering technologies - replace or act directly on cells and tissues 
in the body; repairs damaged tissues from injuries and diseases.   
Stem cell therapy - the use of stem cells as a therapeutic or to repair specific 
tissues or to grow organs. Treatment leads to the production of entire organs.   
Gene therapy - treatment of diseases by introducing new gene into a cell. 
These technologies either use or act directly on nucleic acids.   
Antisense therapy - treat a wide range of diseases such as cardiovascular 
diseases, asthma, and arthritis.   
RNAi (ribonucleic acid interference) - products that act therapeutically via 
an RNA interference mechanism. Most are aimed at treating infections.   
Nanobiotechnology - aim for improved drug delivery systems from the 
convergence between biotechnology and nanotechnology.   
Synthetic biology - the design and construction of new biological parts, 
devices and systems that do not exist naturally; the redesign of existing 
biological systems to perform specific tasks 
  
Bioinformatics - manipulation and analysis of large datasets of genetic and 
health information to identify drug targets    
Pharmacogenetics - identify inherited differences (variation) between 
individuals in drug metabolism and response. It can be applied in clinical trials 
and in prescribing practice. 
  
Gene sequencing - provides ways to identify new antimicrobials. It can 
accelerate the process of drug discovery and fight against infectious diseases.   
Biotechnology Diagnostics - includes both in vitro diagnostics and in vivo 
diagnostics; Provides affordable, simple diagnosis for infectious diseases.   
 
Other Suggestions (if necessary):      
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Validation Instrument I B  
Identification and validation of Technology Development Strategies for the 
Biopharmaceutical Industry in Emerging Countries 
 
The technology development strategies describe how new technologies should be realized 
and implemented. As latecomers in technology development, emerging countries face the 
decisions of “make or buy”, or somewhere in between. This means to develop the 
technology locally, or import from advanced countries, etc.  
The following innovation strategies have been identified through literature review. Please 
indicate whether these strategies are observable in the biopharmaceutical industry. You 
are also welcome to suggest other innovation strategies, that you believe, are observable 
in the biopharmaceutical industry. 
 
Technology Development Strategies in Emerging Countries 
Observable in bio-
pharmaceutical industry? 
Yes No 
Indigenous Innovation – relies on local technology base and available 
innovation resources to build up indigenous competence   
Imitative Innovation – based on imitating, following, and 
improvement of leading innovators’ technology   
Collaborative Innovation – cooperates with other innovators, shares 
resources and develops new technology altogether   
International Technology Transfer – technology import and 
acquisitions, introducing new technology from leaders   
 
Other Suggestions (if any):  
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Validation Instrument I C  
Identification and Validation of Innovation Resources to Support Technology 
Development Strategies in the Biopharmaceutical Industry 
 
The Innovation Resources contribute to the implementation of technology development 
strategies. These are innovators that generate various innovative outputs such as patents, 
publications, and new products or designs. The innovation resources can include all the 
entities that develop, implement, or provide support for the realization of prospective 
technologies. These resources can come from different sources such as public sector, 
private sector, or even foreign countries.  
For the biopharmaceutical industry, various types of innovation resources have been 
extracted through literature review. In the following tables, please indicate and validate 
whether these innovators are supportive to the technology strategies identified in 
Validation Instrument I b.  
You are also welcome to suggest other innovation resources that you believe important 
for the biopharmaceutical industry in emerging countries. 
 
1. Supportive Innovators and resources for the technology development 
strategies 
Contributor? 
Yes No 
University Research Programs 
 
  
Public Research Institutes 
 
  
State-owned Enterprises 
 
  
High-tech Small-to-Medium Enterprises 
 
  
Equity Joint Ventures 
 
  
Contract Research/Manufacture Organizations 
 
  
Foreign R&D Centers   
 Multinational Companies and Wholly-owned Subsidiaries   
 
Other Suggestions (if necessary):  
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Appendix D – Research Instruments 
Pair-wise Comparison Instrument I A 
Prioritization of Prospective Technology Areas in the Biopharmaceutical Industry 
 
1. Introduction 
Identification and investment on prospective technology areas are crucial for improving 
competiveness in the biopharmaceutical industry. Emerging countries not only need to 
identify global technology trends, but also have to adapt to local needs and capabilities. 
The purpose of this instrument is to prioritize such technology areas. The following 
prospective technology areas in the biopharmaceutical industry were suggested by 
literature review and validated by experts. As an expert, you will be asked to make pair-
wise comparisons among the technologies for the objective of enhancing competitiveness 
and innovation in the biopharmaceutical industry. 
2. Instructions 
In the pair-wise comparison tables, please allocate a total of 100 points to represent your 
perceived judgment about how many times an element is more or less important than the 
other. Use any number from 1 to 99 to represent your judgment (Exclude 0 or 100). For 
example, if you think ‘sub-criterion1’ is 3 times more important than ‘sub-criterion2’ for 
the upper level Criterion, then fill "75" in the blank cell on the left, and then “25” (100-75) 
in the cell on the right. If you believe that one element is completely irrelevant in 
comparison to the other element of a pair, allocate 1 and 99 respectively. The working 
process is similar for other pairs, but the judgment values might be very different even for 
the same pair when under a different upper level criterion. The following 2 tables 
demonstrate this procedure. For example: 
Contribution to upper level Criterion1 
Sub-criterion1 75 Vs. 25 Sub-criterion2 
 
Contribution to upper level Criterion2 
Sub-criterion1 1 Vs. 99 Sub-criterion2 
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3. Descriptions of Criteria 
Overall Objective:  
The mission is to achieve technology competitiveness and sustainable innovation in the 
biopharmaceutical industry. 
 Prospective Technology Areas:  
T1 Recombinant therapeutic proteins - treat many non-communicable diseases; 
provide affordable and sustainable sources for treatment of chronic disease. 
T2 Recombinant vaccines - vaccines produced using recombinant DNA 
technology; can be used to effectively treat infectious diseases. 
T3 Monoclonal antibody technology - used for both therapeutic treatment and 
diagnostic tests. Most are concerned with immunological and oncology targets. 
T4 Cell and tissue engineering - replace or act directly on cells and tissues in the 
body; repairs damaged tissues from injuries and diseases. Including stem cell 
therapy. 
T5 Gene therapy - treatment of diseases by introducing new gene into a cell. 
These technologies either use or act directly on nucleic acids. 
T6 Antisense therapy - treat a wide range of diseases such as cardiovascular 
diseases, asthma, and arthritis. 
T7 RNAi (ribonucleic acid interference) - products that act therapeutically via an 
RNA interference mechanism. Most are aimed at treating infections. 
T8 Nanobiotechnology - aim for improved drug delivery systems from the 
convergence between biotechnology and nanotechnology. 
T9 Synthetic biology - the design and construction of new biological parts, 
devices and systems that do not exist naturally; the redesign of existing 
biological systems to perform specific tasks 
T10 Bioinformatics - manipulation and analysis of large datasets of genetic and 
health information to identify drug targets  
T11 Pharmacogenetics - identify inherited differences (variation) between 
individuals in drug metabolism and response. It can be applied in clinical trials 
and in prescribing practice. 
T12 Gene sequencing - provides ways to identify new antimicrobials. It can 
accelerate the process of drug discovery and fight against infectious diseases. 
T13 Biotechnology Diagnostics - includes both in vitro diagnostics and in vivo 
diagnostics; Provides affordable, simple diagnosis for infectious diseases. 
 
 
Please provide you judgment in the next 2 tables. 
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Group A: 
T1 Recombinant therapeutic proteins  Vs.  T2 Recombinant vaccines 
T1 Recombinant therapeutic proteins  Vs.  T3 Monoclonal antibody  
T1 Recombinant therapeutic proteins  Vs.  T4 Cell and tissue engineering 
T1 Recombinant therapeutic proteins  Vs.  T5 Gene therapy 
T1 Recombinant therapeutic proteins  Vs.  T6 Antisense therapy 
T1 Recombinant therapeutic proteins  Vs.  T7 RNAi 
T2 Recombinant vaccines  Vs.  T3 Monoclonal antibody 
T2 Recombinant vaccines  Vs.  T4 Cell and tissue engineering 
T2 Recombinant vaccines  Vs.  T5 Gene therapy 
T2 Recombinant vaccines  Vs.  T6 Antisense therapy 
T2 Recombinant vaccines  Vs.  T7 RNAi 
T3 Monoclonal antibody technology  Vs.  T4 Cell and tissue engineering 
T3 Monoclonal antibody technology  Vs.  T5 Gene therapy 
T3 Monoclonal antibody technology  Vs.  T6 Antisense therapy 
T3 Monoclonal antibody technology  Vs.  T7 RNAi 
T4 Cell and tissue engineering  Vs.  T5 Gene therapy 
T4 Cell and tissue engineering  Vs.  T6 Antisense therapy 
T4 Cell and tissue engineering  Vs.  T7 RNAi 
T5 Gene therapy  Vs.  T6 Antisense therapy 
T5 Gene therapy  Vs.  T7 RNAi 
T6 Antisense therapy  Vs.  T7 RNAi 
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Group B: 
T1 Recombinant therapeutic proteins  Vs.  T8 Nanobiotechnology 
T1 Recombinant therapeutic proteins  Vs.  T9 Synthetic biology 
T1 Recombinant therapeutic proteins  Vs.  T10 Bioinformatics 
T1 Recombinant therapeutic proteins  Vs.  T11 Pharmacogenetics 
T1 Recombinant therapeutic proteins  Vs.  T12 Gene sequencing 
T1 Recombinant therapeutic proteins  Vs.  T13 Biotechnology Diagnostics 
T8 Nanobiotechnology  Vs.  T9 Synthetic biology 
T8 Nanobiotechnology  Vs.  T10 Bioinformatics 
T8 Nanobiotechnology  Vs.  T11 Pharmacogenetics 
T8 Nanobiotechnology  Vs.  T12 Gene sequencing 
T8 Nanobiotechnology  Vs.  T13 Biotechnology Diagnostics 
T9 Synthetic biology  Vs.  T10 Bioinformatics 
T9 Synthetic biology  Vs.  T11 Pharmacogenetics 
T9 Synthetic biology  Vs.  T12 Gene sequencing 
T9 Synthetic biology  Vs.  T13 Biotechnology Diagnostics 
T10 Bioinformatics  Vs.  T11 Pharmacogenetics 
T10 Bioinformatics  Vs.  T12 Gene sequencing 
T10 Bioinformatics  Vs.  T13 Biotechnology Diagnostics 
T11 Pharmacogenetics  Vs.  T12 Gene sequencing 
T11 Pharmacogenetics  Vs.  T13 Biotechnology Diagnostics 
T12 Gene sequencing  Vs.  T13 Biotechnology Diagnostics 
 
Overall level of confidence (Please circle the appropriate number):  
5:  Very high  4:  High 3:  Medium  2:  Low  1: Very Low 
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Pair-wise Comparison Instrument I B  
Prioritization of Technology Development Strategies for the Biopharmaceutical Industry 
in Emerging Countries 
 
1. Introduction 
The technology development strategies describe how new technologies should be realized 
and implemented. As latecomers in technology development, emerging countries face the 
decisions of “make or buy”, or somewhere in between. This means to develop the 
technology locally, or import from advanced countries, etc. The following innovation 
strategies have been identified through literature review and validated by experts. As an 
expert, you will be asked to make pair-wise comparisons among these strategies for the 
identified technology areas in the biopharmaceutical industry. 
2. Instructions 
In the pair-wise comparison tables, please allocate a total of 100 points to represent your 
perceived judgment about how many times an element is more or less important than the 
other. Use any number from 1 to 99 to represent your judgment (Exclude 0 or 100). For 
example, if you think ‘sub-criterion1’ is 3 times more important than ‘sub-criterion2’ for 
the upper level Criterion, then fill "75" in the blank cell on the left, and then “25” (100-75) 
in the cell on the right. If you believe that one element is completely irrelevant in 
comparison to the other element of a pair, allocate 1 and 99 respectively. The working 
process is similar for other pairs, but the judgment values might be very different even for 
the same pair when under a different upper level criterion. The following 2 tables 
demonstrate this procedure. For example: 
Contribution to upper level Criterion1 
Sub-criterion1 75 Vs. 25 Sub-criterion2 
 
Contribution to upper level Criterion2 
Sub-criterion1 1 Vs. 99 Sub-criterion2 
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3. Descriptions of Criteria 
Technology Development Strategies in China:  
Indigenous Innovation – relies on local technology base and available innovation 
resources to build up indigenous competence 
Imitative Innovation – based on imitating, following, and improvement of leading 
innovators’ technology 
Collaborative Innovation – cooperates with other innovators, shares resources and 
develops new technology altogether 
International Technology Transfer – technology import and acquisitions, introducing 
new technology from leaders 
 
4. Prioritization of Strategies for Identified Technologies (T1-T13) 
For T1: Recombinant therapeutic proteins 
S1: Indigenous Innovation  Vs.  S2: Imitative Innovation 
S1: Indigenous Innovation  Vs.  S3: Collaborative Innovation 
S1: Indigenous Innovation  Vs.  S4: Int’l Technology Transfer 
S2: Imitative Innovation  Vs.  S3: Collaborative Innovation 
S2: Imitative Innovation  Vs.  S4: Int’l Technology Transfer 
S3: Collaborative Innovation  Vs.  S4: Int’l Technology Transfer 
 
For T2: Recombinant vaccines 
S1: Indigenous Innovation  Vs.  S2: Imitative Innovation 
S1: Indigenous Innovation  Vs.  S3: Collaborative Innovation 
S1: Indigenous Innovation  Vs.  S4: Int’l Technology Transfer 
S2: Imitative Innovation  Vs.  S3: Collaborative Innovation 
S2: Imitative Innovation  Vs.  S4: Int’l Technology Transfer 
S3: Collaborative Innovation  Vs.  S4: Int’l Technology Transfer 
 
For T3: Monoclonal antibody technology 
S1: Indigenous Innovation  Vs.  S2: Imitative Innovation 
S1: Indigenous Innovation  Vs.  S3: Collaborative Innovation 
S1: Indigenous Innovation  Vs.  S4: Int’l Technology Transfer 
S2: Imitative Innovation  Vs.  S3: Collaborative Innovation 
S2: Imitative Innovation  Vs.  S4: Int’l Technology Transfer 
S3: Collaborative Innovation  Vs.  S4: Int’l Technology Transfer 
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For T4: Cell and tissue engineering 
S1: Indigenous Innovation  Vs.  S2: Imitative Innovation 
S1: Indigenous Innovation  Vs.  S3: Collaborative Innovation 
S1: Indigenous Innovation  Vs.  S4: Int’l Technology Transfer 
S2: Imitative Innovation  Vs.  S3: Collaborative Innovation 
S2: Imitative Innovation  Vs.  S4: Int’l Technology Transfer 
S3: Collaborative Innovation  Vs.  S4: Int’l Technology Transfer 
 
For T5: Gene therapy 
S1: Indigenous Innovation  Vs.  S2: Imitative Innovation 
S1: Indigenous Innovation  Vs.  S3: Collaborative Innovation 
S1: Indigenous Innovation  Vs.  S4: Int’l Technology Transfer 
S2: Imitative Innovation  Vs.  S3: Collaborative Innovation 
S2: Imitative Innovation  Vs.  S4: Int’l Technology Transfer 
S3: Collaborative Innovation  Vs.  S4: Int’l Technology Transfer 
 
For T6: Antisense therapy 
S1: Indigenous Innovation  Vs.  S2: Imitative Innovation 
S1: Indigenous Innovation  Vs.  S3: Collaborative Innovation 
S1: Indigenous Innovation  Vs.  S4: Int’l Technology Transfer 
S2: Imitative Innovation  Vs.  S3: Collaborative Innovation 
S2: Imitative Innovation  Vs.  S4: Int’l Technology Transfer 
S3: Collaborative Innovation  Vs.  S4: Int’l Technology Transfer 
 
 
For T7: RNAi (ribonucleic acid interference) 
S1: Indigenous Innovation  Vs.  S2: Imitative Innovation 
S1: Indigenous Innovation  Vs.  S3: Collaborative Innovation 
S1: Indigenous Innovation  Vs.  S4: Int’l Technology Transfer 
S2: Imitative Innovation  Vs.  S3: Collaborative Innovation 
S2: Imitative Innovation  Vs.  S4: Int’l Technology Transfer 
S3: Collaborative Innovation  Vs.  S4: Int’l Technology Transfer 
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For T8: Nanobiotechnology 
S1: Indigenous Innovation  Vs.  S2: Imitative Innovation 
S1: Indigenous Innovation  Vs.  S3: Collaborative Innovation 
S1: Indigenous Innovation  Vs.  S4: Int’l Technology Transfer 
S2: Imitative Innovation  Vs.  S3: Collaborative Innovation 
S2: Imitative Innovation  Vs.  S4: Int’l Technology Transfer 
S3: Collaborative Innovation  Vs.  S4: Int’l Technology Transfer 
 
For T9: Synthetic biology 
S1: Indigenous Innovation  Vs.  S2: Imitative Innovation 
S1: Indigenous Innovation  Vs.  S3: Collaborative Innovation 
S1: Indigenous Innovation  Vs.  S4: Int’l Technology Transfer 
S2: Imitative Innovation  Vs.  S3: Collaborative Innovation 
S2: Imitative Innovation  Vs.  S4: Int’l Technology Transfer 
S3: Collaborative Innovation  Vs.  S4: Int’l Technology Transfer 
 
 
For T10: Bioinformatics 
S1: Indigenous Innovation  Vs.  S2: Imitative Innovation 
S1: Indigenous Innovation  Vs.  S3: Collaborative Innovation 
S1: Indigenous Innovation  Vs.  S4: Int’l Technology Transfer 
S2: Imitative Innovation  Vs.  S3: Collaborative Innovation 
S2: Imitative Innovation  Vs.  S4: Int’l Technology Transfer 
S3: Collaborative Innovation  Vs.  S4: Int’l Technology Transfer 
 
For T11: Pharmacogenetics 
S1: Indigenous Innovation  Vs.  S2: Imitative Innovation 
S1: Indigenous Innovation  Vs.  S3: Collaborative Innovation 
S1: Indigenous Innovation  Vs.  S4: Int’l Technology Transfer 
S2: Imitative Innovation  Vs.  S3: Collaborative Innovation 
S2: Imitative Innovation  Vs.  S4: Int’l Technology Transfer 
S3: Collaborative Innovation  Vs.  S4: Int’l Technology Transfer 
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For T12: Gene sequencing 
S1: Indigenous Innovation  Vs.  S2: Imitative Innovation 
S1: Indigenous Innovation  Vs.  S3: Collaborative Innovation 
S1: Indigenous Innovation  Vs.  S4: Int’l Technology Transfer 
S2: Imitative Innovation  Vs.  S3: Collaborative Innovation 
S2: Imitative Innovation  Vs.  S4: Int’l Technology Transfer 
S3: Collaborative Innovation  Vs.  S4: Int’l Technology Transfer 
 
  
For T13: Biotechnology Diagnostics 
S1: Indigenous Innovation  Vs.  S2: Imitative Innovation 
S1: Indigenous Innovation  Vs.  S3: Collaborative Innovation 
S1: Indigenous Innovation  Vs.  S4: Int’l Technology Transfer 
S2: Imitative Innovation  Vs.  S3: Collaborative Innovation 
S2: Imitative Innovation  Vs.  S4: Int’l Technology Transfer 
S3: Collaborative Innovation  Vs.  S4: Int’l Technology Transfer 
  
 
Overall level of confidence (Please circle the appropriate number):  
5:  Very high  4:  High 3:  Medium  2:  Low  1: Very Low 
 
 
 
 
 
 
 
 
 
------------------------------------ Thank You ------------------------------------- 
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Pair-wise Comparison Instrument I C  
Prioritization of Innovation Resources to Support Technology Development Strategies in 
the Biopharmaceutical Industry 
 
1. Introduction 
The Innovation Resources contribute to the implementation of technology development 
strategies. These are innovators that generate various innovative outputs such as patents, 
publications, and new products or designs. The innovation resources can include all the 
entities that develop, implement, or provide support for the realization of prospective 
technologies. These resources can come from different sources such as public sector, 
private sector, or even foreign countries. Various types of innovation resources have been 
extracted through literature review and validated by experts. You will be asked to make 
pair-wise comparisons among the innovation resources to supportive the technology 
development strategies.  
2. Instructions 
In the pair-wise comparison tables, please allocate a total of 100 points to represent your 
perceived judgment about how many times an element is more or less important than the 
other. Use any number from 1 to 99 to represent your judgment (Exclude 0 or 100). For 
example, if you think ‘sub-criterion1’ is 3 times more important than ‘sub-criterion2’ for 
the upper level Criterion, then fill "75" in the blank cell on the left, and then “25” (100-75) 
in the cell on the right. If you believe that one element is completely irrelevant in 
comparison to the other element of a pair, allocate 1 and 99 respectively. The working 
process is similar for other pairs, but the judgment values might be very different even for 
the same pair when under a different upper level criterion. The following 2 tables 
demonstrate this procedure. For example: 
Contribution to upper level Criterion1 
Sub-criterion1 75 Vs. 25 Sub-criterion2 
 
Contribution to upper level Criterion2 
Sub-criterion1 1 Vs. 99 Sub-criterion2 
263 
3. Contribution of Resource Level to Strategies (S1-S4) 
This section contains four tables to prioritize the resources for each of the identified 
strategies, which include Indigenous Innovation, imitative Innovation, collaborative 
Innovation and international Technology Transfer  
3.1 Contribution to S1: Indigenous Innovation Strategy 
R1: University Research Programs 
R2: Public Research Institutes 
R3: State-owned Enterprises 
R4: High-tech Small-to-Medium Enterprises 
R5: Equity Joint Ventures 
R6: Contract Research/Manufacture Organizations 
R7: Foreign R&D Centers 
R8: Multinational Companies and Wholly-owned Subsidiaries 
 
For S1: Indigenous Innovation Strategy 
R1  Vs.  R2  R3  Vs.  R4 
R1  Vs.  R3  R3  Vs.  R5 
R1  Vs.  R4  R3  Vs.  R6 
R1  Vs.  R5  R3  Vs.  R7 
R1  Vs.  R6  R3  Vs.  R8 
R1  Vs.  R7  R4  Vs.  R5 
R1  Vs.  R8  R4  Vs.  R6 
R2  Vs.  R3  R4  Vs.  R7 
R2  Vs.  R4  R4  Vs.  R8 
R2  Vs.  R5  R5  Vs.  R6 
R2  Vs.  R6  R5  Vs.  R7 
R2  Vs.  R7  R5  Vs.  R8 
R2  Vs.  R8  R6  Vs.  R7 
      R6  Vs.  R8 
      R7  Vs.  R8 
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3.2 Contribution to S2: Imitative Innovation Strategy 
R1: University Research Programs 
R2: Public Research Institutes 
R3: State-owned Enterprises 
R4: High-tech Small-to-Medium Enterprises 
R5: Equity Joint Ventures 
R6: Contract Research/Manufacture Organizations 
R7: Foreign R&D Centers 
R8: Multinational Companies and Wholly-owned Subsidiaries 
 
For S2: Imitative Innovation Strategy 
R1  Vs.  R2  R3  Vs.  R4 
R1  Vs.  R3  R3  Vs.  R5 
R1  Vs.  R4  R3  Vs.  R6 
R1  Vs.  R5  R3  Vs.  R7 
R1  Vs.  R6  R3  Vs.  R8 
R1  Vs.  R7  R4  Vs.  R5 
R1  Vs.  R8  R4  Vs.  R6 
R2  Vs.  R3  R4  Vs.  R7 
R2  Vs.  R4  R4  Vs.  R8 
R2  Vs.  R5  R5  Vs.  R6 
R2  Vs.  R6  R5  Vs.  R7 
R2  Vs.  R7  R5  Vs.  R8 
R2  Vs.  R8  R6  Vs.  R7 
      R6  Vs.  R8 
      R7  Vs.  R8 
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3.3 Contribution to S3: Collaborative Innovation Strategy 
R1: University Research Programs 
R2: Public Research Institutes 
R3: State-owned Enterprises 
R4: High-tech Small-to-Medium Enterprises 
R5: Equity Joint Ventures 
R6: Contract Research/Manufacture Organizations 
R7: Foreign R&D Centers 
R8: Multinational Companies and Wholly-owned Subsidiaries 
 
For S3: Collaborative Innovation Strategy 
R1  Vs.  R2  R3  Vs.  R4 
R1  Vs.  R3  R3  Vs.  R5 
R1  Vs.  R4  R3  Vs.  R6 
R1  Vs.  R5  R3  Vs.  R7 
R1  Vs.  R6  R3  Vs.  R8 
R1  Vs.  R7  R4  Vs.  R5 
R1  Vs.  R8  R4  Vs.  R6 
R2  Vs.  R3  R4  Vs.  R7 
R2  Vs.  R4  R4  Vs.  R8 
R2  Vs.  R5  R5  Vs.  R6 
R2  Vs.  R6  R5  Vs.  R7 
R2  Vs.  R7  R5  Vs.  R8 
R2  Vs.  R8  R6  Vs.  R7 
      R6  Vs.  R8 
      R7  Vs.  R8 
 
 
 
 
 
 
3.4 Contribution to S4: International Technology Transfer 
R1: University Research Programs 
R2: Public Research Institutes 
R3: State-owned Enterprises 
R4: High-tech Small-to-Medium Enterprises 
R5: Equity Joint Ventures 
R6: Contract Research/Manufacture Organizations 
R7: Foreign R&D Centers 
R8: Multinational Companies and Wholly-owned Subsidiaries 
 
For S4: International Technology Transfer 
R1  Vs.  R2  R3  Vs.  R4 
R1  Vs.  R3  R3  Vs.  R5 
R1  Vs.  R4  R3  Vs.  R6 
R1  Vs.  R5  R3  Vs.  R7 
R1  Vs.  R6  R3  Vs.  R8 
R1  Vs.  R7  R4  Vs.  R5 
R1  Vs.  R8  R4  Vs.  R6 
R2  Vs.  R3  R4  Vs.  R7 
R2  Vs.  R4  R4  Vs.  R8 
R2  Vs.  R5  R5  Vs.  R6 
R2  Vs.  R6  R5  Vs.  R7 
R2  Vs.  R7  R5  Vs.  R8 
R2  Vs.  R8  R6  Vs.  R7 
      R6  Vs.  R8 
      R7  Vs.  R8 
 
 
Overall level of confidence (Please circle the appropriate number):  
5:  Very high  4:  High 3:  Medium  2:  Low  1: Very Low 
 
----------------------------------------- Thank You ------------------------------------------ 
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Appendix E – Disagreement Analysis 
Disagreement Analysis - Technology Level 
Group A 
 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single 
Measures 
.666(b) .404 .912 18.080 6 54 .000 
Average 
Measures 
.952 .872 .990 18.080 6 54 .000 
Two-way random effects model where both people effects and measures effects are random. 
a  Type A intraclass correlation coefficients using an absolute agreement definition. 
b  The estimator is the same, whether the interaction effect is present or not. 
 
 
Group B 
 
Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single 
Measures 
.565(b) .294 .874 12.113 6 54 .000 
Average 
Measures 
.928 .806 .986 12.113 6 54 .000 
Two-way random effects model where both people effects and measures effects are random. 
a  Type A intraclass correlation coefficients using an absolute agreement definition. 
b  The estimator is the same, whether the interaction effect is present or not. 
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Disagreement Analysis - Strategy Level 
T1: Recombinant Therapeutic Proteins 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single 
Measures 
.491(b) .115 .941 6.799 3 21 .002 
Average 
Measures 
.885 .510 .992 6.799 3 21 .002 
Two-way random effects model where both people effects and measures effects are random. 
a  Type A intraclass correlation coefficients using an absolute agreement definition. 
b  The estimator is the same, whether the interaction effect is present or not. 
 
T2: Recombinant Vaccines 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single 
Measures 
.465(b) .094 .935 6.206 3 21 .003 
Average 
Measures 
.874 .455 .991 6.206 3 21 .003 
Two-way random effects model where both people effects and measures effects are random. 
a  Type A intraclass correlation coefficients using an absolute agreement definition. 
b  The estimator is the same, whether the interaction effect is present or not. 
 
T3: Monoclonal Antibody Technology 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single 
Measures 
.387(b) .040 .917 4.785 3 21 .011 
Average 
Measures 
.835 .252 .989 4.785 3 21 .011 
Two-way random effects model where both people effects and measures effects are random. 
a  Type A intraclass correlation coefficients using an absolute agreement definition. 
b  The estimator is the same, whether the interaction effect is present or not. 
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T4: Cell and Tissue Engineering 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single 
Measures 
.204(b) -.059 .853 2.534 3 21 .084 
Average 
Measures 
.672 -.813 .979 2.534 3 21 .084 
Two-way random effects model where both people effects and measures effects are random. 
a  Type A intraclass correlation coefficients using an absolute agreement definition. 
b  The estimator is the same, whether the interaction effect is present or not. 
 
T5: Gene Therapy 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single 
Measures 
.409(b) .055 .923 5.158 3 21 .008 
Average 
Measures 
.847 .319 .990 5.158 3 21 .008 
Two-way random effects model where both people effects and measures effects are random. 
a  Type A intraclass correlation coefficients using an absolute agreement definition. 
b  The estimator is the same, whether the interaction effect is present or not. 
 
T6: Antisense Therapy 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single 
Measures 
.325(b) .003 .900 3.890 3 21 .023 
Average 
Measures 
.794 .025 .986 3.890 3 21 .023 
Two-way random effects model where both people effects and measures effects are random. 
a  Type A intraclass correlation coefficients using an absolute agreement definition. 
b  The estimator is the same, whether the interaction effect is present or not. 
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T7: RNAi 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single 
Measures 
.362(b) .025 .911 4.405 3 21 .015 
Average 
Measures 
.819 .170 .988 4.405 3 21 .015 
Two-way random effects model where both people effects and measures effects are random. 
a  Type A intraclass correlation coefficients using an absolute agreement definition. 
b  The estimator is the same, whether the interaction effect is present or not. 
 
 
T8: Nanobiotechnology 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single 
Measures 
.396(b) .047 .920 4.940 3 21 .009 
Average 
Measures 
.840 .281 .989 4.940 3 21 .009 
Two-way random effects model where both people effects and measures effects are random. 
a  Type A intraclass correlation coefficients using an absolute agreement definition. 
b  The estimator is the same, whether the interaction effect is present or not. 
 
 
T9: Synthetic Biology 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single 
Measures 
.359(b) .023 .910 4.361 3 21 .015 
Average 
Measures 
.818 .159 .988 4.361 3 21 .015 
Two-way random effects model where both people effects and measures effects are random. 
a  Type A intraclass correlation coefficients using an absolute agreement definition. 
b  The estimator is the same, whether the interaction effect is present or not. 
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T10: Bioinformatics 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single 
Measures 
.308(b) -.007 .895 3.665 3 21 .029 
Average 
Measures 
.780 -.057 .985 3.665 3 21 .029 
Two-way random effects model where both people effects and measures effects are random. 
a  Type A intraclass correlation coefficients using an absolute agreement definition. 
b  The estimator is the same, whether the interaction effect is present or not. 
 
 
T11: Pharmacogenetics 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single 
Measures 
.330(b) .006 .902 3.962 3 21 .022 
Average 
Measures 
.798 .048 .987 3.962 3 21 .022 
Two-way random effects model where both people effects and measures effects are random. 
a  Type A intraclass correlation coefficients using an absolute agreement definition. 
b  The estimator is the same, whether the interaction effect is present or not. 
 
 
T12: Gene Sequencing 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single 
Measures 
.242(b) -.041 .870 2.919 3 21 .058 
Average 
Measures 
.719 -.458 .982 2.919 3 21 .058 
Two-way random effects model where both people effects and measures effects are random. 
a  Type A intraclass correlation coefficients using an absolute agreement definition. 
b  The estimator is the same, whether the interaction effect is present or not. 
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T13: Biotechnology Diagnostics 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single 
Measures 
.329(b) .005 .901 3.940 3 21 .022 
Average 
Measures 
.797 .041 .986 3.940 3 21 .022 
Two-way random effects model where both people effects and measures effects are random. 
a  Type A intraclass correlation coefficients using an absolute agreement definition. 
b  The estimator is the same, whether the interaction effect is present or not. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
273 
Disagreement Analysis - Resource Level 
S1: Indigenous Innovation 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single 
Measures 
.333(b) .108 .718 4.941 7 56 .000 
Average 
Measures 
.818 .523 .958 4.941 7 56 .000 
Two-way random effects model where both people effects and measures effects are random. 
a  Type A intraclass correlation coefficients using an absolute agreement definition. 
b  The estimator is the same, whether the interaction effect is present or not. 
 
 
S2: Imitative Innovation 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single 
Measures 
.422(b) .176 .779 6.761 7 56 .000 
Average 
Measures 
.868 .657 .969 6.761 7 56 .000 
Two-way random effects model where both people effects and measures effects are random. 
a  Type A intraclass correlation coefficients using an absolute agreement definition. 
b  The estimator is the same, whether the interaction effect is present or not. 
 
 
S3: Collaborative Innovation 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single 
Measures 
.154(b) -.004 .543 2.436 7 56 .030 
Average 
Measures 
.621 -.041 .915 2.436 7 56 .030 
Two-way random effects model where both people effects and measures effects are random. 
a  Type A intraclass correlation coefficients using an absolute agreement definition. 
b  The estimator is the same, whether the interaction effect is present or not. 
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S4: International Technology Transfer 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single 
Measures 
.407(b) .163 .769 6.399 7 56 .000 
Average 
Measures 
.861 .637 .968 6.399 7 56 .000 
Two-way random effects model where both people effects and measures effects are random. 
a  Type A intraclass correlation coefficients using an absolute agreement definition. 
b  The estimator is the same, whether the interaction effect is present or not. 
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Subgroup Disagreement Analysis - Technology Level 
T4 Cell and Tissue Engineering: Subgroup-G 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single 
Measures 
.721(b) .014 .978 6.813 3 6 .023 
Average 
Measures 
.886 .042 .993 6.813 3 6 .023 
Two-way random effects model where both people effects and measures effects are random. 
a  Type A intraclass correlation coefficients using an absolute agreement definition. 
b  The estimator is the same, whether the interaction effect is present or not. 
 
T4 Cell and Tissue Engineering: Subgroup-F 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single 
Measures 
.691(b) -.040 .975 6.034 3 6 .030 
Average 
Measures 
.870 -.129 .992 6.034 3 6 .030 
Two-way random effects model where both people effects and measures effects are random. 
a  Type A intraclass correlation coefficients using an absolute agreement definition. 
b  The estimator is the same, whether the interaction effect is present or not. 
 
T4 Cell and Tissue Engineering: Subgroup-L 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single 
Measures 
.861(b) -.284 .991 10.320 3 3 .043 
Average 
Measures 
.926 -.792 .995 10.320 3 3 .043 
Two-way random effects model where both people effects and measures effects are random. 
a  Type A intraclass correlation coefficients using an absolute agreement definition. 
b  The estimator is the same, whether the interaction effect is present or not. 
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T12 Gene Sequencing: Subgroup-G 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single 
Measures 
.653(b) -.101 .971 5.241 3 6 .041 
Average 
Measures 
.850 -.378 .990 5.241 3 6 .041 
Two-way random effects model where both people effects and measures effects are random. 
a  Type A intraclass correlation coefficients using an absolute agreement definition. 
b  The estimator is the same, whether the interaction effect is present or not. 
 
T12 Gene Sequencing: Subgroup-F 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single 
Measures 
.633(b) -.131 .969 4.878 3 6 .048 
Average 
Measures 
.838 -.533 .990 4.878 3 6 .048 
Two-way random effects model where both people effects and measures effects are random. 
a  Type A intraclass correlation coefficients using an absolute agreement definition. 
b  The estimator is the same, whether the interaction effect is present or not. 
 
T12 Gene Sequencing: Subgroup-L 
 Intraclass Correlation Coefficient 
 
  
Intraclass 
Correlation(a) 95% Confidence Interval F Test with True Value 0 
    Lower Bound Upper Bound Value df1 df2 Sig 
Single 
Measures 
.867(b) -.251 .991 10.788 3 3 .041 
Average 
Measures 
.929 -.671 .995 10.788 3 3 .041 
Two-way random effects model where both people effects and measures effects are random. 
a  Type A intraclass correlation coefficients using an absolute agreement definition. 
b  The estimator is the same, whether the interaction effect is present or not. 
 
 
